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ABSTRACT 
 
ASSESSING PHYSICAL THERAPY OUTCOMES FOR WOMEN WITH  
URINARY INCONTINENCE 
 
 
 
By 
Jodi Dusi 
May 2011 
 
Dissertation supervised by Diane Borello-France, PT, PhD 
 The purpose of this study was to 1) determine the efficacy of physical therapy 
interventions to reduce pelvic symptoms and improve health-related quality of life and 
global impression of improvement in women with urinary incontinence; 2) determine the 
relationship between selected patient-related characteristics and treatment success; and 3) 
describe interventions utilized to manage the care of women with urinary incontinence. 
 
Methods: A pragmatic study design was used to explore study aims. The physical therapy  
records of 100 female patients with urinary incontinence from  Centers for Rehab 
Services provided data for this study.  Data from routine clinical care was entered into an 
electronic database designed for quality improvement purposes.  Outcome measures to 
determine improvements in pelvic symptoms and health-related quality of life included 
 v 
the Pelvic Floor Distress Inventory-20 (PFDI-20) and Pelvic Floor Impact Questionnaire-
7 (PFIQ-7), respectively. Global impression of improvement was recorded using the 
Patient Global Index of Improvement (PGI-I) administered post-intervention.   The 
relationships between patient-related characteristics and treatment success were explored 
using logistic regression.  Descriptive statistics were utilized to describe the interventions 
received by women. 
 
Results:  Mean pre- to post-intervention PFDI-20 and PFIQ-7 scores were significantly 
reduced indicating that women’s pelvic symptoms and health-related quality of life 
improved following physical therapy intervention.  The median PGI-I score was “2” 
indicating symptoms were “much better” following intervention.  Sixty-six percent of 
women met the study criteria for PGI-I defined treatment success.  Women who achieved 
treatment success had a lower mean age (51.86±15.59 vs. 59.29±13.15 years) and had 
more physical therapy visits (9.05±5.51 vs. 5.74±2.55 visits) than those who did not 
perceive symptom improvement.  Additionally, the distribution of the occurrence of 
barriers between women who did and did not perceive treatment success was different 
than would be expected by chance.  When age, presence of barriers to intervention 
recommendations, and number of physical therapy visits were entered into the logistic 
regression model, only barriers to intervention recommendations (OR 12.82; 95% CI 
4.05-40.55) and number of physical therapy visits (OR 1.26; 95% CI 1.07-1.50) were 
influential in predicting PGI-I outcome.  Women in the study received a combination of 
treatments including education, exercise, modalities, and manual procedures.  
 
 vi 
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Chapter 1 
Introduction 
1.1 Background 
 Urinary incontinence (UI) is defined by the International Continence Society as 
an “involuntary loss of urine which is objectively demonstrable and a social or hygienic 
problem.”1  UI affects approximately 20 million people in the United States2 with 
economic costs of over $16 billion per year.
2
  Moreover, UI leads to social isolation,
3
 
poor self-rated health,
4
 decreased quality of life,
5
 and depressive symptoms.
6
 Physical 
therapists are involved in the clinical management of  female UI because the impairments 
that these women demonstrate (i.e. decreased pelvic floor muscle strength; decreased 
endurance and/or coordination; and decreased awareness of lifestyle factors that 
contribute to UI) fall within the scope of physical therapy practice according to the Guide 
to Physical Therapist Practice.
7
  Consequently, there is a growing need to understand the 
efficacy of physical therapy interventions aimed toward reducing female UI symptoms 
and improving the quality of life.  
There are three main types of UI – stress, urge, and mixed.  Stress urinary 
incontinence (SUI) is the complaint of involuntary leakage on effort or exertion, or on 
sneezing or coughing.
1
   Urge urinary incontinence (UUI) is the complaint of involuntary 
leakage accompanied by or immediately preceded by urgency.
1
  Mixed urinary 
incontinence is the complaint of involuntary leakage associated with urgency and also 
with exertion, effort, sneezing or coughing.
8
   
2 
 
SUI may develop from loss of structural support of the bladder or bladder neck 
which includes damage to the pelvic floor muscles,
9
 endopelvic fascia,
10
 or pudendal 
nerve.
9
  Conservative physical therapy interventions for SUI includes pelvic floor muscle 
exercises
11-18
 which may improve urethral closure
19, 20
 and pelvic organ support.
21, 22
  
Some women with SUI have difficulty contracting their pelvic floor muscles. In these 
women, biofeedback
18, 23-26
 or electrical stimulation
16, 26
 may be utilized to augment 
pelvic floor muscle training.     
 UUI is a symptom of Overactive Bladder (OAB) syndrome which is characterized 
as urinary urgency with or without urge incontinence, as well as nocturia and urinary 
frequency (urinating more often than usual).
27
  OAB may be attributed to structural 
bladder changes  that occur with age
9, 28
 pelvic organ prolapse,
9
 or neurological diseases 
that decrease the parasympathetic control of the bladder.
9
 There are two general 
approaches to the management of UUI. The first, behavioral training, includes pelvic 
floor muscle (PFM) exercises to inhibit bladder contractions and other urge suppression 
strategies. The second approach, bladder training, focuses on restoring normal bladder 
function by modifying bladder habits using structured voiding schedules.
29
   
 It is common for women with UI to have co-existing pelvic symptoms, including 
bowel (constipation or incontinence) and/or pelvic organ prolapse (bladder, bowel, and/or 
uterine). In addition, women may complain that their pelvic symptoms impact sexual 
function. Co-existing UI and fecal incontinence rates of 18-31%
30-32
 are reported, while 
the prevalence of co-existing constipation and UI in women ranges from 31-36%.
33, 34
  
Moreover, Ellerkmann and co-workers reported that 86% of women with pelvic organ 
prolapse had urinary urgency and frequency.
30
   In addition, women with urinary 
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symptoms have a 4-fold higher risk for sexual arousal dysfunction and a 7-fold higher 
risk for sexual pain with intercourse than women without urinary symptoms.
35
    
 Clinicians believe that physical therapy interventions may improve bowel, pelvic 
organ prolapse, and/or sexual function symptoms. The most common interventions for 
constipation include increasing fluid intake, increasing dietary fiber intake, and 
promoting bowel motility via abdominal massage.
36-39
  Limited research has been done 
investigating the efficacy of abdominal massage. However, one published case report 
documented the effectiveness of abdominal massage to restore normal bowel frequency 
in a female client with constipation after only five physical therapy visits.
40
   
Physical therapy interventions for fecal incontinence include PFM exercise, 
biofeedback, and electrical stimulation.
41
 PFM exercise with biofeedback has been shown 
to improve bowel symptoms,
42
 but there is a limited number of trials investigating the 
added effect of biofeedback with PFM training.
43
  Electrical stimulation has not been 
shown to be effective in the small number of clinical trials investigating its use for 
women with fecal incontinence.
42, 44
  Recent practice guidelines by the American College 
of Gastroenterology suggest that electrical stimulation should be considered experimental 
and merits investigation within controlled clinical trials.
45
  
Women seldom seek physical therapy solely for sexual dysfunction or pelvic 
organ prolapse symptoms. Typically these symptoms and limitations accompany UI and 
are identified during the patient history and/or systems review.  Consequently, few 
clinical studies have been performed that have examined the efficacy of physical therapy 
interventions for pelvic organ prolapse and sexual dysfunction. Thus, one primary aim of 
this study was to determine the efficacy of physical therapy interventions provided within 
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a pragmatic setting on global impression of improvement, pelvic symptoms, and health-
related quality of life to women with UI.   
Although separate interventions exist for bowel and bladder dysfunction, there are 
no published reports describing the efficacy of physical therapy interventions for women 
with UI and co-existing pelvic dysfunctions.  Urinary, bowel, prolapse, and sexual 
dysfunction conditions are associated with damage to the pelvic floor either through 
mechanical disruption of connective tissue, or through direct and secondary muscle or 
nerve injury.  Because urinary, bowel, prolapse, and sexual dysfunction conditions share 
common etiologies and risk factors,
46
 it is reasonable to speculate that physical therapy 
interventions aimed toward reducing UI will also contribute, along with other symptom-
specific (bowel, prolapse, sexual dysfunction) interventions, to the reduction of co-
existing bowel, prolapse, and/or sexual dysfunction symptoms.   
 Physical therapy interventions may not be equally beneficial to all women who 
seek treatment for UI and other pelvic floor disorders.  Certain patient-related 
characteristics may be associated with poorer intervention outcomes.  The number and/or 
type of risk factors a woman has for UI may be associated with poor physical therapy 
outcomes.  Identified risk factors for UI include: age;
47-50
 childbirth;
48, 51-54
 Caucasian 
race;
48, 49, 55
 smoking;
56, 57
  daily or greater consumption of  carbonated drinks;
57
 number 
of comorbidities; and presence of barriers to intervention recommendations.  
Comorbidities refer to diseases or health conditions (as defined by the World Health 
Organization
58
) that are associated with UI and include: obesity;
48-50, 57, 58
 respiratory 
disease/chronic cough;
59-61
 pelvic surgery;
48, 60-63
 bowel dysfunction (chronic 
constipation;
53, 60-62
  fecal incontinence;
32, 33, 64
  irritable bowel syndrome
65
); pelvic organ 
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prolapse;
30
 pain (pelvic pain
61, 66
 and low back pain
67
); neurological conditions;
9, 60
 and 
diabetes.
9, 60
  Barriers to intervention recommendations refer to the patient’s physical 
impairments, such as profound muscle weakness or sensory deficits that have the 
potential to impact the effectiveness of physical therapy interventions as well as personal 
barriers that prevent adherence to the physical therapist’s recommendations for exercise, 
change in urinary/bowel habits, and/or other lifestyle modifications.  In addition, the 
number of physical therapy visits a woman attends may also influence physical therapy 
outcomes.  According to a recent systematic review, treatment effect may be greater in 
women with SUI who received a longer duration of PFM training (6 months versus 8 
weeks).
17
 Given the possible influence of patient-related characteristics on physical 
therapy outcomes, the second primary aim of this study was to determine the association 
between patient-related factors (selected risk factors for UI, selected comorbidities, 
barriers to intervention recommendations, and number of physical therapy visits 
attended) and physical therapy treatment outcomes.  
 Although physical therapy treatment interventions utilized in the management of 
women with UI have been well described (including PFM training,
11, 13-18, 20, 22, 68-70
 core 
stabilization training,
71, 72
 and patient education
22, 73-76
), there are no published reports 
describing treatment interventions for women with UI and concomitant pelvic symptoms 
(bowel, prolapse, and/or pelvic pain).  To describe the current physical therapy practice 
trend for women with various pelvic symptoms, it would be useful to gather such 
information from multiple physical therapists in a pragmatic setting. Consequently, the 
secondary aim of this study was to describe the interventions applied by physical 
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therapists to manage the care of women with UI and those with UI and coexisting bowel, 
prolapse, and pelvic pain symptoms. 
 
1.2 Operational Definitions 
Global impression of improvement.  The patient’s global perception of improvement with 
physical therapy intervention was measured and defined as the post intervention Patient 
Global Impression of Improvement (PGI-I) 
77
 score.  The PGI-I was used as a primary 
outcome measure in this study.  The PGI-I includes one question that asks the respondent 
to compare their condition now (at discharge) as to how it was prior to starting physical 
therapy. The PGI-I response range is 1-7, with 1 being “very much better” and 7 being 
“very much worse.”  Thus, the lower the post-intervention PGI-I score, the more 
improved the patient perceives her condition following physical therapy intervention.  In 
this study, treatment success is defined as a post-intervention PGI-I score of 2 indicating 
“much better” or 1 indicating “very much better.” 
Pelvic symptoms.  Three assessment instruments were used to measure pelvic symptoms 
associated with UI, bowel dysfunction, pelvic organ prolapse, and sexual dysfunction.  
Each assessment instrument was administered to subjects pre-and post intervention.   The 
first instrument was the Pelvic Floor Distress Inventory (PFDI-20)
78
 which was used as 
one of the primary outcome measures in this study.  The PFDI-20 has a score range from 
0-300 with lower scores indicating fewer pelvic symptoms and symptom distress 
associated with urinary, bowel, and pelvic organ prolapse.  Thus, pre-post intervention 
changes to lower PFDI-20 scores indicate improvement in pelvic symptoms. The two 
remaining assessment instruments measuring pelvic symptoms were secondary outcome 
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measures in the study and included the Constipation Scoring System (CSS)
79
 and the pain 
subscale of the Female Sexual Function Index (FSFI).
80
  The CSS assesses constipation 
symptoms while the pain subscale of the FSFI measures pain with sexual intercourse.  
The range of CSS scores is 0-30, with higher scores indicating greater constipation 
symptoms. Thus, pre-post intervention changes to lower CSS scores indicate 
improvement in constipation symptoms.  The range of scores for the FSFI subscale is 0-6, 
with a higher score indicating greater reduction in pain associated with sexual 
intercourse. Thus, pre-post intervention changes to higher scores indicate reduced sexual 
pain with intercourse.
 
Health-related quality of life.  Health-related quality of life was measured by the Pelvic 
Floor Impact Questionnaire (PFIQ-7)
78
 and the PFIQ-7 will was used as a primary 
outcome measure in this study. The PFIQ-7 has a score range from 0-300, with lower 
scores indicating better perceived health-related quality of life.
78
 PFIQ-7 scores were 
obtained from patients pre- and post-intervention. Thus, pre-post intervention changes to 
lower PFIQ-7 scores indicate improved health-related quality of life.   
Barriers to intervention recommendations. – Barriers to intervention recommendations  
refer to occurrences during the physical therapy intervention phase that have potential to 
interfere with the patient achieving improvements in pelvic symptoms, health-related 
quality of life, and/or global impression of improvement.  Specific barriers recorded by 
the physical therapist during intervention included any of the following: a) patient did not 
attend all recommended physical therapy visits; b) patient was not adherent to home 
exercise program; c) patient did not adhere to recommended lifestyle modifications; d) 
cognitive impairments interfered with patient’s ability to follow the plan of care; e) 
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comorbidities contributed to UI or interfered with the patient’s ability to follow the plan 
of care; f) medications contributed to UI, limiting outcomes; g) sensory loss limited 
patient’s ability to recognize correct muscle contraction; and h) profound muscle 
weakness/muscle denervation limited potential for increase muscle function. 
 
1.3 Limitations and Assumptions 
1.  A change score of 11 points on the PFDI-20 and 16 points on the PFIQ-7 was 
considered a minimum important difference
81
 for women with UI seeking physical 
therapy services. 
2.  Pre-to post-intervention score differences were attributable to the physical therapy 
interventions.  
3. Patients completed the PGI-I, PFDI-20, PFIQ-7, CSS, and FSFI questionnaires 
accurately and honestly. 
4.  Patients may have failed to return all outcome questionnaires to the physical therapists 
contributing to missing data. 
5.  Physical therapists entered the data into the database accurately and honestly. 
6. Physical therapists may have failed to enter data on all patients contributing to a 
smaller sample for analysis than projected. The ability to enter data on patients was 
linked to the computerized billing system. Data entry was not possible after an account 
was closed.  
 
1.4 Delimitations 
1. Data from 100 women were analyzed. 
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2.  Fifteen physical therapists from twelve physical therapy sites entered data into the 
database. 
3.  The physical therapists provided input throughout the selection of outcome measures, 
standardization of forms/assessment procedures, and creation of database which assisted 
in maximizing compliance by the physical therapists. 
4. The last documented data was used in the final analyses when data was missing. 
5. Physical therapists were reminded monthly to enter data on all patients with UI in a 
timely manner. 
6. Patients that did not return outcome questionnaires during their final physical therapy 
visit were asked to return them via postal mail. 
  
1.5 Problem Statement 
This study proposed the following primary aims: 
a) To determine the efficacy of physical therapy interventions provided within a 
pragmatic setting on global impression of improvement, pelvic symptoms, and health-
related quality of life to women with UI. 
b) To determine the relationship between selected patient-related characteristics (age, 
parity, race, number of comorbidities, carbonated beverage intake, current smoking 
status, presence of barriers to intervention recommendations, and number of physical 
therapy visits) and treatment success. Treatment success was defined as a post-
intervention PGI-I score of “much better” or “very much better;” a reduction in pelvic 
symptoms (reduction in PFDI-20 score at discharge) and improvement in health-related 
quality of life (reduction in PFIQ-7 at discharge).  
10 
 
The secondary aim was to document the percentage of women who received 4 
possible interventions.  Because intervention selection may be determined by the 
constellation of symptoms a woman possesses, separate percentages were calculated for 4 
symptom-based categories of women. The categories included: UI symptoms only, UI + 
bowel symptoms, UI + pelvic pain, or UI + bowel symptoms + pelvic pain. Interventions 
included patient education, modalities, manual physical therapy procedures, and exercise.   
 
1.6 Independent Variables 
1.  Treatment Intervention – Because this is not an experimental trial, the treatment 
interventions included those chosen by the physical therapists to manage the patients’ 
care.  However, the treatment intervention was categorized into one or more of the 
following categories: 
a.  Patient Education: Patient education is determined by the physical therapist and may 
include education in body mechanics/posture; bladder/bowel schedule; diet modification 
(caffeine reduction, carbonated beverage reduction, fluid management [increase or 
decrease water intake as appropriate], and/or fiber intake (increase or decrease fiber as 
appropriate);  relaxation techniques such as diaphragmatic breathing or progressive 
relaxation; SUI strategies (pelvic floor muscle contraction prior to activity that increases 
intra-abdominal pressure such as lifting or sneezing); UUI strategies (pelvic floor muscle 
contraction to decrease urgency and delay voiding); toilet strategies for constipation 
(appropriate toilet posture to promote bowel movement) and to void without straining; 
and soft tissue massage (abdominal massage for constipation, scar massage, or self-
stretching of the vaginal introitus). 
11 
 
b. Modalities: The following modalities may be included in the physical therapy plan of 
care:  biofeedback (to promote pelvic floor muscle strength and endurance, to increase 
pelvic floor muscle coordination, and/or to promote pelvic floor muscle relaxation) 
electrical stimulation (to improve pelvic floor muscle strength, to promote sensory 
awareness of the pelvic floor muscles, and/or to reduce pelvic pain), and heat/cold to 
reduce pelvic pain. 
c. Manual physical therapy procedures: Manual physical therapy procedures may include 
soft tissue mobilization to decrease soft tissue restrictions and improve range of motion; 
and joint mobilization to improve joint range of motion. 
d. Therapeutic exercises: Therapeutic exercises include PFM exercise to promote pelvic 
floor muscle strength, relaxation, and/or coordination (with manual intra-vaginal 
facilitation; in gravity eliminated or anti-gravity positions; or during functional tasks); 
trunk stabilization exercises to improve strength of the transverse abdominus, other 
abdominal muscles, multifidus, and/or to promote trunk stabilization during functional 
activities such as lifting; and flexibility exercises to increase mobility of the hip and/or 
lumbopelvic regions. 
2.  Patient-related characteristics with 8 sublevels:  Patient-related characteristics include 
age (years), parity (nulliparous or parous), race (Caucasian or non-Caucasian), number of 
comorbidities (0-8), carbonated beverage intake (> 1 per week or <1 per week), current 
smoking status (smoker or non-smoker), presence of barriers to intervention 
recommendations (none or ≥1), and number of physical therapy visits. 
 
 
12 
 
1.7 Dependent Variables 
The present study investigated three primary outcomes: 
1.  The post-intervention PGI-I score. 
2.  The difference between pre-intervention and post intervention values on the PFDI-20. 
3. The difference between pre-intervention and post intervention values on the PFIQ-7. 
As not all women represented in this study will experience bowel symptoms and/or 
sexual dysfunction, the present study also investigated two secondary outcomes: 
1. The difference between pre-intervention and post intervention values on the CSS. 
2. The difference between pre-intervention and post intervention values on the FSFI. 
 
1.8 Hypothesis 
Data collected for this study was used to test one specific hypothesis: 
Women with UI receiving pragmatic physical therapy management will attain treatment 
success. Treatment success is defined as a post-intervention PGI-I score of “much better” 
or “very much better;” a reduction in pelvic symptoms (reduction in PFDI-20, FSFI, and 
CSS scores at discharge) and improvement in health-related quality of life (reduction in 
PFIQ-7 at discharge). 
As the remaining study aims are descriptive in nature, no specific hypotheses for these 
aims are stated. 
13 
 
Chapter 2 
Review of Literature 
2.1 Introduction 
 Urinary incontinence (UI) is defined by the International Continence Society as a 
“involuntary loss of urine which is objectively demonstrable and a social or hygienic 
problem.”1  There are three main types of urinary incontinence – stress, urge, and mixed.   
Stress urinary incontinence (SUI) is the complaint of involuntary leakage on 
effort or exertion, or on sneezing or coughing.
1
   During effort or exertion, the intra-
abdominal pressure is raised and the urethral sphincter is unable to maintain a pressure 
higher than that exerted on the bladder.  Subsequently, urine leakage occurs during 
everyday activities such as lifting, laughing, jumping, sneezing, or coughing.  
Urge urinary incontinence (UUI) is the complaint of involuntary leakage 
accompanied by or immediately preceded by urgency.
1
  During bladder filling, the 
bladder contracts abnormally which creates a sensation to urinate that becomes 
progressively stronger, is very difficult to ignore, and ultimately results in urine leakage.  
UUI may be associated with overactive bladder syndrome (OAB).  OAB is a symptom 
syndrome denoting urgency, frequency, and nocturia, with or without UUI.
8
  
Urodynamically, OAB can be described as involuntary detrusor contractions during the 
filling phase.
9
 Literature investigating OAB with UUI is relevant in the discussion of UUI 
because OAB can produce contractions of the bladder that may contribute to UUI.  
Finally, mixed urinary incontinence is the complaint of involuntary leakage associated 
with urgency and also with exertion, effort, sneezing or coughing.
8
 UI affects 
14 
 
approximately 20 million people in the United States
2
 and the prevalence of UI in women 
ranges from 26-46%.
5, 54, 60, 82
  Of women reporting UI, women complain of mixed 
urinary incontinence most often (50-56%),
2, 83
 followed by SUI (33-27%)
2, 83
 and UUI (9-
13%).
2, 83
 In addition, women experience an age-related increase in prevalence of UI with 
67% of post-menopausal women reporting unintentional urine leakage.
59
   
 The economic costs of UI are substantial comprising over $16 billion per year in 
the United States.  Most of the cost is attributed to resources for UI management such as 
absorbent pads, protection, and laundry.
2
  Subak and colleagues reported that community-
dwelling women spend nearly $750 per year out of pocket for incontinence management.  
Nearly 85% of the women reported absorbent pad use, 50% of women reported additional 
loads of laundry due to UI, and 14% reported additional dry cleaning each week due to 
UI.
84
  Incontinence costs increase with more frequent UI episodes.
12, 13
 Those with severe 
and very severe incontinence encounter a 2-fold greater cost than women with slight 
incontinence.
82
  Moreover, women were willing to pay more for greater reduction in UI 
episode frequency
82, 84
 from a mean of $31 per month for 25% reduction, to $44 for 50% 
reduction, and $118 for 100% reduction.
84
   
 UI also leads to social isolation,
3
 poor self-rated health,
4
 decreased quality of life,
5
 
and depressive symptoms.
6
 Subak and colleague found women with UI scored 
substantially lower on the Health Utilities Index (mean score of 0.73)
84
 compared to the 
women aged 45 years and older with no chronic medical conditions (mean = 0.92).  The 
Health Utilities Index utility measures global health-related quality of life on a scale from 
-0.36 to 1.0, where -0.36 is the worst possible state, 0 is associated with death, and 1.0 is 
the best attainable health. 
85, 86
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 Fultz and colleagues asked community dwelling women with UI to indicate the 
degree to which they found their leakage to be bothersome on a scale of 1 to 5 where 1 is 
“not at all bothersome” and 5 is “extremely bothersome.”87  About half of the women 
were slightly bothered and 30% were moderately to extremely bothered by their 
symptoms.  Those that were moderately to extremely bothered reported that their UI had 
a negative impact on physical activity, confidence, daily activities, and social activities
87
 
indicating that UI affects more domains than simply health-related quality of life.  
Additionally, quality of life scores appear to diminish with increasing levels of UI 
frequency.  Ragins and colleagues demonstrated that an increase in UI frequency (e.g. 
from less than monthly to monthly incontinence, from weekly incontinence to daily 
incontinence) is significantly associated with a decrease in quality of life as reported on 
the SF-36 and Incontinence Impact Questionnaire in women aged 40-69.
88
 In addition, 
increased UI frequency has been shown to be associated with increased bothersomeness 
of symptoms.
5, 87
  Moreover, self-assessed health, sleep, fitness and satisfaction with 
work situation has been shown to decrease significantly with increased frequency of UI 
in women aged 20-59.
89
  
UI is an important problem faced by many women that affects their mental and 
physical well-being as well as their function in society.  Physical therapists have become 
involved in the clinical management of UI in women because the presumptive underlying 
impairments (i.e. decreased pelvic floor muscle strength and/or endurance, decreased 
awareness of bladder irritants) fall within the scope of physical therapy practice 
according to the Guide to Physical Therapist Practice.
7
  Consequently, there is a growing 
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need to understand how physical therapy interventions impact women’s UI symptoms, 
impairments, and functional limitations.  
 
2.2 Mechanism of UI 
2.2.1 Anatomic 
 The continence mechanism is embedded within the pelvic floor therefore, it is 
necessary to define the three layers (deep to superficial) of the pelvic floor structure: 
endopelvic fascia, levator ani muscle (LA), and the perineal membrane or external anal 
sphincter.
90
 The endopelvic fascia attaches the cervix and vagina to the pelvic wall on 
each side of the pelvis dividing the pelvis into an anterior and posterior compartment 
(Figure 2.1). This continuous sheet-like mesentery extends from the uterine artery 
superiorly to the point at which the vagina fuses with the LA below as well as fanning 
laterally.
91
 Subsequently, the fascia is intimately associated with the pelvic organs as well 
as the second layer of the pelvic floor, the LA.  The LA is a muscle made up of several 
smaller muscles that function as a group (Figure 2.2).
90
  The iliococcygeal and coccygeal 
portions form a horizontal shelf or hammock that spans from one pelvic sidewall to the 
other, attaching laterally to the ischial spines and arcus tendineus fascia.  The 
pubococcgeus arises from the pubic bone on either side and extends into a sling or U-
shape around the posterior rectum, attaching to the walls of the vagina, urethra, and 
rectum.
91
 The opening between the LA through which the urethra, vagina, and rectum 
pass is the urogenital hiatus.  The urogenital hiatus is supported by the pubic bones and 
LA anteriorly and by the perineal membrane and external anal sphincter posteriorly.
91
 
The perineal membrane is a dense triangular membrane located below the LA with a 
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central opening through which the vagina and urethra pass.
90, 91
 The final member of the 
third layer is the external anal sphincter. 
        
 
 
 The anatomy of the continence system can be organized into those structures that 
provide normal support to the lower urinary tract, and those that determine urethral 
closure force. The structures providing normal support include the 3 layers of the pelvic 
floor discussed previously. Structures that determine urethral closure force include the 
internal and external urethral sphincters and mucosal vasculature.
91
  The continence 
system works to maintain closure of the urethral lumen.  At the vesical neck, the lumen is 
held closed by the trigonal ring and detrusor loop muscles which are smooth, involuntary 
muscles controlled by alpha-adrenergic receptors of the sympathetic nervous system.  
  
Endopelvic Fascia 
Figure 2.1 Endopelvic fascia 
overlying Levator Ani 
 
Figure 2.2 Inferior to superior 
view of the pelvic floor 
musculature  
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During bladder storage, activation of the sympathetic nervous system increases the tonic 
activity or the internal urethral sphincter to assist in preventing urine leakage.  The 
external urethral sphincter encircles the urethra in its midportion and distally the fibers 
diverge to insert in the walls of the vagina and the perineal membrane.  The external 
urethral sphincter is constantly active promoting closure of the urethral lumen.
91
  
 
2.2.2 Neurophysiologic 
 Urinary continence is maintained by an intimate relationship involving anatomical 
support as well as neurophysiology.  The lower urinary tract is innervated by 3 sets of 
peripheral nerves: pelvic parasympathetic nerves (S2-S4 segments) which excite the 
bladder; lumbar sympathetic nerves which inhibit the bladder and excite the internal 
urethral sphincter; and the pudendal nerves which excite the external urethral sphincter 
and pelvic floor muscles.
92
  As the bladder fills with urine, there is little change in the 
intravesical pressure due to viscoelastic properties of the bladder smooth muscles.  As 
filling continues, the β-receptors in the body of the bladder (causing relaxation) and the 
α-receptors in the bladder neck (causing contraction) are stimulated. This sympathetic 
stimulation also inhibits the parasympathetic nerves to prevent excitation of the bladder. 
As bladder filling progresses, somatic discharge to the pudendal nerve increases. This 
leads to increased activity in the external urethral sphincter and effective urethral 
closure.
92
  
 Voiding is initiated by relaxation of the urethral sphincters followed by bladder 
contractions.  When the bladder contracts, there is decreased α-adrenergic stimulation of 
the bladder neck which promotes a funnel appearance of the bladder neck. The bladder 
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contraction is divided into 2 phases: a short, rapid rise in intravesical pressure and a 
second prolonged period of maintained pressure in which the bladder empties. Voiding 
involves coordination of parasympathetic efferent stimulation of the bladder, inhibition of 
sympathetic outflow, and inhibition of pudendal somatic outflow to the external urethral 
sphincter.
92
 
 
2.3 Pathophysiology of SUI 
 The main anatomic hypotheses for development of SUI include loss of structural 
support and the hammock hypothesis.
9
 Supportive structures to the bladder neck and 
urethra are necessary to maintain urethral closure pressure.  Intact attachments of the 
suburethral fascia to the fascia of the arcus tendineus and the LA construct the firm shelf 
that remains stable when faced with increased forces generated by a cough or sneeze.
90
 
Disruption to this shelf, such as weakness to LA or damage to fascial attachments could 
result in UI. Aging and childbirth injury are the main etiological factors for LA weakness.  
When the LA is weak, the urethra is shifted to a lower, more dependent position. Thus, 
increased intra-abdominal pressure during a cough or sneeze is then transmitted 
unequally to the bladder and urethra.  Greater pressure is absorbed by the bladder, 
bladder pressure exceeds urethral pressure, and urine leakage occurs.
9
  
In the hammock hypothesis, the position of the urethra remains constant but there 
is decreased compression of the pelvic floor muscles and fascia supporting the urethra.  
During anatomic dissection, DeLancey reported that the urethra lies on a supportive layer 
comprised of endopelvic fascia and the anterior vaginal wall.  Stability of the layer is 
gained via lateral attachment to the arcus tendineus fascia pelvis and levator ani muscle.  
20 
 
In an intact support system, intra-abdominal pressure pushes the urethra against the 
hammock-like supportive layer and the urethral lumen closes, not allowing urine to pass.  
However, if the supportive layer is not intact, the lumen will not close completely, 
resulting in urine leakage.
10
 
 The main neural hypothesis for development of SUI is pudendal nerve injury. The 
pudendal nerve innervates the external urethral sphincter. Injury to the nerve presumably 
causes denervation and dysfunction of the urethra including decreased urethral resistance 
and SUI.
9
 Damage to the pudendal nerve is associated with recent vaginal delivery and 
SUI.  In a study of  pregnant women, vaginal delivery resulted in prolonged pudendal 
nerve terminal motor latencies in 89/128 women.
93
  It has been suggested that pudendal 
nerve damage persists over time.  Significantly higher pudendal nerve terminal latencies 
have been observed in multiparous women with vaginal births both 48 hours and 5 years 
after delivery compared with nulliparous controls. Moreover, 35% of these women had 
developed SUI over the 5 year period.
94
  
 
2.4 Risk Factors for SUI 
2.4.1 Childbirth 
 Considering that loss of structural support is a main etiological factor in SUI, it is 
not surprising that parity is associated with SUI.  Waetjen and colleagues reported that 
childbearing women were nearly twice as likely to report SUI compared to nulliparous 
women (OR 1.91; 95% CI 1.31-2.79). 
54
 Minassian demonstrated that parity was a 
significant independent risk factor for moderate and severe SUI.  Women with moderate 
and severe SUI were 2.7 (adjusted OR 2.79; 95% CI 1.48-5.29 for moderate SUI and 
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adjusted  OR 2.74; 95% CI 1.41-5.31 for severe SUI) times more likely to report history 
of childbirth compared to women without incontinence.
48
  Furthermore, women who 
have delivered more than one child are at higher risk for SUI than women who delivered 
only one child.  Schytt and colleagues reported a higher risk for SUI in multiparous than 
in primiparous women  (RR 1.3; 95% CI 1.1-1.5).
53
  Similarly, Pregazzi and colleagues 
reported that the prevalence of SUI in multiparous women was significantly higher than 
primiparous women (20.25% versus 8.18%, P=0.0001).
51
   
Regarding mode of delivery, there is an increase risk for SUI with vaginal 
delivery, but a cesarean section does not completely protect against UI.  Schytt
53
 and 
Rortveit
95
 reported that women having a vaginal delivery were two times more likely to 
report SUI compared to those who delivered via cesarean section (RR 2.2; 95% CI 1.6-
3.1
53
 and OR 2.4; 95%  CI 1.7-3.2
95
 respectively).  However, in Rortveit’s and Schytt’s 
studies, 7% and 10% of the women who delivered by cesarean section reported SUI 
respectively.  The presence of SUI in the absence of the mechanical trauma of vaginal 
delivery suggests that other factors during pregnancy may contribute to the development 
of SUI and those with cesarean delivery are also at risk for SUI.  Borello-France reported 
that women who delivered by cesarean section had similar prevalence rates for SUI 
compared to those with vaginal births at both 6 weeks and 6 months post-partum.
12
 When 
compared to no deliveries, both vaginal deliveries and cesarean sections were associated 
with higher rates of SUI (OR 3.0; 95% CI 2.5-3.5 and OR 1.4; 95%  CI 1.0-2.0 
respectively) in the age-adjusted analysis of 15,307 women participating in the 
EPINCONT (Epidemiology of Incontinence in the Country of Nord-Trondelag) study.
51
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Consequently, it appears that women who have had vaginal deliveries or women who 
have had cesarean sections are at risk for SUI. 
 
2.4.2 Age 
 Although prevalence of any UI increases with age, the trend varies in regard to 
type of UI.  In a national survey of a representative sample of US women, Minassian, 
Walter, and Wood reported that prevalence of SUI peaked in the fifth decade of life and 
gradually decreased with older age in women.
48
  This is similar to Hannestad and 
colleagues who demonstrated that SUI symptoms were highest among women between 
25 and 49 years of age, with subsequent relative decrease with increasing age.
47
 
Minassian also investigated risk factors separately for women with mild, moderate, and 
severe UI, where severity was defined by frequency of incontinent episodes. For those 
with moderate SUI, age was a significant risk factor from age 40+.
48
 Hannestad reported 
that among those with severe SUI, severity increased with age from 10% of women aged 
25-44 reporting severe SUI compared to 15% and 33% reporting severe symptoms  in age 
groups 45-59 and 60+, respectively.
47
 
 
2.4.3 Decreased Collagen & Decreased Elasticity 
It is believed that dysfunction of connective tissue in the endopelvic fascia or pelvic 
ligaments may lead to loss of structural support of the pelvic organs, and subsequently 
SUI.   Connective tissue is comprised of collagen and elastin fibers, ground substance, 
and cellular substances.  Collagen primarily provides strength, but may also provide some 
flexibility due to collagen fiber arrangement. Elastin weaves in and out of the collagen 
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fibers and primarily provides flexibility.  Elastin fibers follow the direction of stretch in 
tissues and once the stretching force is removed, assume their original shape. 
 Investigators have demonstrated altered morphological features and decreased 
collagen content in women with SUI.  FitzGerald and colleagues demonstrated frequent 
alterations in the ultrastructural morphological characteristics of urethral collagen in 9 of 
the 15 women with SUI consenting to urethral needle biopsy specimens.
96
 The collagen 
patterns differed from those observed in continent women. Observations included an 
obscured pattern where collagen fibrils were difficult to visualize, a dense pattern in 
which collagen fibrils appeared to be collapsed on one another, and a degenerative 
pattern in which collagen fibrils were rare.
96
 Differences in cervical collagen between 
continent and incontinent women has also been reported. Wong and colleagues compared 
cervical collagen from women with pelvic organ prolapse with and without SUI (who 
underwent hysterectomy) to that from a control group.
97
 Women with pelvic organ 
prolapse with and without SUI were found to have significantly less cervical collagen 
than their unaffected counterparts.
97
   
 
2.4.4 Race/Ethnicity 
 The few studies that have compared the prevalence of UI in women of different 
ethnicities have demonstrated an increased risk for Caucasian women. Sampselle and 
colleagues reported that Caucasian women were more likely to report UI compared to 
African American, Chinese, Hispanic, and Japanese women in cross-sectional study of 
3302 women.
55
  Using prevalence in Caucasian women as the reference, women of other 
ethnicities were approximately two to three times less likely to report any incontinence. 
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When taking account subsets of UI, there appears to be a greater association between 
Caucasian race and SUI. After adjusting for age, BMI, parity, hormone replacement, 
smoking, and medical history, a cross-sectional study of 2875 women found that 
Caucasian women had an increased risk for SUI compared to African American 
women.
48
  Additionally, a study of 2763 postmenopausal women found that Caucasian 
women had a threefold greater prevalence of SUI than postmenopausal black women (OR 
2.9, 95% CI 1.6-5.0).
59
 
 
2.4.5 Obesity 
 Many studies have found that obesity is associated with increasing rates of SUI. 
In a study of postmenopausal women, Brown and colleagues reported that a higher body 
mass index (OR 1.1 per 5 units; CI 1.01-1.27) was associated with increased prevalence 
of SUI.
59
 Additional studies, cross-sectional and longitudinal, have demonstrated an 
association with obesity and SUI. In a large study of 12570 women, women who were 
overweight (BMI >25-30) or obese (BMI >30) had a significantly higher risk for SUI 
(OR 1.2; 95% CI 1.0-1.5 and OR 1.7; 95% CI 1.4-2.1 respectively).  Women who had an 
acceptable BMI at baseline but became obese one year later were 2.3 times more likely to 
develop SUI.
50
  Similarly, a 1-yr longitudinal study of 7046 UK women found, those who 
became obese (BMI >30) in 1-yr were 1.74 times more likely to develop have SUI than 
those with acceptable weight.
57
  Interestingly, this study also found the absence of self-
reported BMI a significant risk factor for the onset of SUI.
57
  
A link between obesity and SUI symptom severity has also been reported. After 
adjusting for age, ethnicity, parity, hormone replacement, smoking, and medical history, 
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women who were obese were nearly twice as likely to have moderate SUI (adjusted OR 
1.93; 95% CI 1.06-3.51) and over 4 times as likely to have severe SUI (OR 4.22; 95% CI 
2.28-7.81) compared to women of normal body mass index.
48
  
 
2.4.6 Smoking, Chronic Cough, Respiratory Disease 
 It is postulated that respiratory disease, chronic coughing, and smoking may cause 
damage to the urethral and bladder supportive structures, causing UI. Two large 
epidemiologic studies have demonstrated that older women with chronic obstructive 
pulmonary disease
98
 and respiratory symptoms (coughing and sneezing)
60
 have a 
significantly higher risk for UI. This association has also been described in younger 
women, specifically in regard to SUI.  After controlling for age, parity, menopausal 
status, waist circumference, medical history, and surgeries, Zhu and colleagues reported 
that history of respiratory disease was a significant risk factor for SUI (OR 1.34; 95% CI 
1.03-1.75) in younger women (mean age = 45yrs).
61
  Additionally, a prospective cohort 
study of older women (mean age of 59.5) found breathlessness significantly associated 
with prevalent SUI (OR 1.4; 95% CI 1.1-1.9).
50
 
 
2.4.7 Pelvic Surgery 
 The prevalence of women with pelvic surgery is significantly higher in women 
with UI compared to continent women.
60
 An association between pelvic surgery and SUI 
is not surprising based on the premise that surgical insult to the pelvis may decrease 
pelvic organ support. Pelvic surgery may include procedures such as hysterectomy, 
radical pelvic surgery, vaginal surgery, perineal trauma surgery, or radiation.
62
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Hysterectomy may or may not be associated specifically with SUI.  Minassian reported 
that a history of hysterectomy was independent risk factor for severe SUI (OR 1.90, CI 
1.07-3.37) in women (mean age = 50.8 years).
48
 However, van der Vaart and colleagues 
found an association between hysterectomy and prevalence and incidence of UUI, not 
SUI.
63
  Exposure to pelvic surgery regardless of type of surgery may increase risk for 
developing SUI. After controlling for age, parity, menopausal status, waist 
circumference, medical history, and gynecological events, women with pelvic surgery 
were at significantly higher risk for SUI (OR 1.28; 95% CI 1.14-1.43) compared to those 
without pelvic surgery.
61
  
 
2.4.8 Chronic Constipation 
 Constipation has been linked as a possible etiological cause of SUI.  In those with 
chronic constipation, prolonged defecatory straining has been shown to contribute to 
progressive neuropathy and dysfunction.
46
  Diokno and colleagues reported that older 
women, aged 60-80+, with UI were significantly more likely to have constipation than 
women without UI.
60
  Specifically, it appears that constipation may be more of a risk for 
SUI. In a cohort study of 2390 parous women, those with post-partum constipation were 
more likely to have SUI 1 year after childbirth.
53
 Moreover, in a large cross-sectional 
survey of 20,000 Chinese women, women with chronic constipation were at significantly 
higher risk for SUI (OR 1.17; 95% CI 1.02-1.34) after controlling for age, parity, 
menopausal status, waist circumference, medical history, and surgeries.
61
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2.4.9 Carbonated Drinks 
 In a study of 7046 women, (median age = 58), those who drank carbonated drinks 
daily or more were significantly more likely to have SUI than those who drank them less 
than once per week.  Women drinking carbonated drinks daily or more had a 2-fold 
increased risk for prevalent SUI (OR 2.10; 95% CI 1.57-2.81); and a 60% increased risk 
(OR 1.62; 95% CI 1.18-2.22) for developing SUI at the 1-year follow-up.
57
 
 
2.5 Pathophysiology of OAB and UUI 
 OAB is considered a symptom syndrome characterized as urgency with or 
without urge incontinence, as well as frequency and nocturia.
27
  Urodynamically, OAB is 
defined as involuntary detrusor contractions during the filling phase.
9
  There are two 
main pathological etiologies of OAB: neurogenic and non-neurogenic causes.  
Neurogenic OAB is associated with the effects on neurologic control by a variety of 
conditions including spinal cord injury, stroke, Parkinson’s disease, Alzheimer disease, 
diabetes, spinal stenosis, and multiple sclerosis or similar demyelinating disease.
27
  Non-
neurogenic causes of OAB  include infection, interstitial cystitis, urolithiasis, bladder and 
urethral changes associated with age, bladder outlet obstruction, and pelvic floor 
disorders.
9
  
The bladder itself undergoes structural changes with age that may contribute to 
overactivity.
9
  Elbadawi, Yalla, and Resnick examined detrusor biopsy specimens by 
electron microscopy from women and men ages 65-96 years. They found structural 
changes associated with age, including excessive deposits of elastic fibers between 
widely separated muscle cells which may contribute to increased bladder distensibility 
28 
 
and chronic retention.
28
   Additionally, older women have decreased urethral closure 
pressure and urogenital atrophy. DuBeau proposed that the decrease in number and 
density of urethral striated muscle fibers with age may contribute to OAB.
99
   
Bladder outlet obstruction in women is due to advanced prolapse or increased 
outflow resistance following continence surgery.  Ultimately, the outlet obstruction 
affects neurological activity by increasing the sensitivity of the detrusor muscle to 
acetylcholine, which binds to detrusor muscle cells to facilitate detrusor contraction.  
Subsequently, the detrusor is in a highly-excitable state resulting in involuntary detrusor 
contractions.
9
  Finally, there is an inverse relationship between activation of the pelvic 
floor muscles and the detrusor.  Afferent activity from the pelvic floor muscles and the 
urethra causes quieting of the detrusor during bladder filling.  If afferent activity is 
decreased due to pelvic floor muscle laxity, detrusor contractions may result.
9
  
 
2.6 Risk Factors for OAB 
2.6.1 Age 
 Epidemiological studies have reported an association between age and OAB. 
After adjusting for ethnicity, body mass index, medical history, parity, and smoking, age 
has been shown to be a significant independent risk factor for women with UUI.
48
  In a 
large cohort study of 12,570 women, those with OAB were more likely to be older (OR 
1.1; 95% CI 1.0, 1.2); 
50
 and for every 10-year increase in a woman’s age, the risk for 
developing OAB increased by 1.2 (OR 1.2; 95%  CI 1.1, 1.3).
50
 A different study 
reported that for every 5-year increase in age, a postmenopausal woman has a 1.2 
increased risk for onset UUI (OR 1.2, 95% CI 1.1-1.3).
59
 Moreover, the severity of UUI 
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appears to increase with age.  Hannestad reported that among women with severe UUI,  
8% were 25-44 years of age,18% were 45-59 years of age, and 45% 60+years of age.
47
 
 
2.6.2 Hysterectomy 
 According to a systematic review by Brown and colleagues, the odds of 
developing any UI after hysterectomy is about 40% higher compared to women who have 
not undergone hysterectomy.
100
 The literature is unclear as to whether there is a direct 
connection between hysterectomy and SUI, as SUI appears to be linked to pelvic 
surgeries and not specifically hysterectomy.  (See section 2.4.7).  However, an 
association exists between hysterectomy and UUI.  In a cross-sectional study of 2,322 
women aged 35-70, women with a hysterectomy reported a significantly higher rate of 
any UUI as well as bothersome UUI (P<0.0001) compared to those not having a 
hysterectomy.  After adjusting for age, parity, and educational level, women with a 
hysterectomy had nearly a 2-fold higher risk for any UUI (OR 1.93; 95%CI 1.40-2.63) 
and over a 2.5-fold risk for bothersome UUI (OR 2.63; 95%CI 1.39-4.41) compared to 
those without a hysterectomy.
63
   
 
2.6.3 Neurological conditions 
 Women with neurological conditions also have an increased risk for UI as certain 
neurological disorders interfere with the normal tonic inhibitory pathways controlling 
micturition.
9
  Specific neurological conditions that may interfere with these pathways 
include stroke, Parkinson’s, brain tumors, traumatic brain injury, Alzheimer’s dementia, 
cerebral palsy, and multiple sclerosis.
9
  Diokno  and colleagues demonstrated that the 
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percentage of women, aged 60 to 80+, with diseases of nerves and/or muscles was 
significantly higher in women with UI compared to continent women.
60
    
 Specifically, bladder dysfunction is a very common problem in those with 
multiple sclerosis (MS), with as high as 84% of persons with MS reporting bladder 
symptoms.
101
 The most common underlying bladder abnormality in persons with MS is 
neurogenic detrusor overactivity, affecting 37-99% of those with bladder dysfunction.
102
  
Neurogenic detrusor overactivity refers to a voiding dysfunction due to neurologic 
damage from trauma or disease.  Irritative symptoms associated with neurogenic detrusor 
overactivity include urgency to urinate, frequent urination, nocturia, and urge 
incontinence.  Patients with MS may also demonstrate detrusor-sphincter dyssynergia in 
which there is incomplete bladder emptying because the external urethral sphincter does 
not relax during detrusor contraction.  Patients with detrusor-sphincter dyssynergia 
experience obstructive voiding symptoms of urinary hesitancy and interrupted urinary 
flow as well as urinary retention.
103, 104
 Obstructive symptoms affect between 34-79% of 
patients with MS.
102
  Additionally, approximately 51% of women with MS experience 
both detrusor overactivity and detrusor-sphincter dyssynergia demonstrating symptoms 
both of failure to store and failure to empty.
102
  
 
2.6.4 Caffeine & Carbonated Drinks 
 Arya, Myers, and Jackson reported an association between high caffeine intake 
and OAB.
56
  Women with urodynamically confirmed OAB consumed significantly more 
caffeine (484 mg/day) than women without OAB (194 mg/day, p=0.002).  After 
controlling for age and smoking, women with high caffeine intake (> 400 mg/day) were 
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2.4 times (OR 2.4, 95% CI 1.1-6.5) more likely to have OAB than women with minimal 
caffeine intake (<100 mg/day).
56
  To put the amount of caffeine in perspective, a 5 ounce 
cup of brewed coffee with caffeine has 128 mg, a 8-oz glass of iced tea has 47 mg of 
caffeine, and a 8-oz glass of cola soft drink has 25 mg.
56
   
 Women consuming just 2-6 carbonated beverages per week are at increased risk 
for OAB.  When examining the impact of carbonated beverages alone, Dallosso and 
colleagues found that women who consumed 2-6 carbonated beverages per week had 
nearly a 50% increased risk for onset OAB (OR 1.44; 95% CI 1.12-1.85) compared to 
those consuming less than one beverage per week. Risk increased to 70% for women 
consuming at least one carbonated beverage daily.  When considering carbonated 
beverages along with other potential risk factors, women consuming at least one 
carbonated beverage daily increased their risk for onset OAB 1.4 times (OR 1.41; 95% CI 
1.02-1.95) compared to those drinking less than one such beverage per week.
57
 
 
2.6.5 Lifestyle Habits: Smoking and Obesity 
 Women who smoke are also at higher risk for OAB.  Data suggests that women 
with urodynamically diagnosed OAB were significantly more likely to be current 
smokers compared to those without OAB (p<0.04).  Those who were current smokers 
were nearly twice (OR 1.9; CI 1.0-3.8) as likely to demonstrate OAB compared to those 
that never smoked.
56
 Similarly, Dallosso and colleagues reported that current smokers 
were 1.44 times more likely to develop OAB than nonsmokers (OR 1.44, 95% CI 1.05-
1.98).
57
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Obesity is significantly associated with an increased risk of OAB. Women that are 
obese have a significantly increased risk of onset OAB (OR 1.46, 95% CI 1.02-2.09) 
compared to those who are of acceptable weight.
57
  Waetjen and colleagues reported that 
an increased body mass index was a significant risk factor for prevalent and incident 
UUI.  For every unit increase in BMI, the prevalent and incident risk was 1.03 (adjusted 
OR 1.03; 95% CI 1.00-1.60).
54
 
 
2.6.6 Functional Status: Decreased mobility, decreased ADLS, & Arthritis 
 Mobility issues vary significantly between incontinent and continent elderly 
women.
60
 Goode and colleagues investigated risk factors for UI over a 3 year period in 
older women (mean age = 75 years).
105
 Participants completed an in-home interview and 
in-home physical tests. Women with a slower time for 5 chair stands were at a 
significantly higher risk (OR 1.3; 95% CI 1.0-1.6) for developing UI.
105
   The status of 
mobility may possibly impact women with UUI more than SUI. In another study, older 
women (aged 60 to 80+) with UUI reported more assistive device use (wheelchair, cane, 
crutches, or walker) compared to those with SUI or mixed UI. 
60
 
 Logically, co-morbidities affecting mobility may also have in impact on 
continence status. Diokno and colleagues demonstrated that the percentage of women, 
aged 60 to 80+, with a medical diagnosis of arthritis was significantly higher in women 
with UI compared to continent women.
60
 With respect to type of UI, arthritis may have 
more of an association on UUI than SUI. In a study of women with a median age of 50.8 
years, those who reported having arthritis were 2.32 times (adjusted OR 2.32; 95% CI 
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1.17-4.63) more likely to report severe UUI compared to women without incontinence. 
Such an increased risk was not apparent for SUI.
48
 
 
2.7 Non-specific risk factors for UI 
2.7.1 Pelvic Organ Prolapse 
Pelvic organ prolapse (POP) is defined as the descent of  the apex of the vagina or cervix 
(or vaginal vault after hysterectomy), anterior vaginal wall, or posterior vaginal wall; and 
can occur in association with UI.
1
 As the prolapse advances, organs can protrude outside 
the vaginal canal. Women with POP may describe a feeling of a lump, low backache, 
heaviness, dragging sensation, or the need to digitally replace the prolapse to void or 
defecate.
1
  The inter-relation between POP and pelvic floor symptoms can be generally 
explained by the following scenarios:
106
 
1. POP is the direct cause of the symptom (i.e. vaginal bulging, pelvic pressure). 
2. Loss of vaginal support contributes dysfunction of nearby organs (i.e. SUI in 
women with anterior vaginal prolapse). 
3. A common pathogenic mechanism is shared by POP and the condition causing the 
symptoms (i.e. muscular injury and pelvic floor denervation after vaginal delivery 
as a cause of prolapse and fecal incontinence). 
4. The symptom is a contributor to the development of POP (i.e. chronic straining to 
defecate). 
5. There is no causal relationship between vaginal prolapse and the condition 
causing the symptoms, but both conditions are common and are seen together in a 
subset of women (i.e. chronic low back pain).  
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 Normal pelvic organ support depends upon the integrity of the LA, supportive 
connective tissue (endopelvic fascia), and normal innervations.
91
 If the LA functions 
normally, the urogenital hiatus narrows and the connective tissue is under minimal 
tension, able to stabilize the organs in their position above the LA.   If the LA relaxes or 
is damaged, the urogenital hiatus opens and the vagina must be held in place by the 
fascia.  Although the fascia can sustain the load for short periods of time, the connective 
tissue eventually fails, resulting in prolaspe.
91
  Loss of connective tissue support
107
 and/or 
LA function
91
 have been proposed as mechanisms for POP.  
 Urinary symptoms are common among women with POP.  The anterior vaginal 
wall supports the bladder and urethra and loss of this support may lead to urethral 
hypermobility which may contribute to SUI.
106
  Mechanical obstruction of the urethra 
may contribute to UUI; and the obstruction may be due to either anterior or posterior 
vaginal prolapse. Anterior vaginal prolapse may cause the urethra to kink, while posterior 
vaginal prolapse may cause direct urethral compression rather than kinking.
106
  Over 
time, the obstruction may result in structural changes of the bladder or urethra leading to 
OAB.
9
  Typically, when the prolapse is mild, SUI coexists.  Conversely, when the 
prolapse extends beyond the hymen, women are less likely to report SUI but more likely 
to report UUI as the prolapse is obstructing the urethra. In a study of 237 women with 
symptomatic POP, a significant inverse correlation was observed between the severity of 
prolapse and SUI. Additionally, as prolapse worsened, direct correlations were noted with 
symptoms indicative of UUI including hesitancy, intermittent flow, and difficulty 
voiding.
30
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 2.7.2 Medications 
 Older women are more likely to take medications that may cause UI. 
Approximately 60% of older men and women take at least one prescribed medication. 
About one third of older adults take more than five prescribed medications, and many 
also take over-the-counter and naturopathic/herbal drugs.
99
  Medication that affects 
cognition, mobility, fluid balance, coughing, detrusor contractility, or sphincter function 
can impair continence. Several medications are associated with UI in women including: 
diuretics, estrogen, benzodiazepine, tranquilizers, antidepressants, hypnotics, laxatives, 
and antibiotics.
108
  Medications may impair detrusor contractility (anticholinergics, 
narcotics, calcium channel blockers, nonsteroidal anti-inflammatory agents), cause 
urinary retention (anticholinergics, narcotics, calcium channel blockers), or promote 
nocturia from pedal edema (calcium channel blockers, gabapentin and pregabalin, 
thiazolidinediones, nonsteroidal anti-inflammatory agents).
99
  
 Medications that may promote SUI symptoms include ACE inhibitors and α-
blockers. ACE inhibitors may cause excessive coughing, while α-blockers can cause 
sphincter relaxation.  Medications that may lead to UUI symptoms include: β-blockers, 
which irritate the bladder; cholinergics and diuretics which promote high urine flow; and 
sedatives-hypnotics, antipsychotics, narcotics, and alcohol, which depress the central 
nervous systsm.
62
 
 
2.7.3 Fluid Intake 
 The amount, timing, and type of beverages consumed my increase a woman’s risk 
for UI.  Some women believe that drinking excessive amounts of water will promote 
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health and weight loss. Unfortunately, this behavior may lead to polyuria and 
exacerbation of urinary frequency and urgency. Other women may limit fluid intake to 
decrease their bladder symptoms.
62
  Yet, dehydration leads to concentrated urine within 
the bladder and low urine production.  Low urine volume will limit bladder expansion, 
and over a period of time can lead to reduced bladder capacity, decreased detrusor tone, 
and increased bladder wall thickness.
109
  These structural changes may contribute to 
further continence problems.  Additionally, low fluid intake may contribute to urinary 
tract infection and fecal impaction which may irritate the detrusor causing urgency and 
frequency. Concentrated urine can aggravate the bladder mucosa and trigone and lead to 
urgency and frequency.  It is recommended that patients avoid extreme fluid intake. 
Instead it is recommend that adults consume 30mL per kg of body weight (or  0.5 oz  per 
lb of body weight).
62
   
The timing of fluid intake is crucial for women with nocturia.  Nocturia is the 
complaint of waking at night one or more times to void.
1
 It affects up to 90% of older 
women by age 80.
99
  Older women have delayed fluid excretion, and tend to void later in 
the day, evening, and night.
110
 50% or more of their 24-hour urine output may occur 
during the night.
99
 Subsequently, women consuming most of their fluids later in the day 
may be more prone to UI episodes in the evening or night.  Regarding type of fluid, 
carbonated drinks increase the risk of SUI
57
 and OAB,
57
 while caffeine increases the risk 
for OAB.
56
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2.7.4 Fecal Incontinence 
 Women with fecal incontinence (FI) are at a higher risk for UI.  When controlled 
for age, parity, antidepressant use, and previous  hysterectomy, FI has been shown to be 
independently associated with UI (OR 6.3; 95% CI 2.6-19.1) in women with POP or UI.
33
  
Markland and colleagues demonstrated that in overweight and obese women (mean age = 
53 years), FI was independently associated with increased urinary tract symptoms.
32
 
Conversely, women having more frequent UUI symptoms have increased risk (OR 1.2; 
95% CI 1.0-1.3) of FI.
64
 Women with both FI and UUI scored significantly lower on the 
Urinary Distress Inventory compared to women who have isolated UUI
64
 indicating 
greater symptom impact. This finding gives strength to the presumption that dual 
incontinence may have more impact on urinary distress than having UI alone. 
 
2.7.5 Pelvic Pain  
 According to the American College of Obstetricians and Gynecologists, chronic 
pelvic pain (CPP) is a descriptive diagnosis that refers to pain of 6 months or more that is 
localized to the anatomic pelvis, anterior abdominal wall at or below the umbilicus, the 
lumbosacral back, or the buttocks and is of sufficient severity to cause functional 
disability or lead to medical care.
111
  After controlling for age, parity, alcohol 
consumption, waist circumference, constipation, menopausal status, and medical history, 
chronic pelvic pain was found a significant risk factor (OR 1.53; 95% CI 1.36-1.72) for 
SUI in a large cross-sectional survey of 20,000 Chinese women.
61
  In a smaller cross-
sectional survey (319 Iranian women, mean age = 33.8), women with pelvic pain reported 
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statistically significant higher rates of SUI and OAB symptoms (urgency, frequency) than 
women without pelvic pain.
66
 
 
2.8 Co-existing pelvic symptoms 
2.8.1 Dual Incontinence and Pelvic Organ Prolapse (POP) 
 A varying proportion of women will experience UI, FI, and/or POP.  Jackson and 
colleagues found that among 247 women with either UI or POP,  coexisting FI occurred 
in 31%  and 7%  of those UI and with POP, respectively.
31
  Ellerkmann and co-workers 
reported that 86% of women with POP had urinary urgency and frequency, while 31%  
reported co-existing FI.
30
  Finally, Markland reported that  presence of dual incontinence 
(UI and FI) was 18% in women (mean age = 57) participating in a treatment study for 
UUI.
64
 
 The rationale for why pelvic symptoms co-exist is complex.  These conditions are 
associated with damage to the pelvic floor either through mechanical disruption of 
connective tissue, or through direct and secondary muscle or nerve injury.  Because the 
conditions share common etiologies, they also share many common risk factors.
46
 
Vaginal delivery, POP, higher body mass index, and UUI symptoms have been reported 
as significant risk factors for dual incontinence (DI).
64
  Ng and colleagues reported 
similar findings, identifying vaginal delivery, POP, and urinary symptoms to be 
predictors of FI in women (mean age 45) with SUI, OAB, or mixed incontinence. 
Difficulties in ADLS, depressive symptoms, chronic diarrhea, and higher co morbidity 
scores have been correlated with DI older women.
112
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2.8.2 Constipation 
 Prevalence rates of constipation in women with urinary symptoms are much 
higher than in the general population, with typical U.S prevalence rates ranging from 15-
19%.
113, 114
   In a study of 302 women (mean age = 60 yrs)  with either POP or UI, 36% 
had constipation as defined by the Rome II criteria, a symptom-based questionnaire 
developed by clinical consensus.
33
 Similarly, Ng and colleagues reported  31.5% of 
women with SUI or OAB (mean age= 45 yrs) experienced co-existing constipation 
defined as ≤3 bowel movements per week.34   The literature linking constipation as a co-
existing symptom is based on the premise that straining during defecation may lead to 
pudendal nerve damage and subsequent denervation of the pelvic floor.  Such etiologies 
have also been implicated in UI, FI, and POP.
46
 
 
2.8.3 Sexual Dysfunction 
 Women with UI or lower urinary tract symptoms (LUTS) have a higher rate of 
sexual dysfunction compared to the general, healthy female population without urinary 
symptoms.
115
 Women aged 19-66 years with UI or LUTS have been found to score lower 
on the Female Sexual Function Index when compared to healthy controls.  Specifically, 
women with UI or LUTS had lower scores for items assessing sexual desire, lubrication, 
and sexual satisfaction as well as significantly higher scores for sexual pain.
115
  
Moreover, in a large national survey of  1749 women aged 18-59 years, those with 
urinary tract symptoms had a 4-fold higher risk for sexual arousal dysfunction (OR 4.20; 
95% CI 2.75-5.89) and a 7-fold risk for sexual pain with intercourse (OR 7.61; 95% CI 
4.06-14.26) after adjusting for health and lifestyle factors, social status, and sexual 
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experience.
35
  Pain with sexual intercourse, termed dyspareunia, can be classified as a 
subset of chronic pelvic pain provided that the patient has symptoms for ≥6 months.   
 
2.8.4 Chronic Pelvic Pain 
 In women, several causes of chronic pelvic pain (CPP) are recognized, and many 
disorders of the reproductive tract, urological organs, and gastrointestinal, 
musculoskeletal, and psychological systems may be associated with CPP.  The most 
frequent causes of CPP include  interstitial cystitis,
116-118
 irritable bowel syndrome,
116, 117
 
post-operative adhesions,
117
 pelvic varices,
117
 vulvodynia
116, 118
 and musculoskeletal 
issues.
118
  There is controversy whether to include endometriosis as a cause of CPP as 
most consider endometriosis to be its own entity.
117
  Endometriosis is the presence of 
extrauterine endometrial tissue and usually presents with symptoms concurrent with the 
menstrual cycle.
116
 This condition affects other organ systems causing bowel motility 
issues, bladder dysfunction, and pain. Unlike other causes of CPP, endometriosis can be 
treated effectively with drugs, surgery, or both.
117
 
 
2.8.4.1 Sources of CPP 
Interstitial cystitis:  According to the National Institute of Diabetes, Digestive and Kidney 
diseases, interstitial cystitis is pain, pressure, or discomfort of the bladder and the 
surrounding pelvic region. Symptoms include urinary urgency and/or urinary frequency 
in addition to pressure, discomfort, or tenderness in the bladder area.
119
  The National 
Institute of Diabetes, Digestive and Kidney diseases research-related definition of 
interstitial cystitis has inclusion and exclusion criteria based on cystoscopic, urodynamic, 
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and other laboratory tests.
116
  Because of this strict definition, there is acknowledgement 
of a more generic painful bladder syndrome which simply refers to painful urinary 
symptoms. In interstitial cystitis/painful bladder syndrome, the bladder wall may become 
irritated causing scarring and glomerulations.  People with severe cases of interstitial 
cystitis/painful bladder syndrome may urinate up to 60 times a day and complain of 
nocturia.
119
  In addition, about 10-15% of patients with interstitial cystitis/painful bladder 
syndrome have OAB.
117
 
Irritable bowel syndrome:  Irritable bowel syndrome is a disorder in which abdominal 
discomfort or pain is associated with defecation or altered bowel habits.  Approximately 
35% of women with CPP have irritable bowel syndrome.
120
  The diagnosis is based upon 
the Rome II criteria. The patient must experience over the past 12 weeks abdominal 
discomfort or pain that has at least two out of the three following features:  relieved with 
defecation, onset associated with a change in frequency of stool, and/or onset associated 
with a change in form (appearance) of stool.
121
  The suggested etiology of irritable bowel 
syndrome includes altered bowel motility, visceral hypersensitivity, and psychological 
factors.  Pain may be produced from the visceral hypersensitivity of the intestinal wall 
and/or degranulation of activated mast cells
117
 whose contents aggravates nociceptors via 
the inflammatory response.  Additionally, the overdistention of the colon wall by bowel 
content and gas may stimulate stretch receptors.
117
 
Post-operative adhesions:  Adhesions in the pelvis may be caused by acute or chronic 
inflammatory disorders (i.e. tubo-ovarian infections and enometriosis) or a physico-
chemical trauma such as surgery.  The role of adhesions in CPP is controversial and 
although adhesions are found in 25-50% of women with CPP, it is unclear whether the 
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association is causal.  It has been postulated that intraperitoneal adhesions may cause pain 
with activities such as running or sexual intercourse due to the stretching of the 
peritoneum or visceral serosa at the adhesion’s attachment site. When the peritoneum is 
compressed or stretched, nociceptors in the adhesion become activated potentially 
signaling pain.  However, although adhesions contain nerve fibers, the presence of nerve 
fibers alone is not evidence of a causative role as pain perception requires a complex 
linking network.
117
 
Pelvic varices:
117
  Pelvic congestion syndrome is a myriad of pain symptoms associated 
with presence of ovarian and pelvic (internal iliac) varices and result in decreased 
function of the venous system.  The pain related to pelvic congestion syndrome is 
possibly due to pelvic congestion, leading to dilation and stasis that aggravate the local 
inflammatory response.  The etiology of pelvic congestion syndrome is unknown but it is 
hypothesized that psychological, sexual, and genetic-biological factors may be related. 
Approximately 30% of patients with CPP have pelvic varices as the source of their CPP, 
and an additional 12% have pelvic varices in addition to other pelvic pathologies.
117
  
Patients with pelvic varices as the source of their CPP complain of a changing location of 
pain, congestive dysmenorrhea, deep dysparenia and post-coital pain, and a dull chronic 
pain exacerbated after activities of pelvic engorgement including prolonged standing and 
working for many hours in a sitting position.
117
  
Vulvodynia:  The International Society for the Study of Vulvar Disease defines 
vulvodynia as “chronic rawness, irritation, burning and soreness in the absence of 
abnormal finding except redness at times.”122 Two broad categories exist for further 
defining this condition:  secondary and primary vulvodynia.  Secondary vulvodynia is 
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pain that is due to an observable vulvar or vaginal lesion and include dermatological 
conditions which cause inflammation, ulceration, blisters, fissures and adhesions, and 
conditions that cause vaginitis. Primary vulvodynia is pain that is experienced in the 
absence of any observable vulvar pathology and may include neuropathic pain, referred 
pain, and introital dyspareunia in patients with a normal vulva.
123
  Women with 
vulvodynia may experience allodynia or hyperalgesia in conjunction with the symptoms 
of rawness, irritation, and burning. In women with neuropathic pain, it is postulated that 
injury to sensory nerves to the vulva (ilioinguinal and genitofemoral from L1-2) or to the 
pudendal nerve is the source of the condition.  In women with referred pain to the vulva, 
it is postulated that the low back or bladder may be the primary source of the dysfunction.  
Additionally, women with vulvodynia may complain of frequency, urgency, and burning 
on urination due to alterations of sensation to nearby viscera.
123
   
Musculoskeletal issues 
Trigger points: CPP can be due to the presence of active myofascial triggers points in the 
external and internal muscles of the pelvic region. Trigger points are focal points of 
tenderness found at multiple sites in a muscle and the fascia of muscle tissue.
124
  Trigger 
points typically have a clear and consistent referred pain pattern; arise in response to 
acute or chronic overload; cause increased muscle tension, weakness, and limited range 
of motion; and disrupt the proprioceptive, nociceptive, and autonomic functions of the 
affected areas.
124
 Trigger points in the anterior pelvis may refer pain to the vagina and 
can cause entry dyspareunia and pain in the perineal region.  Trigger points in the deeper 
pelvic muscles (LA, obturator internus) can affect bladder and bowel function.
124
  By 
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manually releasing trigger points in the pelvic floor muscles in patients with severe 
urinary urgency and frequency, Weiss reported an 83% reduction in symptoms.
125
 
Pelvic floor muscle dysfunction:  Pelvic floor muscle dysfunction refers to hypotonicity 
or hypertonicity of the pelvic floor muscles (LA and coccygeus). Hypotonus dyfunction 
may be due to hormonal factors, mechanical damage, weakness and are generally 
associated with UI, FI, and POP.
46
  Bernstein demonstrated that women with urinary 
symptoms and subpubic pain had significantly less pelvic floor muscle activity when 
asked to contract their pelvic floor muscles compared to controls.
126
 This suggests that 
hypotonus of the pelvic floor muscles may play a role in pelvic pain.  More commonly, 
hypertonus or spasm of the pelvic floor muscles may contribute to CPP and has been 
implicated in interstitial cystitis,
125, 127
 dyspareunia,
128
 severe urgency and frequency 
with/without urethral pain,
125
  and vulvodynia.
123
 Women with interstitial cystitis and 
hypertonicity of the pelvic floor muscles who underwent physical therapy consisting of 
intravaginal massages using the Thiele technique reported significantly decreased 
symptoms, improved quality of life, and significantly decreased pelvic floor muscle 
hypertonicity when compared to pre-treatment scores.
127
 Similarly, 10 women with 
interstitial cystitis who received  Thiele massage to hypertonic pelvic floor muscles 
demonstrated post-treatment decreased pelvic floor muscle tone  as measured by surface 
electromyography.
125
  Although it is acknowledged that intravaginal palpation and 
surface electromyography are not the gold standard for measuring muscle tone, such 
investigations shed light that pelvic floor tone may play a crucial role in the 
pathophysiology of CPP. The relationship between hypertonicity and pain is not 
completely understood. In response to pain, a muscle may contract or guard to protect 
45 
 
against further injury thus contributing to the pain-spasm-pain cycle.  Persistent muscle 
overactivity can lead to excessive activity of gamma efferent neurons (gamma gain) 
which may cause muscle spindles to become hyperactive and lead to adaptive shortening 
of surrounding fascial tissue.
129
  Thus, pelvic floor muscle dysfunction may be primary or 
secondary generators of nociceptive signals. Although their role is not clearly defined as 
causal, it is evident the PFM dysfunction should be considered when treating patients 
with CPP. 
Low back pain:  Low back pain (LBP) can be considered part of CPP if, according to the 
CPP definition, it is greater than 6 months in duration and of sufficient severity to cause 
functional disability or lead to medical care.  Additionally, low back pathology can refer 
pain to the pelvic floor and should be considered in differential diagnosis of CPP.
130
  
Eliasson reported an association of LBP and UI.
67
  In a cross-sectional study of 200 non-
pregnant women seeking physical therapy for LBP, those with LBP reported significantly 
more UI (p<0.001) and more severe UI (p<0.001) than a reference group of women 
without LBP of comparable age and parity.  Additionally, women with LBP were 3 times 
more likely to have UI compared to the reference group (nulliparous OR 3.1; 95% CI 1.8-
5.6; parous OR 2.7; 95% CI 1.6-4.5).  Interestingly, women with LBP were significantly 
less able to interrupt the urine flow than the reference group; and the inability to interrupt 
urine flow was a significant risk factor for UI (nulliparous OR 1.8; 95% CI 1.3-2.5; 
parous OR 3.8; 95% CI 2.7-5.7).
67
   
Hip Pain: Gender differences exist in the anatomy of the hip and pelvis.  Specifically, the 
female pelvis is broader than men, and those women who have even broader pelvises 
may have greater hip range of motion.
130
  In addition, women are more likely to have 
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developmental dysplasia of the hip which also may contribute to hypermobility.
131
  Based 
on orthopedic treatment principles, if hypermobility exists, there is a need to increase 
strength of the surrounding muscles (in this case the pelvis) to reduce the hypermobility.  
Additionally, there may be a component of hypomobilty in surrounding structures (i.e. 
pelvic floor muscles) that may need to be addressed.  Moreover, hip pathology may refer 
pain to the pelvic floor muscles
130
 and when determining the source of CPP, the hip joint 
should be considered as possible etiology.  
Postural and Movement Considerations:  Poor posture, such as exaggerated lumbar 
lordosis or thoracic kyphosis, or poor body mechanics may cause excessive loading on 
the spine, hip or pelvic floor muscles leading to CPP.
117, 128, 132
 Faulty posture may cause 
muscle weakness and deconditioning, and lead to muscle imbalances and development of 
trigger points and hypertonicity.
117
  Hodges and colleagues observed a connection 
between the pelvic floor muscles to both postural and respiratory functions.
133
 Using 
surface EMG, Hodges reported that pelvic floor muscle (PFM) activity increased in 
anticipation of arm movements designed to challenge postural stability.  Furthermore, 
PFMs remain active during sustained postural tasks (in this case, repetitive arm 
movements).  During quiet breathing in the standing position, PFM activity was 
significantly increased during expiration verses inspiration.  Compared to quiet breathing, 
PFM activity  increased during larger breaths, increased tidal volumes, and expiration.
133
  
Hodges’ work is the first to provide evidence that the PFMs play a role in both postural 
and respiratory functions; and to give insight into the coordination of posture, continence, 
and respiration.  Based on this evidence, it is possible that changes in postural stability or 
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respiratory patterns may contribute to increased demands on the PFM. However, more 
research is necessary to support this assumption.  
 
2.9 Interventions for SUI 
2.9.1 PFM exercise 
 One of the most frequent treatments for SUI is PFM exercises or contraction of 
the LA. The premise of this intervention is that a strong LA contraction will improve 
urethral closure and pelvic organ support. It is hypothesized that compression of the 
urethra by contraction of the PFM will stop urine leakage if the contraction is of 
sufficient force and properly timed. Miller and colleagues reported a significant increase 
in mean urethral closure pressure during a PFM contraction in continent women (mean 
age = 55.7) measured urodynamically.
20
 In addition, mean urethral closure pressure was 
significantly lower in women with SUI than continent women. Moreover, urethral closure 
pressure had the largest effect size in differentiating between continent and incontinent 
women.
19
 Thus, if women with SUI have a reduced urethral closure pressure, 
interventions aimed at increasing this pressure (i.e. PFM contraction) may lessen urinary 
leakage. Additionally, contraction of the PFM may prevent urethral descent with abrupt 
rises in intra-abdominal pressures that occur with activities such as coughing, sneezing, 
and lifting.  DeLancey and colleagues reported that women with SUI had greater urethral 
descent at maximal valsalva compared to continent women, however the trend did not 
reach statistical significance.
19
 Miller compared bladder neck mobility of 11 young, 
continent, nulliparous women to 11 older, incontinent parous women during coughs with 
and without a concomitant PFM contraction.  Bladder neck mobility significantly 
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decreased from a median 5.4 to 2.9 mm when the PFM contraction was performed.
22
  
Thus, PFM contraction appears to minimize urethral descent, but whether or not it leads 
to reduced SUI symptoms has not been scientifically verified.  However, hypertrophy of 
the PFM as a result of exercise may improve urethral closure pressure and structural 
support of the pelvic organs.  
The levator ani (PFMs) muscles consist of type I and type II muscle fibers.  The 
type I fibers contribute to the static function of the muscle which is to support the pelvic 
viscera.  The type II fibers are associated with rapid, forceful muscle contraction.  When 
LA biopsy specimens   of women with SUI were analyzed by Koelbl et al, women with a 
greater diameter of type II fibers had significantly higher urethral closure pressures 
during coughing.
134
  This finding suggests that LA type II fiber size is associated with 
urethral sphincter performance.  Because specific strength training exercises can affect 
type II muscle fiber size through hypertrophy, it seems likely that LA exercise could 
increase the compression function of the muscle.  In this way, strengthening type II fibers 
of the LA could aid the urethral sphincter in maintaining continence.  Additionally, 
intensive LA strengthening may increase connective tissue stiffness and muscle 
hypertrophy. These morphological and functional changes may improve structural 
support of the pelvis by elevating the LA to a permanently higher location.  
Subsequently, the increased support may assist in preventing downward descent during 
increases in abdominal pressure.
21
  
 Practitioners treating persons with SUI frequently utilize PFM exercise, also 
known as Kegel exercises.  PFM exercises are taught either by verbal instruction or 
manual palpation, and specifically elicit contraction of the LA.  While PFM exercises are 
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a reasonable way to address SUI, this treatment is not uniformly effective.  The severity 
of the incontinence being treated and characteristics of the exercise program itself 
influence the effectiveness of treatment.   
 It appears that PFM exercises are most effective when used to treat persons with 
mild incontinence. When women suffering from mild or severe SUI were treated with 
PFM exercises for three months, those with mild SUI reported symptom improvement 
86% of the time, those with severe SUI only reported improvement 13% of the time.
15
  
Moreover, those with mild SUI  who improved with exercise also had significantly 
improved urethral closure pressures.
15
  Cammu et al studied outcomes of women with 
SUI following at least one session of PFM exercise training with a physical therapist.
14
  
Approximately 50% of the women were treated successfully. Women with more severe 
incontinence, defined as > 2 episodes of leakage per day and having a leakage at first 
cough during a stress test, were more likely to have poor outcomes associated with PFM 
training.  Similarly, Burgio reported that women with severe SUI (defined as having 
more than 10 incontinent episodes per week on bladder diary) were less likely to have a 
successful outcome with PFM exercise compared to those with lesser severity.
13
 
 PFM exercise efficacy studies including women with mild to moderate SUI vary 
with respect to frequency and intensity exercise.  For example, Goode and colleagues 
tested a protocol in a sample of women with mild to moderate stress and mixed UI that 
required women to perform 15 repetitions of 2-4 second contractions, three times per day 
for 8 weeks.
16
 These investigators reported at least 50% of women reported a 67% 
decrease in voiding frequency and an 80% reduction of incontinence.  Eighteen percent 
of the women reported cure or 100% reduced symptoms.  It must be noted that in 
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addition to PFM exercises, subjects were instructed in the “Knack” principle.  The Knack 
or counterbracing technique is taught by clinicians to prevent leakage during increases in 
abdominal pressure.   The patient is taught to contract the PFM just prior to the physical 
stress.  For instance, if a woman is about to sneeze, she should contract her PFM just 
prior to and throughout the sneeze to prevent SUI.  In theory, the PFM contraction 
increases the pressure of the urethra to assist in preventing leakage of urine.   
A randomized controlled trial, performed by Miller et al, evaluated the 
effectiveness of the Knack alone to reduce SUI. In this study, women were taught to 
contract their PFMs before and during a cough. A paper towel test served as the study 
outcome measure and was compared between baseline and 1 week later.  Using the 
Knack decreased urinary leakage by 98.2 % for a medium cough and 73.3% for a deep 
cough.
73
   
Because Goode, et al incorporated the Knack, it is unclear what contribution each 
intervention (PFM exercises or behavioral training utilizing the Knack) made to reducing 
UI in the women observed. Other limitations of Goode, et al’s study include a short time 
period for muscle training.  The maximal effect of strength training does not occur before 
5 months of training.
21
 Thus, the duration of Goode’s study may have been insufficient to 
promote PFM hypertrophy.  Additionally, this study did not include PFM muscle testing 
to support or discredit whether 8-weeks of PFM exercise increased PFM strength. 
 Studies that trained women longer and tested the impact of PFM exercise alone to 
reduce SUI have found favorable results. According to a Cochrane Review of PFM 
training, greater improvements occur when women receive a supervised PFM exercise 
program of at least three months.
17
   Bo et al. found that women with SUI who performed 
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PFM exercises were 17 times more likely to report cure than a control group.  In Bo et 
al.’s study, subjective cure was defined as a condition that was “unproblematic” after 
treatment. Women in this study performed 8-12 high intensity PFM contractions, three 
times a day. In addition to the home exercises, they attended PFM training in groups once 
a week with a physical therapist over a 6 month trial period.  Women who performed 
PFM exercises also demonstrated significant improvements in PFM strength, episodes of 
leakage, and quality of life.
11
   
 Morkved, et al reported a 29% subjective cure rate for women with SUI using a 
similar protocol of 10, high intensity PFM contractions three times a day, and additional 
training with a physical therapist (weekly for 2 months, then bi-weekly for 4 months), 
18
  
Women in the study also demonstrated significant improvements in gram leakage on a 
pad test and quality of life after treatment.  Interestingly, the investigators utilized 3 time 
points to measure PFM strength: 0-3 months, 3-6 months, and 0-6 months.  They found 
significant improvements in strength from baseline to 3 months and from baseline to 6 
months. This suggests that perhaps hypertrophy gains in the PFM could be obtained in as 
little as 3 months or that the 3 month intervention increased neural activation of the PFM 
resulting in improved manual muscle testing scores. 
 Other investigators have demonstrated improvements in subjective cure rates and 
objective measures in women with SUI participating in a supervised program of PFM 
exercises for 3 months.  Borello-France and colleagues found 41% of women with SUI 
performing PFM contractions for 9-12 weeks experienced a 100% resolution of SUI 
symptoms while another 20.5% experienced at least a 75% reduction in symptoms.  
Additionally, the women demonstrated significant improvements in the number of urine 
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leaks per week, PFM strength, and quality of life.
70
  Women performed a home exercise 
program ranging from 20-90 repetitions per day and attended weekly individual sessions 
with a physical therapist. It should be noted that the women were also taught the “stress 
strategy” which is the same strategy as the Knack, described previously.  Yet, because 
Borello-France, et al observed women increased PFM strength, it is possible that PFM 
hypertrophy and not merely the Knack behavioral instruction contributed to reducing 
SUI.  Additionally, the protocol utilized by Borello-France called for a high maximum 
exercise dosage.  By visit 12, the maximum exercise prescription possible was 60 
repetitions (3 sets of 20) of a 3-second contraction and 30 repetitions (3 sets of 10) of a 
12-second contraction performed twice daily.  Given the high number of exercises 
prescribed, hypertrophy of the PFM could have occurred and contributed to the 
effectiveness of the intervention.  Another high exercise intensity protocol described by 
Aukee et al resulted in decreased UI measured by a 24-hour pad test. The protocol 
required women with SUI to perform PFM contractions 20 minutes per day, and attend 5 
structured physical therapy sessions over a 12 week treatment period. This study also 
supports that a 3 month protocol of PFM exercise may be effective in decreasing SUI.
23
 
 It appears that PFM training is an effective conservative treatment for women 
with mild to moderate SUI.  If the treatment protocol is over a longer period, for instance 
6 months, then appropriate dosage of contractions may include 8-12 high-intensity 
repetitions performed three times a day.  However, if the treatment protocol is over a 
shorter period, for instance 3 months, then it appears that similar results could be 
obtained if a more aggressive dosage is prescribed.  Borello-France and colleagues 
utilized an individualized approach to exercise prescription.  The physical therapist 
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determined the subjects’ level of fatigue when performing the PFM exercise based on 
performance on electromyography biofeedback. Based on the performance, the physical 
therapist prescribed the number of repetitions for the patients to perform during the home 
exercise program.  Borello-France et al’s approach reflects common practice in physical 
therapy settings.  The physical therapist evaluates the patient and prescribes exercises 
based on examination findings of the patient’s muscle performance.  Additionally, 
Borello-France et al incorporated both 3-second maximum and 12-second submaximal 
PFM contractions to train both type II muscle fibers and type I muscle fibers respectively. 
Activation of type II muscle fibers may encourage hypertrophy, while activation of type I 
muscle fibers may contribute to pelvic organ support and prevent strain on pelvic 
ligaments and fascia.  Both Morkved et al
18
 and Bo et al
11
 exercise protocols incorporated 
3-4 fast PFM contractions on top of each 6-8 second muscle contraction. This protocol 
also incorporates both type I and type II muscle training.  According to the Cochrane 
Review, it seems likely that treatment effectiveness will be enhanced if the exercise 
prescription is based on sound physiological principles.
17
  The studies mentioned in this 
review are consistent in incorporating both PFM endurance and strengthening principles.  
In summary, PFM training is better than no treatment, for women with SUI.  Although 
exercise variables differ, an effective PFM training program should include both 
endurance and strengthening contractions, and may be more effective if the number of 
repetitions is individually based upon the patient’s level of fatigue during performance.  
Studies reveal that a 3-month regime is effective if sufficient repetitions are included in 
the program.   
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 In addition to considering the intensity and duration of a PFM exercise program, 
physical therapists may also need to consider the body position in which woman exercise. 
Bo and Finckenhagen reported that mean resting vaginal pressure (cm HOH) was higher 
when recorded with women standing than when women were supine. The positions of 
standing or sitting did not affect the subjects’ ability to produce maximum squeeze 
pressure or maximum PFM contraction.
68
 Yet, the higher resting pressure recorded in 
standing suggests that vaginal pressure may be influenced by gravity. Borello-France and 
colleagues compared the efficacy of a PFM exercise progression that included practice in 
upright positions (supine, sitting, and standing) with the effectiveness of a PFM exercise 
program performed only in the supine position in reducing SUI.
70
 Women in both 
exercise groups achieved statistically significant improvements in urinary leakage, 
quality of life, and PFM strength. Position of PFM exercise did not impact outcomes
70
 
indicating that perhaps exercise position may not play as important of a role in reducing 
UI.  However, the authors did incorporate “Knack” training in both groups, which 
allowed women in the supine only exercise group the opportunity to contract their 
muscles in anti-gravity postures. This, combined with the high-intensity of both exercise 
regimes, may have reduced the impact of exercise position on study outcomes. Clinically, 
physical therapists utilize exercise progression from gravity-eliminated to anti-gravity 
when strengthening the PFM. Although one study
70
 disputed this common practice, the 
specificity theory regarding motor tasks states that greater gains in motor performance 
occur when practice most closely resembles the functional task.
135
 Thus, until additional 
studies corroborate the findings of Borello-France et al, exercise position should continue 
to be considered as a variable for PFM exercise. 
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2.9.2 SUI: PFM exercise and Biofeedback 
 Although PFM exercises are effective in reducing SUI in women with mild to 
moderate symptoms, the methods by which exercises are taught may contribute to the 
extent of effectiveness achieved.   For example, verbal instruction of PFM exercise to 
women with and without incontinence was found ineffective 60% of the time, and led to 
incorrect techniques that could potentially increase symptoms.
136
  Correct contraction can 
be verified by biofeedback or manual palpation.  In women, biofeedback can be obtained 
using small electrodes placed around the anus or by using an internal, vaginal electrode.  
Using biofeedback allows women to see almost instantly their muscle output during 
exercise.  Incontinence rates obtained with the use of biofeedback range from 54% to 
95%.
137  
For biofeedback to be successful, four conditions must be met:  an easily 
measurable and detectable response, the ability to detect change in that response, a cue to 
control need, and a motivated client who is actively involved.  Randomized controlled 
trials have found biofeedback assisted PFM exercise to be effective in reducing SUI.  
Women with SUI performing biofeedback-assisted PFM exercise 1 time per week for 8 
weeks reported a significant decrease in UI episodes when compared to women in a no 
treatment control group.
18, 108
      
 Although the effectiveness of biofeedback-assisted PFM exercise for women with 
SUI is established when compared to no treatment, conclusions regarding its efficacy 
when compared to PFM exercise alone are divided. Women with SUI performing 
biofeedback-assisted PFM exercise weekly for 8 weeks reported a similar decrease in UI 
episodes and percentage of improvement as those performing PFM exercise alone during 
8 weekly sessions.
24
 Aukee and colleagues reported similar results in women with SUI 
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using a home biofeedback unit.
23
   In this study, one group received 5 supervised exercise 
sessions with a physical therapist over 12 weeks plus practice at home with a home 
biofeedback unit. The intervention for the comparison group did not include use of a 
home biofeedback unit. Groups did not differ in urine leakage or quality of life outcomes.  
The biofeedback group only  showed  a significant change in mean PFM EMG 
(electromyography) activity measured supine.
23
  No other differences were noted with 
reference to EMG activity in sitting or standing.  This result may have reflected a training 
effect; those that used biofeedback may have done so in the supine position.  As the study 
did not include tests for PFM force output, it cannot be concluded that women using 
biofeedback achieved greater strength than women not using biofeedback.  Moreover, 
Pages and colleagues found no significant differences in incontinent episodes between 
women with SUI that participated in group exercise 5 times/ week for 4 weeks that 
emphasized PFM exercise compared to women who received individual therapy sessions 
using biofeedback 5 times per week for 4 weeks.
25
  After 4 weeks, both groups of women 
continued the exercise program once daily at home for 2 months.  Both groups 
demonstrated similar significant improvements in frequency of incontinence, PFM 
strength, and closure of the introitus.   
 Based on the literature, PFM exercise with biofeedback is not more efficacious 
than PFM exercise alone. However, PFM training with biofeedback may be a clinically 
useful and acceptable treatment for some women.  A practical strategy may be to initiate 
PFM exercise with biofeedback for those who have difficulty understanding how to or 
are unable to contract their PFMs. 
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2.9.3 SUI: PFM exercise and electrical stimulation 
 Electrical stimulation is another intervention used by physical therapist to manage 
UI.  The physiological goals of electrical stimulation (ES) are to build muscle 
hypertrophy, to normalize reflex activity of the lower urinary tract, and to increase 
circulation to muscles and the capillary system.
137
  The rationale for ES as an intervention 
for SUI is based on evidence that has shown ES of the pudendal nerve improves urethral 
closure by activating the PFM.
138
 It may also increase conscious awareness of the action 
of these muscles to yield an improved ability to perform a voluntary muscle contraction.   
 Results are mixed regarding the efficacy of ES in the treatment of SUI. Sand and 
colleagues found that women with SUI using home ES twice daily for 12 weeks reported 
significantly less UI based on pad test and voiding diary outcomes when compared to 
women using a sham device. Additionally, those using ES demonstrated significantly 
improved PFM strength compared to the sham group.
26
  On the contrary, Brubaker et al. 
reported no differences between women with SUI who used ES daily for 8 weeks 
compared to those who used a sham device based on changes in incontinent episodes, 
quality of life scores, and urodynamic diagnosis of SUI. 
139
 Similarly, women with SUI 
using home ES one hour per day for 8 weeks demonstrated similar PFM strength, urine 
leakage based on pad test, and quality of life as women using sham ES.
140
 
 Investigations that compared ES to PFM exercise, or combined ES and PFM 
exercise, have not shown superior results to PFM exercise used alone in the treatment of 
SUI.  Goode et al. compared outcomes in women with SUI utilizing PFM training, PFM 
training and home ES, or a control condition consisting of a self-administered 
incontinence booklet.
16
  Women who received PFM training combined with ES reported 
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a mean 72% reduction in incontinent episodes.  When compared with PFM exercise 
alone, the addition of ES did not improve the results.  However, patients’ perception of 
progress was better for women receiving the ES combined with PFM exercise. 
Furthermore, Bo and colleagues reported greater improvements in pad test results, PFM 
strength, and subjective cure for women with SUI treated with PFM exercise compared to 
those receiving PFM exercise and ES.
11
 According to a recent systematic review, ES did 
not improve UI more  than sham stimulation or PFM exercise.
141
  Based on the evidence, 
it may be most appropriate to utilize ES for women who are initially unable to contract 
their PFM.  Once PFM activation is achieved, PFM exercise alone may be more 
effective.
29
  
 
2.10 Interventions for UUI 
2.10.1 Behavioral Training 
 There are two general approaches to the management of UUI. The first is 
behavioral training which includes PFM exercises to inhibit bladder contractions and 
other urge suppression strategies. The second strategy is bladder training which focuses 
on restoring normal bladder function by modifying bladder habits using structure voiding 
schedules.
29
  Few studies have investigated the effectiveness of PFM exercise to reduce 
symptoms of urgency and/or UUI thus making it difficult to understand the mechanisms 
by which PFM exercise impact UUI.  Aside from the potential to hypertrophy the LA 
muscle, PFM training along with urge suppression strategies are believed to reduce UUI 
by inhibiting bladder contractions. Shafik and Shafik investigated the role of the PFMs in 
suppressing involuntary voiding in healthy controls and those with OAB and concurrent 
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UUI.
74
  In those with OAB the bladder was filled to a volume inducing involuntary 
detrusor contractions while vesical and urethral pressures were recorded.  Subjects were 
then asked to perform a 10 second PFM contraction.  With the addition of a PFM 
contraction, a significant decrease in bladder pressure and a significant rise in urethral 
pressure were observed.  Moreover, those with OAB did not demonstrate involuntary 
voiding when incorporating the PFM contraction.
74
   
 A main component of a behavioral intervention approach to UUI is PFM training.  
Once patients learn how to properly contract and relax their PFMs, they are instructed to 
contract them whenever they experience urgency to suppress detrusor contractions and 
prevent UUI.  Urge suppression strategies also include informing patients of better ways 
to control the sense of urgency.  For instance, instead of rushing to the bathroom when 
the urgency strikes, patients are advised to stop, sit down, relax their body, and contract 
their PFM to diminish the urge.  After the urgency passes, patients are told to walk to the 
bathroom, but at a normal pace.  
The effectiveness of behavioral training to reduce UUI has been tested in several 
clinical trials.  Subak and colleagues evaluated the effect of a behavioral program for 
women with stress, urge, or mixed incontinence.
75
  The intervention consisted of six 
weeks of group instruction in bladder training, PFM exercise, and the use of urinary 
diaries to monitor UI episodes and voiding schedules.  At 6 weeks, the behavioral 
treatment group experienced a 40% reduction in mean weekly UI episodes.  Moreover, 
31% of women were 100% improved after behavioral therapy.
75
  Even though these 
results are promising, there were several limitations to this study.  First, PFM training 
was based on verbal and written instructions, rendering it impossible to verify if PFM 
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exercise was done appropriately.  Second, the multi-component regimen had subjects set 
new voiding schedule goals each week (referred to as bladder training). Thus, it is 
difficult to ascertain which aspects of the intervention program contributed to the 
successful outcomes.  Finally, the subjects had stress, urge, or mixed UI.  Although the 
investigators state that no differences were found for type of UI, the relative small 
distribution of those with UUI may not be representative of results if only those with UUI 
were studied.  Investigations focusing on persons with UUI and/or overactive bladder 
exclusively may provide more applicable results to the population in question.     
 Wang and colleagues investigated the efficacy of PFM training in the 
management of overactive bladder with accompanying UUI.
76
  Thirty-eight percent of 
subjects performing  PFM exercise three times daily for 12 weeks reported a 100% 
resolution of UUI.  The exercises were prescribed based on the results of an evaluation by 
a physical therapist.  Specifically, the physical therapist utilized Laycock’s PERFECT 
scheme to grade PFM strength.  This schema grades the subjects’ power (P), endurance 
(E), number of repetitions (R), and number of fast (1-second) contractions (F).  
Additionally, every (E) contraction (C) is timed (T). Thus, subjects were performing both 
fast and slow contractions with the repetitions and intensity individually based on 
performance at initial evaluation.  Additionally, the subjects were instructed to contract 
their PFM during an urge to void, thus incorporating the urge suppression strategy.
76
  The 
generalizability of results of this investigation however, is limited.  Women performed 
exercises at home and did not receive ongoing supervision. Thus, the investigators did 
not include a process for verifying that the subjects were indeed performing PFM 
exercise correctly.  Additionally, Wang reported women adhered to exercise for only 14.5 
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days instead of the intended 84 days of training.  Yet, it is promising that the investigators 
found positive results utilizing a home exercise program even with poor compliance. 
Thus, one would expect a supervised PFM exercise protocol to yield greater exercise 
adherence and UI outcomes.   
 Women with UUI participating in a home exercise program and four clinical 
visits over twelve weeks reported significant improvements in UI episodes per day, and 
improvements in nighttime frequency, PFM strength, and urge score on a leakage 
index.
142
  Specifically, women with UUI reported a 35% decrease in the number of UI 
episodes per day.  Women were instructed to perform PFM exercises twice a day for 5 
minutes each session.  They were to begin with 4-second contractions and progress to 8-
second contractions.  In addition to the home exercise program, subjects were evaluated 
in the clinic at 4, 8, and 12 weeks.  During these visits, they were instructed on increasing 
exercise efficiency and incorporating the PFM contraction into daily life.
142
  Although the 
intervention was focused on home exercise, the additional clinic visits served to reinforce 
correct PFM contraction and progress exercises which may have attributed to significant 
improvements in both subjective and objective measures.  This study also included a 
long-term follow-up. At 6-months post-intervention, 50% of those who completed the 
treatment described their progress as excellent or good and desired no further treatment. 
 Another common treatment for UUI is drug therapy.  Burgio and colleagues 
performed a prospective randomized clinical trial that compared the effectiveness of a 
behavioral intervention to drug therapy for UUI.
143
  All subjects received 4 clinic visits at 
2-week intervals during an 8-week period.  The behavioral training group was instructed 
in PFM exercise with the use of biofeedback and urge suppression strategies, Women 
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were provided a home exercise program consisting of 45 pelvic muscle exercises daily.  
The drug group received oxybutynin, a commonly prescribed drug for UUI, and the 
control group only attended clinic visits.  Behavioral training resulted in a mean 80.7% 
improvement in UUI episodes, and was significantly more effective than drug treatment 
(68% improvement) and the control condition (39% improvement). Of the women in the 
behavioral training group, 30% reported 100% improvement.  Additionally, Burgio et al 
demonstrated women in the behavioral group achieved increased bladder capacity by 17 
mL.  Thus, in this group of community dwelling women with UUI, behavioral training 
(including PFM exercise) was found to be more effective at improving patient’s 
perception of incontinence than drug therapy or a control group.  Only a relatively small 
percentage of patients in the behavioral treatment group indicated they would like to 
receive another form of treatment (14%), while much larger proportions in the drug 
(75%) and control groups (75%) desired another form of treatment at the conclusion of 
the study.
144
  According to commentary in the Cochrane Review discussing Burgio’s 
study, querying subjects about their desire for additional treatment may yield richer 
information than asking about cure rates.
17
  This type of question may help clinicians 
between patients who are better and satisfied from those who are better but not 
sufficiently so to be satisfied with the treatment outcome. Burgio’s protocol utilized an 
individualized approach to PFM training as well as structured, supervised clinic visits 
which may attribute to the large success in the study.    The clinician determined the 
subjects’ level of fatigue when performing the PFM exercises and prescribed the 
appropriate intensity level for the PFM contraction.  This approach parallels common 
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practice by physical therapists who prescribe exercises based on examination findings of 
the patient’s performance. 
 
2.10.2 UUI:  PFM exercise and Biofeedback 
 The effectiveness of PFM exercise as an intervention for UUI may be enhanced 
by the use of biofeedback. Women with OAB and associated UUI that participated in a 
graded PFM home exercise regimen for 12 weeks, along with 4 clinic visits that included 
biofeedback, reported a 57% decrease in the number of UI episodes per week.
145
  This 
study suggests that this particular protocol, which utilized biofeedback, is an effective 
treatment for women with overactive bladder.  The study could not determine if the 
addition of biofeedback was beneficial because it lacked a comparison group.    
Burgio and colleagues investigated behavioral training with and without 
biofeedback for the treatment of UUI.
144
  The behavioral training with biofeedback group 
underwent 4 clinic visits at 2-week intervals for 8 weeks and utilized biofeedback in the 
clinic to assist with PFM exercises.  Additionally, subjects were taught urge suppression 
strategies and a home exercise program.  The behavioral training only group utilized the 
same protocol but instead of biofeedback during the clinic visits, received verbal 
feedback based on vaginal palpation.  The control group utilized a self-administered 
behavioral program booklet.  All groups experienced a reduction in UI frequency, with 
the biofeedback group having a 63% decrease; behavioral training group a 69% decrease; 
and the control (booklet) group having a 38% decrease.  Thus, the treatment groups had 
greater UI reduction compared to the control group by 40-55%.  Bladder capacity was 
improved in all 3 groups, with the biofeedback group demonstrating a 42% greater 
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improvement than the control group; and the behavioral group demonstrating a 23% 
greater improvement than the control group.  Moreover, patient satisfaction was higher in 
the behavioral training alone and the biofeedback groups. Patient satisfaction included 
comfort with treatment, satisfaction with progress, and less activity restriction.  Thus, 
from this particular study of women with UUI, both biofeedback and vaginal palpation 
were effective means of teaching PFM exercises.  Furthermore, both treatment groups 
demonstrated improved outcomes when compared to the control group.  Additionally, 
women with overactive bladder participating in PFM exercises with and without 
biofeedback demonstrated similar improvements regarding UI episodes, voiding 
frequency, urgency episodes, and number of continence pads used.
76 
 However, the 
biofeedback group demonstrated significantly higher quality of life scores based on the 
total score of King’s Health Questionnaire. No significant differences were noted when 
comparing the subscales of this questionnaire between the groups.   
  The studies cited above and a recent meta-analysis 
146
  strongly suggest that the 
addition of biofeedback may not produce better results compared to PFM exercise alone. 
However PFM with biofeedback is a common and clinically acceptable intervention for 
women with UUI. A practical strategy may be to initiate PFM exercise with verbal or 
tactile feedback, and utilize biofeedback only for those who do not respond to this form 
of teaching or do not progress as anticipated.   
 
2.10.3 Bladder Training 
 The second main approach for treatment of UUI is bladder training.  Bladder 
training focuses on restoring normal bladder function by changing voiding habits, 
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specifically decreasing voiding frequency and increasing bladder capacity.
147
  When a 
woman has UUI, she experiences an overwhelming urgent sensation to void thereby 
leading to frequent voids, decreased bladder capacity, and detrusor overactivity. 
Ultimately, this cycle makes it very difficult for the patient to suppress bladder 
contractions. Bladder training attempts to break this cycle by having the patient resist the 
sensation of urgency in order to postpone urination and gradually increasing the voiding 
interval.  Subsequently, bladder capacity is increased and detrusor overactivity 
minimized.  The key component of bladder training is helping the patient set a reasonable 
voiding schedule with an eventual voiding interval goal of 3 to 4 hours.  Patients are 
instructed to empty their bladder on waking and at the end of each time interval 
subsequently during the day. If they have to void sooner, they are told to use urge 
suppression techniques (i.e., distraction, relaxation, or self-affirming statements) to get 
them through to the next scheduled voiding time. Specific urge suppression examples 
include having the patient concentrate on a task they want to complete (i.e. making 
dinner), take 5 deep breaths, or perform 5 PFM contractions quickly.
147
  The 
effectiveness of bladder training has been demonstrated in a randomized trial by Fantl 
and colleagues. These investigators found bladder training alone reduced UI episodes by 
57% and the volume of fluid loss by an average of 54% in older women compared to an 
untreated control group.  A remarkable finding in this study was that the improvement in 
UI episodes occurred in absence of urodynamic improvement.
148
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2.11 PFM exercises and the Transverse Abdominus connection 
 There is a growing body of evidence that suggests a relationship between the 
PFMs and transverse abdominus (TA) muscle.  Specifically, there appears to be a 
concurrent increase in TA muscle activity with PFM contraction. Neumann and Gill 
demonstrated a 66% increase in normalized TA activity recorded by intramuscular EMG 
when healthy women positioned supine were asked to perform a PFM contraction.
149
  
Similarly, Sapsford and colleagues demonstrated an increase in normalized intramuscular 
TA EMG amplitude between 32-42% when 7 healthy women performed a maximal PFM 
contraction in supine.
150
   
 Since a concurrent increase in TA activity occurs with PFM activity, it may be 
logical to assume a reversal relationship; specifically, that a concurrent increase in PFM 
activity occurs with TA activity.  When 6 healthy women and 1 man performed a TA 
contraction in supine, PFM EMG activity, measured using a vaginal or anal surface 
electrode, increased above the resting level.  Subjects performed different intensities of 
the TA contraction (gentle, moderate, strong), and the concurrently PFM activity 
increased in gradation of the different TA intensities.  Moreover, the PFM activity 
recorded during a strong TA contraction did not differ from that recorded while subjects 
strongly contracted the PFM in isolation.
151
 Similarly, Neumann and Gill
149
 and 
Sapsford
150
 demonstrated increased  PFM activity when healthy women performed a TA 
contraction in supine. Interestingly, one subject in Sapsford’s study inadequately 
performed the TA contraction, achieving only minimal intramuscular TA EMG activity.  
However, this subject demonstrated an 8% increase in PFM activity 
150
 suggesting that a 
less than ideal TA contraction may coincide with  a small rise in PFM activity.  
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 In a theoretical paper, Sapsford proposed that weak abdominal muscles may relate 
to the development of SUI.
71
  Sapsford noted that during coughing and nose-blowing, the 
abdominal wall of women with SUI bulges forward, especially when they are in a 
slumped supported position, without pretensioning of the abdominal muscles.   In 
comparison, healthy women will pull their abdomen inward and contract their PFMs to 
increase intra-abdominal pressure to maintain continence.
71, 150
  Other recent studies 
confirm that PFM activity is influenced by sitting posture in women with and without 
SUI.  Specifically, PFM activity was significantly decreased in slumped supporting 
sitting verses upright sitting in healthy women and those with SUI, but a significantly 
greater decrease was noted in those with SUI.  Additionally, women with SUI 
demonstrated a trend for increased activity in the superficial rectus abdominus in both 
slumped sitting and upright sitting.  Activation of the rectus abdominus may increase the 
intra-abdominal pressure, thus making it more difficult for women with SUI to maintain 
continence during activities that elevate intra-abdominal pressure. The increased activity 
of the rectus abdominus was not observed in continent women which suggests that 
women  with SUI may demonstrate altered abdominal muscle recruitment.
72
  Thus, 
Sapsford proposed a rehabilitation program for women with SUI that utilizes the 
abdominal muscles to initiate PFM activity. 
71
 Inclusion of TA exercises into the 
intervention plan for women with SUI may contribute to improved PFM recruitment and 
better outcomes. However, this approach has not been investigated for efficacy in 
improving outcomes for women with SUI. 
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2.12 Lifestyle Measures to decrease SUI and UUI 
2.12.1 Caffeine and Fluid Intake 
 Anecdotal reports have led to a list of potential dietary triggers for UI including 
chocolate, citrus fruits and juices, tomatoes and tomato-based products, vinegars, dairy 
products, aspartame, and spicy foods.  However, none of these have been linked 
scientifically as bladder irritants.
62
 Caffeine and overall fluid intake however have been 
investigated for their impact on UI.  
Swithinbank and colleagues investigated the effect of fluid manipulation in 
women with SUI and OAB.
152
 The four week study included a baseline week followed by 
3 weeks of caffeine restriction and alterations in fluid intake.  During week 2, participants 
drank normally, without fluid manipulation. During week 3 or 4, participants either 
increased decaffeinated fluids to 20 cups per day or decreased fluids to 5 cups per day.  
Decreasing fluid intake significantly improved urinary frequency, urgency, and 
incontinence, and quality of life in those with OAB; and decreased urinary frequency in 
women with SUI. Alternatively, increasing fluid intake significantly increased voiding 
frequency, UI episodes, and urgency in those with OAB compared to baseline and the 
week of decreased fluids.  In those with SUI, increased fluid intake significantly 
worsened UI episodes when compared to the week of decreased fluid.
152
  In another 
study, women and men with OAB who participated in a prospective, cross-over trial were 
required to alter fluid intake by drinking 25% and 50%  less than baseline, as well as 25% 
and 50% more than baseline.
153
 A significant reduction in urgency, frequency, and 
nocturia occurred when subjects decreased their fluid intake by 25%. As expected, a 
significant increase in daytime UI episodes was reported when fluid intake was 
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increased.
153
  Conversely, Dowd and colleagues reported no improvement in UI 
symptoms with fluid manipulation. However, a significant proportion of participants did 
not adhere to the protocol.
154
  Similarly, Dallosso showed no association between total 
fluid intake and either OAB or SUI in women aged >40 years. The literature is 
conflicting regarding the efficacy of fluid manipulation in treatment of UUI. It appears 
that decreasing fluid intake may decrease symptoms of UUI more so than symptoms of 
SUI. Therefore, is reasonable to advise patients to maintain adequate fluid hydration to 
prevent dehydration.  
 Although the stimulatory effect of caffeine has been shown to directly influence 
the bladder by increasing bladder pressure during filling,
155
 altering caffeine intake does 
not necessarily decrease UI symptoms. Swinthinbank and colleagues also investigated the 
role of caffeine restriction in 110 women with SUI and OAB.
152
 Changing from caffeine 
containing to decaffeinated drinks produced no improvement in urinary symptoms.  
Similarly, Dowd found no association between caffeine intake and UI episodes in 32 
women >50 years.
154
 After controlling for other lifestyle factors, Dallosso showed no 
relation between caffeine and OAB or SUI.
57
 Although evidence regarding effectiveness 
of caffeine restriction is lacking, there is an association between caffeine and OAB.
56, 155
   
Arya and colleagues reported a significant association between high caffeine intake 
(>400mg) and OAB.
56
  An 8-ounce cup of brewed/drip coffee has a caffeine content 
range of 71-280mg
156
 or a mathematical mean of 175.5mg per cup.  Thus, consuming 2.5 
cups of coffee per day would yield a high caffeine intake of >400mg and for those with 
OAB, consuming high amounts of caffeine should be considered a risk factor.  
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2.12.2 Weight Loss 
 There is a growing body of evidence supporting weight-loss for overweight and 
obese women as a lifestyle intervention for UI.  Obese and overweight women with UI 
participating in an intensive 6-month weight-loss program consisting of diet, exercise, 
and behavior modification reported significantly less UI symptoms when compared to 
controls.
157
 Women in the weight-loss group lost a mean of 8% of body weight, and 
reported significantly less UI episodes and smaller volume of urine leaks. Moreover, 
when compared to controls, women in the weight-loss group reported less UI symptom 
impact and higher satisfaction with the improvement in continence status.
157
  Overweight 
pre-diabetic women participating in a weight-loss program demonstrated significantly 
less UI episodes than women taking an anti-diabetic drug or placebo drug.
158
   Women in 
the weight-loss program lost an average of 3.7% of body weight (7.49 pounds) and 
reported significantly less weekly UI episodes than those in the drug or placebo groups. 
After adjusting for baseline hormone therapy use, general health status, and post-
challenge glucose categories, women in the weight-loss group had significantly lower 
odds of weekly UI compared with women in the placebo group (OR 0.76; 95% CI 0.61-
0.95).
158
  It appears that even small amounts of weight loss in overweight and obese 
women may significantly decrease UI and improve patient perception of UI symptoms. 
Thus, a decrease in UI episodes may be another benefit among the numerous health 
benefits associated with weight reduction. 
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2.13 Bowel Dysfunctions 
2.13.1 Constipation 
 The most common interventions for constipation include increasing fluid intake, 
increasing dietary fiber intake, and promoting bowel motility via abdominal massage.  
Based on a review of four studies,
36-39
 Muller concluded that there was no conclusive 
scientific evidence to support that constipation can be successfully treated by increasing 
fluids.
159
  Of the reviewed studies, one found fluid intake volume to be similar in 
constipated subjects and controls. Another study that examined whether constipation 
could be improved by increasing fluid intake reported no changes in subjects’ stool 
frequency, consistency, or ease of defecation. Finally, another study that examined the 
effect of increasing fluid intake in constipated patients reported increased stool 
frequency. However, subjects drank mineral water containing magnesium and other ions 
that may have acted as a light laxative.
159
 
 Dietary fiber has been recommended for improved bowel function.
159
  The 
National Academy of Sciences Institute of Medicine recommends that female adults over 
50 years of age have 20-25 g of fiber daily. Most Americans consume only 5-10 g daily. 
There are 2 types of dietary fiber.  Soluble fiber is thought to be beneficial in lowering 
blood cholesterol and decreasing plaque-forming low density lipoprotein.  Insoluble fiber 
increases fecal volume density by slowing digestion, colon distention, peristalsis, and 
increased water absorption.
160
 Women with constipation who supplemented their diet 
with high-fiber cereal reported significantly improved constipative symptoms, as well as 
significantly decreased use of laxatives, and the need for vaginal and/or perineal 
splintings to assist bowel movements.
160
  The 30 women in the study also significantly 
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decreased their caffeine intake compared to baseline which may have contributed to the 
favorable results. Muller cautioned that a diet low in fiber should not be assumed to be 
the cause of constipation, but may be a contributory factor.
159
 Patients with more severe 
constipation may experience gas production from fiber metabolism which limits 
effectiveness of fiber.  Moreover, a review of four studies that examined dietary fiber 
intake by people with chronic constipation, found no differences compared to controls.
159
 
 For patients with a specific type of constipation, slow-transit constipation, 
abdominal massage may be beneficial.  Slow-transit constipation is due to decreased 
neuromuscular function of the colon; therefore, interventions are aimed at increasing gut 
mobility. Klauser and colleagues reported that abdominal massage performed three times 
per week for three weeks did not improve slow-transit constipation.
161
 However, a case 
study utilizing a more frequent approach yielded positive results.  Harrington and 
Haskvitz instructed an 85-year old woman with slow-transit constipation in bowel 
management, as well as a 10-minute home abdominal massage program.
40
 After five 
visits over a 13 week period, the patient reported a return of normal bowel frequency 
without the need to strain or use digital evacuation. 
 
2.13.2 Fecal Incontinence 
 Fiber intake also plays a role in the management of FI by promoting increased 
stool consistency. Subjects with FI that took fiber supplements for 31 days demonstrated 
a significant decrease in the percentage of incontinent stools, and an improvement in 
stool consistency compared to a placebo control group.
162
  However, fiber supplements 
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can potentially worsen diarrhea by increasing fermentation of inabsorbable fiber in the 
colon.
45
  
 Physical therapy interventions for FI include PFM exercise, biofeedback, and 
electrical stimulation.
41
 PFM training is used to improve coordination of muscle 
contractions, improve muscular strength, and increase awareness and isolated contraction 
of the PFMs. The use of biofeedback and electrical stimulation augment such goals as 
discussed previously.  In addition, biofeedback can be used for rectal sensitivity and 
coordination training.
43
  The rationale for rectal sensitivity training is to enhance 
detection of a lower stool volume in the rectum to promote earlier opportunity for a 
patient to find a toilet and/or contract their PFMs to delay or prevent FI. In rectal 
sensitivity training, a rectal balloon is filled with air or water to imitate rectal contents, 
and the patient is asked to report first sensation with rectal filling. Repeated re-inflations 
of the balloon are performed to the determined volume with the goal of teaching the 
patient to feel the distension at progressively lower volumes. In coordination training, 
typically a three balloon system is utilized: one situated in the rectum, and the second and 
third (recording balloons) are placed in the upper and lower anal canal. When the rectal 
balloon is distended, the patient is taught to counteract the momentary anal relaxation by 
voluntary squeezing the PFM until the relaxation period is over.
43
  
 Norton and Kamm investigated PFM exercise and biofeedback in 100 patients 
with FI.
163
  Patients performed PFM exercise with biofeedback for a median of 4 
sessions; and for those who demonstrated high stool threshold volumes, rectal sensitivity 
training was also included. Forty-three percent of subjects regarded themselves as 
“symptomatically cured” while 24% were “improved” after treatment. Patients with 
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structurally intact sphincters (as measured by anal endosonography) were most likely to 
benefit from treatment, although some with structural changes also improved.
163
  In a 
systematic review, Palsson and colleagues concluded that biofeedback for FI provides a 
significantly higher probability of successful outcome than standard medical care, and 
should be viewed as a valuable adjunct to medical management.
164
 On the contrary, the 
Cochrane review regarding biofeedback and/ or PFM exercise for FI concluded that the 
limited number of clinical trials combined with their methodological weaknesses do not 
allow for a definitive assessment of the role of biofeedback and/or PFM exercise in the 
management of FI. However, there were suggestions that rectal sensitivity training 
improves FI more than sham training.
43
 As biofeedback and PFM exercises are safe and 
certainly more conservative compared to surgical options, the American College of 
Gastroenterology Practice Parameter Committee contends that biofeedback is an effective 
treatment in patients with weak sphincters and/or impaired rectal sensation.
45
  
 A Cochrane review of electrical stimulation (ES) as an intervention for FI 
concluded a lack of evidence to judge whether ES is efficacious. 
147
  Norton and 
colleagues found no differences regarding FI episodes, patient satisfaction, or 
manometric squeeze pressures following 8 weeks of daily anal ES compared to sham 
stimulation in 90 patients with FI.
148
  Ostenberg and colleagues compared surgery with 
ES in patients with FI.
44
  Electrical stimulation lasted 20 minutes for a total of 12 sessions 
over a period of 4-5 weeks. Compared to baseline status, those receiving ES 
demonstrated significantly improved incontinence scores on a condition-specific 
questionnaire and less absorbent pad use at 3, 12, and 24 months after treatment.  
However, manometric squeeze measures were unchanged.  Surgery was superior to ES at 
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3 months but not at 12 or 24 months.
44
 Conclusions regarding the effectiveness of ES for 
FI are unclear. Recent practice guidelines by the American College of Gastroenterology 
suggest that ES should be considered experimental and merit controlled clinical trials.
45
  
 
2.14 Interventions for Chronic Pelvic Pain 
 Physical therapists use a variety of techniques for treatment of musculoskeletal 
causes of CPP.  Treatment is aimed at reducing or eliminating the impairments found 
during the initial examination.  Table 2.1 outlines common physical therapy interventions 
as well as the impairments that the intervention attempts to influence. 
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Table 2.1: Physical therapy interventions utilized in the treatment of CPP   
           
Physical Therapy Intervention Impairment 
Biofeedback
130, 132
 Weak PFM, Hypertonic PFM 
Electrical Stimulation
130, 132
 Pain in hip, lumbar, or pelvic region; 
Hypertonic PFM, Weak PFM 
Superficial Heat and Cold Modalities
130
 Pain in hip, lumbar, or pelvic region 
Joint mobilization
128
 or Muscle energy 
techniques
128
 
Restricted joint motion of the hip and/or 
pelvis 
Soft tissue mobilization,
127, 130
 Myofascial 
release,
125, 128, 130
 Trigger Point release
125, 
130
 externally or internally 
Hypertonic PFM; Spasm of hip, lumbar, 
or pelvic musculature; Trigger points 
Connective and scar tissue release
130, 132
 Hypomobile scars due to abdominal 
and/or pelvic surgery (i.e. episiotomy, 
cesarean section) 
Vaginal dilation
132, 165
  Hypertonic PFM and/or introitus pain 
Stretching / Range of motion techniques
132
 Shortening of hip, low back, or pelvic 
muscles 
Therapeutic Exercise
132
 which  may 
include postural exercises
130
 
Weak muscles of the hip, low back, or 
pelvic region 
 
2.15 Outcomes  
 To assess if interventions are effective, outcome questionnaires are needed to 
quantify patient perceptions of symptom improvement.  Because the clinical presentation 
of women with UI is varied, it is necessary to utilize outcome measures that incorporate 
the myriad of co-existing pelvic symptoms.  
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2.15.1 Pelvic Floor Distress Inventory and Pelvic Floor Impact Questionnaire   
 Generic health-related quality of life (QOL) instruments such as, the Medical 
Outcomes Survey Short-36 and the Sickness Impact Profile, have been used to examine 
the QOL in women with UI.  Although generic health-related QOL measures have the 
advantage of comparing results among groups, such instruments may lack the sensitivity 
to measure the unique aspects of a specific disease and its impact on a patient’s QOL. 
 The Pelvic Floor Distress Inventory (PFDI) and Pelvic Floor Impact 
Questionnaire (PFQI) are condition specific quality of life instruments that assess the 
impact of urinary, bowel, and prolapse symptoms on a woman’s QOL.  Although there 
are several standardized quality of life instruments specific to UI symptoms,
49, 166
 only 
the PFDI and PFIQ encompass the ability to assess co-existing disorders of UI, 
specifically, bowel dysfunction and POP.  Because several pelvic floor disorders may co-
exist in the same woman,
31
 the use of instruments that assess the whole spectrum of 
interrelated symptoms is essential when evaluating the efficacy of treatment 
interventions.  
Both the PFDI and the PFIQ are based on the structure and content of two widely 
used condition-specific health related QOL instruments for women with lower urinary 
tract symptoms: the Urinary Distress Inventory (UDI) and the Incontinence Impact 
Questionnaire (IIQ).
166
  The UDI contains 19 symptom questions related to lower urinary 
tract dysfunction including urinary frequency, UI, nocturia, incomplete bladder emptying, 
and lower abdominal pressure. The UDI measures symptoms and the perceived degree of 
bother associated with each symptom.  The IIQ is a 30-item questionnaire that measures 
the degree to which UI impacts social relationships, physical activities, travel, and 
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emotional health. Data on the reliability, validity, and sensitivity to change of these 
measures demonstrate that they are psychometrically strong.
166
 Both the UDI and IIQ 
subscales demonstrate acceptable internal consistency reliability with Cronabach’s alpha 
coefficients for the UDI subscales ranging from 0.48-0.77; and for the IIQ ranging from 
0.87-0.90. Only one subscale of the UDI, stress symptoms, demonstrated reliability 
(0.48) below the desired range recommend (0.7-0.95) by Portney and Watkins.
167
  When 
compared to well-validated generic health related QOL measures including the RAND-36 
Health Survey, the Centers for Epidemiological Studies Depression Scale, the Medical 
Outcomes Study measure of Social Support 1992, and the Profile of Mood States, the 
UDI and IIQ scores generally correlated well with scores on these measures verifying 
convergent validity. For the IIQ, 15 of the 16 correlations between the four IIQ subscales 
and the four generic measures were significantly significant with correlations ranging 
from 0.37 to 0.52, mean = 0.37.  For the UDI, 9 of the 12 correlations between the three 
UDI subscales and four generic measures were significant with correlations ranging from 
0.09 to 0.40, mean = 0.22.  Such moderate correlations demonstrate that the IIQ and UDI 
measure more than general health constructs.  Moreover, the UDI and IIQ are responsive 
to change, and significantly correlate with clinical measures of condition severity 
including number of incontinent episodes and the amount of urine leakage as measured 
by a pad test.
166
  
 All questions from the UDI and IIQ are included in the PFDI and PFIQ along 
with additional items regarding POP and bowel dysfunction.
168
 These additional items 
were included to ensure that the full range of QOL issues  of women with pelvic floor 
dysfunction were addressed. The PFDI has 46 items and contains 3 subscales: the UDI, 
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Pelvic Organ Prolapse Distress Inventory (POPDI), and the Colorectal-anal Distress 
Inventory (CRADI).  Respondents are asked if they experience symptoms and if so, to 
rate the degree on which they are bothersome on a scale from 1 (not at all) to 4 (quite a 
bit).  The PFIQ has 93 items and contains 3 scales:  the Urinary Impact Questionnaire 
(UIQ), the Pelvic Organ Prolapse Impact Questionnaire (POPIQ), and the Colorectal-anal 
Impact Questionnaire (CRAIQ).  Each subscale contains 31 items with 30 of these items 
identical to the questions in the IIQ referring to the degree to which symptoms affect 
social relationships, physical activity, travel, and emotional health.  One question was 
added to each subscale to assess the effect of bladder, bowel, or vaginal symptoms on the 
patient’s relationship with her husband or intimate partner. The psychometric properties 
of the PFDI and PFIQ were assessed in study of 100 women (mean age 56 years) with 
pelvic floor dysfunction who underwent a standard pelvic floor dysfunction evaluation 
including a structured interview, physical examination that included POP quantification, 
and urodynamic evaluation.  Additionally, women kept a 1-week prospective bladder and 
bowel diary.  Subjects completed the PFDI and PFIQ at their initial visit and completed it 
again 7 days later. The PFDI and PFIQ demonstrated good internal consistency, with 
Cronbach’s α reported as 0.88 for the overall PFDI score and 0.98 for the PFIQ.  Test-
retest reliability was good for both instruments with the ICCs of 0.87 and 0.86 for the 
PFDI and PFIQ respectively.  Content validity was confirmed by an expert panel.  
Finally, content validity of the PFDI and PFIQ was tested by comparing objective data of 
symptom severity, responses to structured interviews, and final pelvic floor diagnoses 
with the appropriate scales of each instrument. POP subscales of the PFDI and PFIQ  
positively correlated with a validated measure of prolapse severity and two pelvic floor 
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conditions associated with prolapse (voiding dysfunction and defecatory dysfunction). 
Colorectal subscales of the PFDI and PFIQ correlated with one measure of symptom 
severity (number of FI episodes per week), two symptoms associated with abnormal 
defecation (hard straining and perineal splinting), and three diagnoses of bowel 
dysfunction (FI, defecatory dysfunction, and rectal prolapse). Urinary subscales of the 
PFDI and PFIQ significantly correlated with three measures of symptom severity from 
the bladder diary including number of UI episodes per week, number of pads used per 
week, and the average daytime voiding interval.
168
  Thus, the PFDI and PFIQ are valid 
and reliable instruments for women with pelvic floor disorders.  
 Although the PFDI and PFIQ are psychometrically strong, the time it takes 
patients to complete the questionnaire (23 minutes (+11 minutes)) may limit their clinical 
utility.
168
  Barber and colleagues developed two short form versions of these 
questionnaires that are valid, reliable, and responsive to change.
78
   The short form 
versions (PFDI-20 and PFIQ-7) were tested in 45 women (mean age 59 years) having one 
or more pelvic floor disorders including UI, voiding dysfunction, ≥stage 2 pelvic organ 
proplape, defecatory dysfunction, and/or rectal prolapse; and were scheduled for 
reconstructive pelvic surgery or continence surgery.  Preoperatively, subjects underwent a 
standardized evaluation consisting of a structured urogynecologic history, physical 
examination with POP quantification; and they completed the Medical Outcomes Study 
Short Form-36 (SF-36) and  the short and long forms of the PFDI and PFIQ.   The short 
versions demonstrated significant correlations with the long versions for both the PFDI 
and PFIQ with ICCs ranging from 0.86-0.93 and 0.94-0.96, respectively. Additionally, 
each of the PFDI-20 and PFIQ-7 subscales demonstrated good to excellent test-retest 
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reliability with ICC values between 0.70 and 0.91.  To assess the responsiveness of the 
PFDI and PFIQ, subjects completed the instruments and the SF-36 again 3 to 6 months 
after the surgery. The instruments were responsive to change as demonstrated by 
significant improvements pre- to post-surgery in PFDI-20 and PFIQ-7 scores. 
Additionally, the PFDI-20 demonstrated moderate to excellent responsiveness with an 
effect size and standardized response mean (SRM) values ranging from 0.70 to 1.28, 
repectively. The PFIQ had moderate responsiveness with an effect size of 0.67 and SRM 
of 0.63.
78
  For both the effect size and SRM,  a value of 0.5 to 0.7 is considered moderate 
responsiveness, 0.80 to 1.00 is considered good, and more than 1.0 is considered 
excellent.
169
  In contrast, the majority of the scales of the SF-36 were not responsive to 
change. Moreover, the summary scores of PFDI-20 and PFIQ-7 significantly correlated 
with subjects’ global index of improvement score, indicating that the instruments are able 
to differentiate between those who got “better” from those who got “worse” (C-statistic 
0.96 and 0.88, respectively, where 1 indicates a perfect test and 0.56 indicates a test with 
no discriminative ability).
167,154
  Based on comparisons to global index of improvement 
scores, Barber and colleagues determined that a  ≥ 45 point change in the PFDI-20  
summary score and a ≥36 point change in PFIQ-7 summary score were clinically 
meaningful changes in QOL life in patients undergoing surgery for pelvic floor 
dysfunction.
78
  
 
2.15.2 Patient Global Impression of Improvement 
 Global indices are utilized in order to obtain a very simple and direct appraisal of 
the patient perceptions of improvement.  In contrast to QOL and symptom distress and/or 
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impact questionnaires, a global index usually contains one question that asks the patient 
to rate the severity of the condition or the response of the condition following therapy. 
The Patient Global Impression of Improvement (PGI-I) is a global index used in recent 
research trials to assess patient perception of treatment intervention.
170-173
 The PGI-I has 
been shown to have good construct validity in women with SUI.
77
  Yalcin and Bump 
demonstrated significant correlations between the PGI-I and frequency of UI episodes, 
urine leakage on pad test, and a validated condition-specific QOL questionnaire in a 
prospective study of women assigned to drug therapy or placebo for UI.
77
  
 
2.15.3 Constipation Scoring System 
 Although the PFDI-20 and PFIQ-7 are comprehensive instruments to evaluate 
women with pelvic floor dysfunction, the subscales assessing bowel dysfunction 
primarily refer to FI.  Women with UI report often report co-existing constipation.
33, 34
 
Inclusion of a questionnaire assessing constipation symptoms is necessary to determine 
the effectiveness of interventions. The Constipation Scoring System (CSS) is a valid 
instrument that correlates with objective physiologic findings in constipated patients.  
Agachan and colleagues reported that the CSS demonstrated convergent and divergent 
validity in 185 women and 47 men (mean age 65 years) with constipation confirmed via 
physiological tests.
79
  Subjects’ scores on the CSS were significantly correlated with anal 
and colorectal physiologic studies.  Agachan and colleagues also demonstrated divergent 
validity of the CCS using 2 groups of subjects, those with and without constipation 
confirmed by physiologic studies.  CSS scores differentiated between those that were 
constipated and were not constipated with 96% accuracy.  Advantages to the CSS are that 
83 
 
it is valid, and that it includes only 8 items.  The reliability, responsiveness, or sensitivity 
to change of the CSS has not been determined.  
 
2.15.4 Female Sexual Function Index 
  The Female Sexual Function Index (FSFI) is a 19-item questionnaire that 
measures sexual function across 6 domains: desire, arousal, lubrication, orgasm, 
satisfaction, and pain. FSFI items are rated on a 5 point Likert-type scale with higher 
scores indicating better sexual function.
80
  The maximum possible score for a domain is 
6.0. A full scale score can range from 2.0 to 36.0, and is obtained by adding the 6 domain 
scores. The FSFI has been reported to have good internal consistency, reproducibility, 
and discriminative validity.
80
  Rosen and colleagues reported acceptable internal 
consistency reliability for all six FSFI domains with Cronbach’s α values of 0.82 – 0.97 
in women aged 21-69 years with and without Female Sexual Arousal Disorder. Test-
retest reliability was also confirmed with significant Pearson product-moment correlation 
coefficients ranging from 0.69 – 0.91. Moreover, females with sexual function had 
significantly poorer scores when compared to healthy controls, indicating that the FSFI is 
able to differentiate between clinical and nonclinical populations.
80
 One domain, instead 
of the entire questionnaire, can be administered as Rosen reported the psychometrics for 
all of the specific domains. Because women with UI are at a higher risk for 
dyspareunia,
35
 it seems prudent to include an instrument assessing sexual pain when 
evaluating the efficacy of UI interventions. 
 
 
 
84 
 
2.16 Barriers to successful physical therapy outcomes  
 Women seeking physical therapy for treatment of UI are typically seen one time 
per week over a period of 4-8 weeks.  An integral part of the patient’s intervention 
program is instruction and performance of pelvic floor muscle training at home to 
supplement the weekly physical therapy visits.  A woman’s adherence or non-adherence 
to the prescribed home exercise program may logically impact the success of physical 
therapy for UI treatment.   
For postpartum women, factors that may influence whether women perform PFM 
exercise include education, activity level, parity, smoking status, type of child delivery, 
UI status, and pelvic pain.
174
 Women who performed PFM at least once a week 6 months 
postpartum were significantly more educated, had more children (2 children OR 1.07; 
95% CI 1.09-12.26 and 3 children OR 1.45; 95% CI 1.33-1.59) and were twice as likely 
to participate in a general fitness activities 3 or more times a week (OR 2.06; 95 %CI 1.3-
2.33) than women who women who performed PFM exercises less frequently or not at 
all.  Additionally, women who were experiencing UI and/or pelvic pain were also more 
likely to do PFM exercises.  On the contrary, women who smoked daily or had cesarean 
section were less likely to do PFM regularly.  Rates of performance of PFM exercise at 6 
months postpartum vary from 58%
174
- 67%.
175
  Reasons women gave for not initiating 
PFM or for stopping PFM exercise in the 6-month postpartum period include the 
rationale that exercise was unnecessary if the woman was not experiencing any UI, they 
forgot to perform the PFM exercise, or that they were too busy.
175
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For women with UI, PFM exercise adherence rates at 5 years vary from 10%
176
-
70%.
177
  Only one study investigated adherence after 15 year after cessation of PFM 
training and reported that 28% of women performed PFM exercise at least weekly.
178
    
Those that do not regularly engage in PFM exercise after cessation of formal PFM 
training are at increased risk of frequency of UI episodes.  Lagro-Janssen reported that 
those who performed PFM exercise at five years were over 8 times more likely to report a 
50% or greater decrease in the frequency of UI episodes compared to UI episodes one 
year after cessation of physical therapy.
179
 Patients who did not perform PFM exercise at 
follow-up cited lack of discipline, interference with daily activities, lack of time, and 
disinterest as reasons for failure to perform PFM exercise at home.
176
  
 Studies have reported an inconsistent relationship between patient characteristics 
and exercise adherence.  Alewijnse and colleagues investigated predictors of long-term 
adherence to PFM exercise among women with UI who sought physical therapy 
treatment.
180
  The most striking association reported was that women who performed 
PFM exercise after cessation of physical therapy were more likely to continue adherence 
at one year follow-up.  Additionally, women who had more frequent weekly UI episodes 
before physical therapy treatment and at one year follow-up had higher adherence levels 
one year after therapy than women with fewer weekly losses.
180
  Lagro-Janssen reported 
that age, parity, severity of incontinence, and patients’ psychological characteristics such 
as anxiety, did not predict successful urinary outcomes.
179
  On the contrary, Alewijnse 
reported that the amount of urine loss per incontinent episode as well as a women’s 
perception of their ability to do the exercises as recommended under various 
circumstances were significant predictors of the intention to adhere to PFM exercise.
181
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The discrepancy regarding the severity of incontinence in Lagro-Janssen and Alewijnse’s 
studies could be explained in the fact that Lagro-Janssen defined severity as a function of 
frequency of urine loss, amount of urine loss, use of protective pads, and restriction in 
daily activities due to incontinence, while Alewijnse utilized a strict definition of urine 
loss per incontinent episode.  
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Chapter 3 
 
Methods 
 
3.1 Experimental Design & Setting 
 
The first primary aim of this retrospective descriptive study was to determine the 
efficacy of physical therapy interventions provided within a pragmatic setting on global 
impression of improvement, pelvic symptoms, and health-related quality of life to women 
with a primary diagnosis of UI.  Women’s post-intervention PGI-I scores were 
summarized to determine the subjects’ global impression of improvement with physical 
therapy intervention.  To determine the efficacy of physical therapy intervention on 
pelvic symptoms, women’s pre-post intervention PFDI-20, CSS, and FSFI change scores 
were analyzed.  In addition, women’s pre-post PFIQ-7 change scores were examined to 
determine the effectiveness of the physical therapy intervention on health-related quality 
of life.  The second primary aim was to determine the relationship between selected 
patient-related characteristics (age, parity, race, number of comorbidities, carbonated 
beverage intake, current smoking status, presence of barriers to intervention 
recommendations, and number of physical therapy visits) and treatment success.  
Treatment success was defined as a post-intervention PGI-I score of “much better” or 
“very much better;” a reduction in pelvic symptoms (reduction in PFDI-20 score at 
discharge); and improvement in health-related quality of life (reduction in PFIQ-7 at 
discharge).  
The secondary aim was to document the percentage of women who received 4 
possible interventions.  Because intervention selection may be determined by the 
constellation of symptoms a woman possesses, separate percentages were calculated for 4 
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symptom-based categories of women. The categories included: UI symptoms only, UI + 
bowel symptoms, UI + pelvic pain, or UI + bowel symptoms + pelvic pain. Interventions 
included patient education, modalities, manual physical therapy procedures, and exercise.  
(See Table 3.5 for delineation of interventions).  
 Data for this study were obtained from the Centers for Rehabilitation Services 
(CRS) Women’s Health Physical Therapy Database.  Fifteen physical therapists (PTs) 
from 12 different CRS clinic locations managed the care of women referred to physical 
therapy services at the CRS for UI.  Each physical therapist (PT) hand entered patient 
data into the Women’s Health Physical Therapy Database.  The locations of the 12 clinics 
are delineated in Table 3.1. 
Table 3.1:  CRS Locations 
CRS Cranberry 
Rowan Towers  
8050 Rowan Rd.  
Suite 101 
Cranberry, PA 16066 
CRS Harmarville 
Alexander's Athletic Club 
2585 Freeport Rd. 
Suite 205 
Pittsburgh, PA 15238 
CRS Delmont 
Salem Place 
6530 Route 22 
Suite 100 
Delmont, PA 15626 
CRS Monroeville 
UPMC at Oxford Drive 
600 Oxford Drive 
Suite 310 
Monroeville, PA 15146 
CRS Moon Township 
UPMC West 
1600 Coraopolis Heights Rd. 
Coraopolis, PA 15108 
CRS Oakland 
Kaufmann Medical Bldg. 
3471 Fifth Ave. 
Suite 1201 
Pittsburgh, PA 15213 
UPMC South Hills 
1300 Oxford Dr. 
Suite 1F 
Bethel Park, PA 15102 
 
CRS Squirrel Hill 
2345 Murray Ave. 
Suite 300 
Pittsburgh, PA 15217 
CRS-UPMC St. Margaret 
Park Place at Chapel Harbor 
300 Chapel Harbor Dr. 
Suite 200 
Pittsburgh, PA 15238 
Chippewa 
2580 Constitution Blvd. 
Beaver Falls, PA 15010 
CRS Gibsonia 
Northtowne Square 
5600 William Flynn Highway 
Gibsonia, PA 15044 
CRS McCandless 
9365 McKnight Rd. 
Suite 300 
Pittsburgh, PA 15237 
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3.2 Subjects 
 Data from female patients with UI (of both neurogenic and non-neurogenic 
origin) managed by CRS PTs between November 1, 2009-November 15, 2010 were 
included for study analysis.  Potential patient records were excluded from this study if the 
patient: 
 was seen for less than 2 therapy visits; 
 did not complete at least one of the three initial primary outcome measures (PGI-
I, PFDI-20, and/or PFIQ-7); and/or 
 reported pain with urination (indicating possible urinary infection). 
 
In addition, women with neurogenic bladder symptoms (predominate etiology of 
multiple sclerosis), who indicated that they were currently experiencing a neurological 
relapse or a score of 8 (indicating a walking status of “bedridden”) on the Patient-
Determined Disease Steps were not eligible for inclusion in the study.  The Patient-
Determined Disease Steps is a disease-specific measure for individuals with multiple 
sclerosis used to assess mobility based on the patient’s own perception of her walking 
ability. For patients with multiple sclerosis, this questionnaire was completed at baseline 
and discharge physical therapy visits.  This measure was also used to define the level of 
disability for women with multiple sclerosis and to determine if a decline in function 
occurred over the course of physical therapy management.  
 Based on previous behavioral training and  physical therapy trials for women with 
UI, it is estimated that 15%
144, 182
-18%
16
  will be treated < 2 visits or will not complete at 
least one of the three initial primary outcome measures and 2%
16
 will report pain with 
urination indicating possible infection.  Thus, data from approximately 20% of women 
managed by CRS PTs during the study period were expected to be excluded from 
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consideration.  Data from 166 women were expected to be reviewed with the expectation 
that data from 138 women would eligible for study inclusion. 
 
3.3 Procedures  
3.3.1 Uniform Data Collection Procedures 
 Data were entered by the PT responsible for the patient’s care into an electronic 
database designed for quality improvement and research purposes. The database was 
developed based upon input from the CRS Director of Women’s Health Physical Therapy 
at CRS, the CRS Chief Operating Officer, and the 15 CRS PTs who specialized in 
women’s health physical therapy.  The database had the capacity to store the following 
data: patient demographics; medical, surgical (including obstetric and gynecologic) and 
medication history; urinary symptoms; dietary intake (fiber, fluid, caffeine); 
musculoskeletal and neuromuscular impairments identified during the physical therapy 
examination; physical therapy interventions administered during the course of patient 
care; barriers to intervention recommendations; and study outcome scores (PGI-I, PFDI-
20, PFIQ-7, CSS, FSFI).   
To promote consistency and uniformity in data collection, the medical history 
form completed by the patient at the initial physical therapy examination was developed 
to parallel medical, surgical, and medication history database fields.  Likewise, physical 
therapy examination and intervention forms were developed to ensure uniform and 
comprehensive documentation, adherence to CRS documentation standards, and 
concurrence with examination and intervention database fields.  In addition, one in-
person meeting between the CRS Women’s Health PTs and the primary study 
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investigators occurred to discuss and operationally define the tests and measures utilized 
during the physical therapy examination. 
 Finally, three in-person meetings were conducted between the CRS Women’s 
Health PTs and the primary study investigators to discuss and educate the PTs on existing 
valid and reliable pelvic-floor specific symptom and quality of life outcome measures. 
Based on input from the PTs, outcome measures were selected to assess the impact of 
physical therapy management on the patient’s global impression of improvement, pelvic 
symptoms, and patient’s health-related quality of life.  The PTs were educated on 
procedures for administering and scoring these measures.  
   
3.3.2 Selected Outcome measures/questionnaires 
  Study primary outcome measures included the PGI-I, PFDI-20, and PFIQ-7.   Only 
the PGI-I score obtained at the discharge examination was collected.  The PFDI-20 and 
PFIQ-7 questionnaires were completed by women at their initial (baseline) and discharge 
physical therapy examinations.  
The PGI-I is a global index to assess the patient’s perception of improvement 
following treatment intervention.
170-173
 The PGI-I has been shown to have good construct 
validity for treatment response in women with SUI.
77
  It includes one question that asks 
the respondent to compare their current condition to how it was prior to starting 
treatment.  The response range is 1-7, with 1 being “very much better” and 7 being “very 
much worse.”  Thus, lower scores indicate an improvement in the condition, while higher 
scores indicate a worsening of the condition.  
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 The PFDI-20 and PFIQ-7 are condition-specific instruments that assess urinary, 
bowel, and prolapse symptoms, and the impact of urinary, bowel, and prolapse symptoms 
on a woman’s quality of life, respectively.  Because it is common for several pelvic floor 
disorders to co-exist in the same woman,
31
 the use of instruments that assess the whole 
spectrum of interrelated symptoms is essential when evaluating the efficacy of treatment 
interventions.  The PFDI-20 has a total of 20 questions and contains 3 subscales: the 
Urinary Distress Inventory-6,
183
  the Pelvic Organ Prolapse Distress Inventory-6, and the 
Colorectal-anal Distress Inventory-8.  Respondents are asked to endorse the presence of 
symptoms and the degree of bother on a scale from 1 (not at all) to 4 (quite a bit) 
associated with each symptom.  The 3 subscales of the PFDI-20 are scored from 0 (least 
distress) to 100 (greatest distress), and the summary PFDI-20 score includes the sum of 
the 3 scales and ranges from 0 to 300.  The PFIQ-7 has 21 items and contains 3 
subscales:  the Urinary Impact Questionnaire-7,
183
 the Pelvic Organ Prolapse Impact 
Questionnaire-7, and the Colorectal-anal Impact Questionnaire-7.  On this questionnaire, 
respondents are asked to rate the degree their bladder, prolapse, and/or bowel symptoms 
affect their activities, relationships, and feelings on a scale from 0 (not at all) to 3 (quite a 
bit). Each of the subscales are scored from 0 (symptoms do not impact) to 100 (symptoms 
greatly impact) with an overall PFIQ-7 summary score ranging from 0 to 300.  Both the 
PFDI-20 and PFIQ-7 are valid, reliable, and responsive to change, and demonstrate 
significant correlations with the long versions of the PFDI and PFIQ ( ICCs ranging from 
0.86-0.93 and 0.94-0.96 respectively).
78
   
Secondary study outcome measures included the CSS and FSFI.   These 
questionnaires were completed at initial (baseline) and at discharge physical therapy 
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examinations.  The CSS is a valid instrument that assesses the bowel habits and 
symptoms of constipated patients.
79
  The CSS contains 7 items that are scored from 0-4. 
A score of 0 indicates less distress and a score of 4 indicates greatest distress.  An 
additional CSS item queries the type of assistance needed to produce a bowel movement. 
Score range on this item is from 0 (without assistance) to 2 (digital assistance or enema).  
Thus, the total CSS score ranges from 0-30, with a score greater than 15 indicating 
constipation. The brevity of CSS is advantageous. In addition, Agachan and colleagues 
reported that the CSS demonstrated convergent and divergent validity as well as 
significant correlation with anal and colorectal physiologic studies.
79
  However, the 
reliability, responsiveness, and sensitivity to change of the CSS have not been 
determined. 
 
 
The FSFI is a 19-item questionnaire that measures sexual function across 6 
domains: desire, arousal, lubrication, orgasm, satisfaction, and pain.
80
 An advantage of 
the FSFI is that one domain, instead of the entire questionnaire, can be administered.  
This study utilized only the pain domain which includes 3 questions. The questions query 
how often the respondent experiences pain during vaginal penetration, after vaginal 
penetration, and the degree of discomfort during or following penetration. FSFI items are 
rated on a 5 point Likert-type scale with “1” indicating that the respondent “almost 
always” has pain and “5” indicating she “almost never” has pain.  The respondent is also 
given the choice of “0” indicating “did not attempt intercourse” for each item yielding an 
overall score range of 0-6.  Consequently, higher scores on the FSFI indicate better 
sexual function.  The pain domain of the FSFI has high internal consistency (Cronbach’s 
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alpha 0.92-0.94), moderately high test-retest reliability (r=0.69-0.87), and discriminant 
validity.
80
 
 
3.3.3 Selected Patient Demographic, History Data 
 Based on the pathophysiology and risk factors for UI, the history review for a 
woman with UI should be multi-factorial taking into account the patient’s demographics; 
gynecologic/obstetric history; comorbid conditions (including presence of co-existing 
pelvic symptoms); medication use; dietary habits (fiber, fluid, and caffeine intake); and 
current smoking status. Table 3.2 identifies selected patient demographic and history 
information investigated for their possible impact on intervention outcomes. The table 
also includes the rationale for inclusion into the database. In addition, the number of 
physical therapy visits may also impact physical therapy outcomes.  According to a 
recent systematic review, treatment effect may be greater in women with SUI who 
received a longer duration of PFM training (6 months versus 8 weeks).
17
 Subsequently, 
the association between the number of physical therapy visits and outcomes was also 
investigated.   To describe the study sample, the following selected patient demographic 
and history data were used:  marital status (married/living as married or not married), 
menopausal status (regular cycle, perimenopause, or menopause), medications (drug 
therapy for UI, diuretics, hormone replacement, psychotropic medications, and/or 
narcotics/analgesics), pelvic surgeries (hysterectomy, abdominal/ anal-rectal/bladder 
surgery, and/or urethral dilation) types of urinary symptoms (difficulty emptying, urinary 
frequency, urinary urgency, nocturia, SUI symptoms, and/or UUI symptoms), duration of 
UI (years) and dietary habits including caffeine intake (< 2.5 cups per day or ≥ 2.5 cups 
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per day), water (< 3 or 3-6 or >6 glasses per day) and fiber intake (do or do not include 
fiber in diet).  Both predictor variables and selected demographic/history data were 
extracted from the patient’s medical record and entered into the database.   
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Table 3.2: Components of the Demographic/History Review 
Demographic Factors  
Age (years) 
 
 
Race/Ethnicity 
(Caucasian or non-Caucasian) 
Older age significant risk factor for UUI
48, 50, 59
 and increased 
severity of symptoms
47
 
 
Caucasian significant risk for UI
55
 
 
Obstetric History 
Parity (0,1,2,3,>3) Possible injury to pudendal nerve, disruption of intravaginal 
attachments of vagina, stretching and tearing of PFM
9
 
 
Comorbidities that affect bladder function 
Body Mass Index (kg/m
2
) 
 
 
Respiratory disease, chronic 
coughing 
 
Bowel dysfunction 
   Constipation  
   Irritable Bowel Syndrome     
   Fecal incontinence 
 
 
Neurological conditions 
(Cerebrovascular accident, 
Multiple sclerosis, Other) 
 
Diabetes 
 
 
Pelvic organ prolapse 
 
 
Pain 
   Pelvic pain 
 
    
Low back pain 
 
 
Pelvic surgery 
 
BMI > 30 significant risk for SUI
50, 57
 and increased severity of 
symptoms
48
 
 
Increase bladder volume and pressure
184
 
 
 
 
Straining during defecation may lead to pudendal nerve injury
46
 
Possibility of contributing to smooth muscle dysfunction
65
 
Mechanical disruption of connective tissue, muscle or nerve injury 
disrupt normal bladder support or function
46
 
 
Impair sensorimotor function and impair normal tonic inhibition of 
parasympathetic pathway
9, 184, 185
 
 
 
Impair sensorimotor function and impair normal tonic inhibition of 
parasympathetic pathway
9, 184, 185
 
 
Mechanical disruption of connective tissue, muscle or nerve injury 
disrupt normal bladder support or function
46
 
 
 
Urologic
116-118
 or musculoskeletal
116-118
 causes of pelvic pain may 
directly impact bladder function 
 
May disrupt PFM function via pain inhibition or decreased muscle 
reaction
67
 
 
Cause possible tissue injury or impair neuromuscular function
184
 
 
Dietary and Lifestyle Habits 
 
Carbonated beverages 
(> 1 per week or <1 per week) 
 
Smoking 
Postulated that the ingredients in these beverages (sugar, artificial 
sweeteners, citric acid) may irritate the bladder
57
 
 
Increase bladder volume and pressure
184
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3.3.4 Tests and Measures 
Data obtained from the patient during the initial and discharge physical therapy 
examinations included the presence of pelvic organ prolapse, PFM strength, and PFM 
tension/pain.  The examination data were entered into the database and utilized to 
describe the study sample. 
 
3.3.4.1 Pelvic organ prolapse  
 To measure pelvic organ prolapse (POP) via vaginal palpation, patients were 
positioned in hook-lying. The PT inserted two lubricated fingers to the level of the PIP 
joint into the patient’s vagina.186  The examiner then pressed down on the patient’s 
posterior vaginal wall to enhance visualization of the anterior vaginal wall. The patient 
was then asked to bear down or cough.  Bulging tissues on the anterior vaginal wall 
indicate a prolapse of the bladder (cystocele), urethra, or cervix, which werwe 
subsequently graded on a scale of 0-IV (Table 3.3).  To examine the posterior vaginal 
wall, the examiner separated the examining fingers laterally and pressed against the 
posterior vaginal wall. The patient was then asked to bear down or cough.  Bulging of the 
posterior wall indicates a rectocele which was subsequently graded on the 0-IV scale.
186
  
If the patient had multiple pelvic organ prolapse (i.e. rectocele and cystocele), the PT 
entered the most severe prolapse grade into the database.   
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Table 3.3: Pelvic Organ Prolapse Grades  
 
Grade Description 
Grade 0 No prolapse is demonstrated 
Grade I Deep prolapse; palpable only 
Grade II Prolapse half-way toward level of introitus; palpable and 
visualized 
Grade III Prolapse at level of introitus; visualized 
Grade IV Prolapse outside level of introitus; visualized 
 
3.3.4.2 Pelvic Floor Muscle Strength 
 Several methods have been described to examine and evaluate pelvic floor muscle 
(PFM) strength, including manual muscle testing via vaginal palpation and manometry.
69
 
Correct contraction of the PFM includes both a squeeze around the pelvic openings and 
an upward lift.  Measures to examine and evaluate strength should take into account both 
the squeeze and lift components.  Most PTs utilize vaginal palpation and the modified 
Oxford scale to evaluate PFM strength because squeeze pressure and lift are included in 
the Oxford scale criteria.
69
 
 To measure PFM strength via vaginal palpation, patients were positioned in hook-
lying. The examiner inserted two lubricated fingers approximately 3.5 cm inward from 
the patient’s vaginal introitus to palpate the levator ani. The patient was then asked to 
“lift and squeeze” the PFM as tightly as possible around the examiner’s fingers. PFM 
strength was graded based on the modified Oxford Scale as detailed in Table 3.4.
187
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Table 3.4: Modified Oxford Scale for PFM Strength 
 
Grade Description 
0 No movement palpable 
1 Minimal or very small muscle bulging on palpation 
2 Small range of motion, weak with brief hold 
3 Definite muscle movement, upward lift to half range 
4 Firm muscle movement closing around finger, upward lift to half to 
three-quarter range 
5 Very firm muscle pull that compresses finger, upward lift to full range 
and strong hold 
 
The modified Oxford scale has good intra-tester and inter-tester reliability.
187, 188
   
Neumann investigated the intra- and inter-rater reliability of PTs performing the modified 
Oxford scale in a multi-site study.  For intra-rater reliability, Neumann found complete 
agreement between test 1 and test 2 in 13 out of 14 tests, representing 93% overall 
agreement and 100% agreement to within one grade (Kappa coefficient 0.9, p<0.001: 
suggesting almost perfect agreement).
187
  Inter-tester reliability between 50 PTs at 6 
different sites showed 56% inter-rater agreement (Kappa coefficient = 0.4, p<0.001), 
suggesting fair agreement between the PTs and Neumann.   In 42% of the tests, there was 
a difference of one grade.  Thus, there was 96% agreement within one grade between the 
PTs and Neumann.
187
 Similarly, Bo and Finckenhagen reported acceptable inter-test 
reliability (Kappa coefficient = 0.47) between PTs utilizing the modified Oxford scale.  
In 9 of the 10 cases of disagreement, one PT consistently rated subjects one grade lower 
than the other PT,
188
 indicating a systematic difference between the raters. It is 
recognized that PFM testing via vaginal palpation  may not provide the sensitivity and 
responsiveness necessary for scientific investigations, while other measures may be more 
appropriate in measuring force.
69
  However, vaginal examination and rating the PFM 
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using the modified Oxford scale is a clinically accepted method by PTs for evaluating 
PFM function. 
 
3.3.4.3 PFM Tension and Pain 
 Muscle tension testing via palpation is a test performed by PTs to assess the 
quality of the muscle.
7
  For example, if a muscle feels excessively “soft,” the PT may 
suspect muscle atrophy. Conversely, if a muscle feels excessively “hard,” the PT may 
suspect muscle spasm.  There are no standard measures to evaluate muscle tension. Thus, 
we operationally defined muscle tension for the purpose of evaluating pelvic floor muscle 
tension.  A grade of atrophy indicated low muscle bulk, a grade of normal indicated 
normal muscle bulk, and a grade of spasm indicated tissue restriction to palpation or 
stretch. In addition,  pain noted upon palpation of muscle tension was rated by the patient 
on a 0-10 scale  (0 = no pain and 10 = worst imaginable pain).
7
 
 
3.3.5 Intervention 
3.3.5.1 Treatments Received 
 The PT evaluated data gathered from the initial examination and determined the 
patient’s plan of care. The plan of care was individualized for each patient and included 
standard physical therapy interventions.   Standard physical therapy intervention for 
pelvic floor dysfunction may consist of standard physical therapy interventions used to 
treat other diagnoses.
7
 Such interventions include those to address pain (modalities), 
improve strength and coordination of the PFM (PFM exercise with or without 
biofeedback and/or electrical stimulation), improve strength of abdominal and/or lumbar 
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extensor muscles, and improve range of motion (flexibility exercises, soft tissue/joint 
mobilization).  Patient education was also recorded including recommendations for 
bladder and/or bowel training, fluid management, and diet modification.  PTs entered 
their interventions in their plan of care and in the database at the initial examination, 
monthly following the initial examination, and at the time of discharge from physical 
therapy. Intervention categories included in the database are outlined in Table 3.5.  
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Table 3.5: Intervention categories with evidence-based references of justification noted 
 
Modalities Manual physical therapy procedures 
Heat
130
 
 
Ice
130
 
 
PFM Biofeedback
18, 23-26, 76, 144, 145
 
 To promote strength and endurance 
 To increase coordination 
 To promote muscle relaxation 
 
PFM Electrical Stimulation
16, 26
  
 To improve PFM muscle strength (if  
< 2/5 PFM strength) 
 To promote sensory awareness due to 
sensory impairment 
 To reduce pain 
Soft tissue mobilization to decrease soft tissue   
restriction and improve range of motion
125, 127
 
 
Joint mobilization to improve range of 
motion
128
 
 
  
 
Exercises Education 
PFM
11, 13-18, 20, 22, 23, 68, 70, 141
 
 Manual facilitation 
 Gravity eliminated 
 Anti-gravity 
 During functional tasks 
 Downtraining 
 
Core Stabilization
71, 72
 
 Transverse Abdominus 
 Other Abdominal 
 Multifidus 
 Functional 
 
Flexibility 
 Hip130 
 Lumbopelvic67, 130 
Body mechanics/posture
117, 128, 132
 
 
Bladder/bowel schedule
75
 
 
Diet modification 
 Caffeine reduction56 
 Carbonated beverage reduction56 
 Increase water intake159 
 Decrease water intake152, 153 
 Fiber education159, 160 
 
Relaxation techniques to decrease muscle 
tension
132, 165
 
 
SUI strategies
22, 73 (PFM contraction before   
 increase in intra-abdominal pressure) 
 
UUI strategies
74-76
 (inhibition techniques to 
suppress bladder contractions) 
 
Toilet strategies 
 Constipation (toilet posture to 
promote bowel movement)
40, 189
 
 Voiding without straining 
 
Soft tissue massage (abdominal massage,
40
 
scar massage,
130, 132
 self-stretching for 
introitus
127
) 
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3.3.5.2 Barriers to Intervention Recommendations and Changes in Intervention 
 If a patient was not progressing with the plan of care, the PT recorded changes in 
the plan of care and barriers impacting outcomes during monthly re-evaluation visits. The 
presence or absence of barriers to intervention recommendation was utilized as a 
predictor variable for statistical analysis.  The changes in plan of care were reported 
descriptively for the entire study sample. Table 3.6 defines the categories utilized in the 
database.  
Table 3.6:  Barriers to Intervention Recommendations and Changes in Plan of Care 
 
Barriers to Intervention Recommendations 
 
 Patient did not attend all recommended physical therapy visits 
 Patient was not adherent to home exercise program 
 Patient did not adhere to recommended lifestyle modifications (fluid management, diet 
modification, urge/stress, strategy, etc) 
 Cognitive impairments interfered with patient’s ability to follow through with physical 
therapy recommendations 
 Comorbidities contributed to UI or interfered with the patient’s ability to follow the 
plan of care 
 Medications contributed to UI, limiting outcomes 
 Sensory loss limited patient’s ability to recognize correct muscle contraction 
 Profound muscle weakness/muscle denervation limited potential for increased muscle 
function 
Changes in plan of care due to barriers encountered during physical therapy sessions 
 
 Patient education on importance of visit attendance 
 Change in exercise intensity (increased intensity to promote strength, decreased 
intensity due to lack of patient adherence to home exercise program) 
 Internal PFM facilitation due to lack of ability to contract PFM 
 Functional PFM activation (progression of PFM exercise in standing postures) 
 Further interdisciplinary or specialist consultation 
 Increase in core (abdominal, lumbar extensor) exercises to promote PFM recruitment  
 
 
 
3.4 Statistical Analysis 
 Statistical analysis was completed using a commercially available software 
package (SPSS; Chicago, IL).  Descriptive statistics were calculated to describe the 
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selected demographic and history information, examination findings, and to describe 
primary (PGI-I, PFDI-20, PFIQ-7) and secondary (CSS, FSFI) outcome scores of women 
with UI following pragmatic physical therapy management.  Demographic sample 
characteristics included: age, race/ethnicity, body mass index, and marital status.  History 
sample characteristics included: parity; number of comorbidities; pelvic surgeries; 
menopausal status;  medications; types of urinary symptoms; duration of UI; smoking 
status; and dietary habits including caffeine, carbonated beverage, water, and fiber intake. 
Examination findings described for the study sample included pelvic organ prolapse 
grade, PFM strength grade, and PFM tension/pain.  
 To determine if pelvic symptoms (PFDI-20) or health-related quality of life 
(PFIQ-7) was altered by physical therapy interventions, mean baseline and post-
intervention scores for each dependent variable were compared with a paired t-test. To 
determine if constipation symptoms (CSS) or pain with sexual intercourse (FSFI) was 
altered by physical therapy interventions, mean rank baseline and post-intervention 
scores for each dependent variable were compared with a Wilcoxon signed-rank test.  To 
determine women’s perception of improvement attributed to physical therapy 
interventions, the median post intervention PGI-I score was reported. No pre-post 
intervention on this outcome was performed as this measure was obtained only at 
discharge from physical therapy.  
 Correlation coefficients were calculated to determine if age, number of physical 
therapy visits, and number of comorbidities were related to PFDI-20 and PFIQ-7 
outcomes. Correlations between PFDI-20 change scores (PFDI-20 postintervention – 
PFDI-7 baseline) and age (years) and number of physical therapy visits were 
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independently assessed using Pearson correlation coefficients. Correlations between 
PFDI-20 change scores and number of comorbidities were assessed using Spearman’s 
rho.  In a similar fashion, PFIQ-7 change scores were assessed.  Variables with 
correlations with a p-value of < 0.10 were entered into a stepwise linear regression. 
 To examine the relationship between PFDI-20 change scores and the dichotomous 
independent variables of parity (nulliparous or parous), presence of barriers to 
intervention recommendations (none or ≥1), race, (Caucasian or non-Caucasian), 
carbonated beverage intake (≥1 per week or <1 per week), and current smoking status 
(smoker or non-smoker) a stepwise linear regression was used.  To determine the 
dichotomous variables to be included in the stepwise linear regression, the mean PFDI-20 
change scores associated with both categories of a dichotomous variable were calculated 
and compared using a two sample t-test. For example, the mean PFDI-20 change score 
for Caucasian subjects was compared to that of non-Caucasian subjects.  Should a 
significant difference in mean score (p < 0.10) exist between the two categories of a 
dichotomous variable; the dichotomous variable was included in the stepwise linear 
regression.  The same procedure was used to examine the relationship between PFIQ-7 
change scores and dichotomous variables.    
Two sample t-tests and chi-square analysis were used to determine if predictor 
variables were related to treatment success or failure.  For these analyses, post 
intervention PGI-I scores were divided into 2 categories:  scores indicating treatment 
success and scores indicating treatment failure.  Treatment success was defined by a post-
intervention PGI-I score of “much better” or “very much better” while treatment failure 
was defined by the PGI-I scores of “a little better,” “no change,” “a little worse,” “much 
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worse,” and “very much worse.”  Two sample t-tests were used to compare the mean age, 
number of comorbidities, and number of physical therapy visits between success and 
failure groups. Variables showing statistically significant differences between groups (p-
value ≤0.10) were entered into a stepwise logistic regression.  Finally, chi square analyses 
were utilized to determine if parity (nulliparous or parous), presence of barriers to 
intervention recommendations (none or ≥1), race (Caucasian or non-Caucasian), 
carbonated beverage intake (> 1 per week or <1 per week), and current smoking status 
(smoker or non-smoker) significantly influenced the distribution of women to the 
categories of success and failure. Variables resulting in a p-value of < 0.10 were entered 
into a stepwise logistic regression. 
Descriptive statistics were utilized to address the secondary aim of describing the 
types of interventions received by women. For these analyses, data from women were 
presented according to symptom constellation (UI symptoms only, UI + bowel 
symptoms, UI + pelvic pain, or UI + bowel symptoms + pelvic pain). However, for 
selected interventions, the proportion of women receiving the intervention was 
presented for specific subgroups. For example, education on the stress strategy was only 
applicable to women with SUI symptoms.  Thus, the percentage of women who received 
education on the stress strategy was documented for women with SUI symptoms only.   
 
3.5 Power Analysis 
 The minimum important difference (MID) is the smallest change in score 
associated with a clinically meaningful change in a questionnaire.
81
  Statistical tests are 
not responsive to practical or clinical implications of the data.  Subsequently, statistical 
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differences may not be clinically meaningful changes and determining the MID is 
essential in interpreting questionnaire results. To date, there have been no trials 
investigating the impact of physical therapy interventions on concurrent urinary, bowel, 
pelvic organ prolapse, and sexual function symptoms in women utilizing the PFDI-20 
and PFIQ-7.  However, Barber and colleagues estimated the MID for the urinary 
subscales in the PFDI and PFIQ long questionnaires.
190
  Women with SUI were 
randomized into 1 of 3 interventions:  an incontinence pessary, a 12-week behavioral 
therapy program, or both. The behavioral program consisted of 4 clinic visits at 2-week 
intervals and included PFM exercise and education in SUI strategies. Using both anchor- 
and distribution-based approaches to calculate the MID, Barber evaluated the change in 
score from baseline to 3 months after initiating treatment.  Anchors used were the PGI-I, 
incontinence episodes from a urinary diary, and the Incontinence Severity Index.  The 
MID for the urinary subscales of the PFDI and PFIQ were 11.1 and 16.0 respectively.
190
  
Essentially, a change score of 11 on the PFDI urinary subscale differentiated those who 
were “about the same” from those who were “better.”  Although this study utilized the 
long forms of the PFDI and PFIQ, the short forms (PFDI-20 and PFDI-7) have been 
shown to be significantly correlated with the long forms with ICC values between 0.70 
and 0.91.
78
  Using a 99% CI, a MID of 11, and standard deviations from Barber’s trial, an 
initial sample size of 138 patients was determined based on the formula below.  Taking 
into account that 20% of the available medical records will meet exclusion criteria, the 
sample size appropriate for this study is 166. 
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PFDI-20 
((2.58*standard deviation) / MID))=n
2
 
((2.58*32)/11)
2
=56 
Based on the proportions reported in Barber, we would expect that approximately 10% of 
women would get worse (overestimate) [n=6], 10% would stay about the same [n=6], 
30% would get better [n=57], and 50% would get much better [n=69] for a total of 138 
patients.   
Although an initial sample size of 166 was calculated to determine efficacy of 
physical therapy treatment on the PFDI-20 and PFIQ-7 scores, a second power 
calculation was performed to determine the number of subjects necessary to perform the 
stepwise linear regression analysis using the 2-step rule-of-thumb based on Cohen’s 
power analytic approach. The calculations utilize a power of 0.80, alpha of 0.05, and an 
effect size (f
2
) for regression analysis of 0.15 which indicates a medium effect size based 
on Cohen’s work.191 
Step 1: Compute lambda (L): L = 6.4 + 1.65m – 0.05m2 where m equals the number of  
independent variables. 
 
Step 1 results:  L = 6.4 + 1.65(8) + 0.05(82) = 16.4 
Step 2: Compute required minimum sample size: N = L / f
2
  
Step 2 results: N = 16.4 / 0.15 = 109.3 = 110 
Since 138 > 110, the most appropriate sample calculation for this study was 166 taking 
into account that 20% of the medical records will meet exclusion criteria.   
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Chapter 4 
Results 
4.1 Subjects 
 Between November 1, 2009 and November 15, 2010, 500 physical therapy 
records were screened by the CRS honest broker. Data from 100 women met study 
inclusion criteria, were extracted from the database, and included for data analysis.    
 Ninety eight percent of the participants were Caucasian and their mean age was 
54.4 ± 15.2 years.  Most women (82%) were parous, 16% were nulliparous, and 2% did 
not report parity.  Median parity of the sample was 2.0 (1
st
 quartile value = 1.0 and 3
rd
 
quartile value = 3.0).  Body mass index was reported for 70/100 subjects (mean 27.9 
kg/m
2
± 7.1).  Only one participant (1%) reported smoking.  Participants reported a 
variety of urinary symptoms, with most women (49%) reporting more than one urinary 
symptom. Most of the women in the study complained of SUI (54%), while 37% 
described urgency symptoms and 35% noted UUI.  The mean duration of UI and the 
mean number of physical therapy visits attended for all women in the study was 5.4 ± 7.0 
years and 7.9 ± 4.9 visits, respectively. The remaining participant characteristics are 
presented in Table 4.1.  Table 4.2 summarizes the participants’ history of pelvic surgeries 
and comorbid conditions and the use of medications that are known to impact bladder 
function.  The most commonly reported comorbidities were pelvic pain, constipation, 
irritable bowel syndrome, and low back pain. Forty-three percent of women were taking 
medications known to impact urinary continence.  
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Table 4.1:  Characteristics of participants 
Characteristic (n=100) 
 
Values (n) 
Age (years), mean (SD) 54.4 (15.2) 
Race/Ethnicity  
     Caucasian 98 
     Non-Caucasian   2 
Parity  
     Nulliparous 16 
     Parous 82 
     Unreported   2 
Marital Status   
     Married, living as married 75  
     Separated, divorced, widowed, single, or never married 25 
Menopausal status  
     Regular cycle  27  
     Irregular cycle   4 
     Peri-menopause   4 
     Menopause  63  
     Unreported    2  
Types of Urinary Symptoms  
     Difficulty emptying  13  
     Frequency  35  
     Urgency  37  
     Nocturia   15 
     Stress urinary incontinence  54  
     Urge urinary incontinence  35  
Number of physical therapy visits attended, mean (SD)    7.9 (4.9) 
Body mass index (kg/m
2
), mean (SD) (n=70)  25.9 (7.1) 
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Table 4.2:  Medical history / medications of participants 
Characteristic (n=100) Values (n) 
Pelvic Surgeries 
    Hysterectomy 
    Abdominal surgery 
    Anal/rectal surgery 
    Bladder surgery 
    Urethral dilation 
    None 
 
26 
23  
11  
15  
  4  
21  
Comorbidities 
     Lung disease 
     Diabetes 
     Irritable bowel syndrome 
     Constipation 
     Fecal incontinence 
     Stroke 
     Multiple sclerosis 
     Other neurological 
     Frequent UTI (> 3 per year) 
     Abdominal pain 
     Low back pain 
     Pelvic pain 
 
  3  
  4  
30  
38  
12  
  4  
  1  
  4  
  6  
17  
27  
45 
Medications that impact urinary continence 
     Drug therapy for urinary incontinence 
     Diuretics 
     Hormone replacement 
     Psychotropic 
     Narcotics / Analgesics    
     None 
 
  8  
  3  
  7  
11  
14  
57 
 
Table 4.3 summarizes selected physical therapy examination findings including 
presence of pelvic organ prolapse and PFM tension/pain; and reported dietary habits. 
Less than half of the women (43%) presented with pelvic organ prolapse. Most women 
(78%) demonstrated abnormal pelvic floor muscle tension /pain upon vaginal palpation. 
Most participants reported intake of < 1 carbonated beverage/wk and ≤ 2.5 cups of 
caffeine per day.  Forty-three percent of women were drinking fewer than 3 glasses of 
water per day. Less than half of women included fiber in their daily diet.  In addition, the 
sample median Oxford muscle strength grade was 2, indicating the levator ani contraction 
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was weak and brief; and that the contraction resulted in a small range of pelvic floor 
motion. 
Table 4.3: Examination findings of participants 
 
Characteristic (n=100) Values (n) 
 Pelvic organ prolapse 
   Grade 0        
   Grade I 
   Grade II 
   Grade III 
   Grade IV 
   Unreported 
 
 53  
 17  
 18  
   4  
   1 
   7  
PFM tension/pain  
  Normal 
  Abnormal         
     Atrophy 
     Spasm 
     Pain upon vaginal palpation 
 
 22  
 78  
 32  
 56  
 59  
Dietary Habits  
   Caffeine intake ≥2.5 cups per day 
   Caffeine intake < 2.5 cups per day 
   Carbonated beverage intake ≥ 1 beverage per week 
   Carbonated beverage intake < 1 beverage per week 
   Fiber included in diet 
   Fiber not included in diet 
   Water intake  
         <3 glasses per day 
         3-6 glasses per day 
         >6 glasses per day 
         Unreported 
    
 
 27  
 73  
 16  
 84  
 43  
 57  
 
43  
43  
  9  
  5 
 
4.2 Physical Therapy Outcomes 
 Fifty-four and 52 participants completed the initial and discharge PFDI-20 and 
PFIQ-7 questionnaires, respectively. In addition, 3 women did not complete either 
questionnaire at initial or discharge evaluations. All participants reported a PGI-I score 
post-intervention.  Secondary outcomes including the CSS and FSFI were not 
administered routinely to study participants with only 10 participants and 5 participants 
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completing the CSS and FSFI, respectively. Consequently, CSS and FSFI scores were 
excluded from statistical analysis.  
Baseline, post-intervention, and baseline-post-intervention change scores for the 
PFDI-20, PFIQ-7; and the distribution of post-intervention PGI-I scores are presented in 
Table 4.4.  Baseline to post-intervention PFDI-20 and PFIQ-7 scores were significantly 
reduced (p<0.001) indicating that women’s pelvic symptoms and health-related quality of 
life improved following physical therapy intervention.  The median value in the PGI-I 
frequency distribution was “2” indicating that women perceived their symptoms as 
“much better” following physical therapy. Sixty-six percent of women achieved the study 
criteria for PGI-I treatment success, with 28 women reporting a PGI-I score of “1” 
(symptoms are “very much better”) and 38 women reporting a PGI-I score of “2” 
(symptoms are “much better”).  
Because only about half of the sample completed the PFDI-20 and PFIQ-7 at 
discharge, results of an intention-to-treat analysis (n= 97) are presented. For these 
analyses, the initial PFDI-20 and PFIQ-7 scores were carried forward when the discharge 
outcome scores were missing. This intention-to-treat analysis supported the efficacy 
analysis that showed that both PFDI-20 and PFIQ-7 scores significantly improved 
following physical therapy intervention (p<0.001). The results of the intention-to-treat 
analysis may be found in Appendix Table A1.1.  
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Table 4.4: Outcome scores of study participants 
 Mean 
Baseline 
Value 
(±SD) 
Mean Post-
intervention 
Value 
(±SD) 
Baseline to 
post-
intervention 
change score 
(±SD) 
95% CI t- 
statistic 
p-value 
PFDI-20 
(n=54) 
88.69±49.19 
 
50.80±46.25 37.89±48.97 24.52-
51.25 
5.686 <0.001 
PFIQ-7  
(n=52) 
52.21±56.50 21.96±34.96 30.25±51.21 
 
15.99-
44.51 
4.260 <0.001 
 
 
 Frequency 
Count 
    
PGI-I Score 
(n=100) 
1=very much   
     better 
2=much   
     better 
3=a little    
     better 
4=no  
    change 
5=a little  
     worse 
6=much  
     worse 
7=very much  
     worse 
NA  
 
28 
 
38 
 
26 
 
7 
 
1 
 
0 
 
0 
 
NA NA NA NA 
 
4.3 Factors associated with Physical Therapy Outcomes 
Mean PFDI-20 and PFIQ-7 pre- to post-intervention change scores did not differ 
between women based on parity, presence of barriers to intervention recommendations, 
or carbonated beverage intake (p>0.10). In addition, age, the number of physical therapy 
visits, and the number of comorbidities were not statistically associated with PFDI-20 or 
PFIQ-7 scores (p >0.10).  (See Appendix A1.2 and A1.3 for tables.) 
Age and number of physical therapy visits differed between women who did and 
did not achieve PGI-I defined treatment success.  Women who achieved treatment 
success had a lower mean age (51.86±15.59 vs. 59.29±13.15 years, p<0.019) and had 
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more physical therapy visits (9.05±5.51 vs. 5.74±2.55 visits, p<0.001) than those who did 
not perceive symptom improvement. (See Appendix A1.4 for table.) There was no 
difference in the mean number of comorbidities between women who perceived and did 
not perceive treatment success.   
 The distribution of the occurrence of barriers between women who did and did 
not perceive treatment success was different than would be expected by chance (Fisher’s 
exact test p-value<0.001; Table 4.5).  Specifically, 56% of women perceiving treatment 
success reported no barriers to intervention recommendations and only 10% of women 
perceiving treatment failure reported no barriers to intervention.  The distribution of the 
occurrence of parity and carbonated beverage intake was not significantly different 
between women perceiving and not perceiving treatment success. (See Appendix A1.5 
for tables.) 
Table 4.5:  Distribution of the occurrence of barriers when women are divided by PGI-I   
success/failure  
 
 PGI-I Success 
 
PGI-I Failure 
 
Total 
No barriers 56 (56%) 13 (13%) 69 (69%) 
Presence of barriers 10 (10%) 21 (21%) 31 (31%) 
Total 66 (66%) 34 (34%) 100 (100%) 
Fisher’s exact test p-value<0.001 
 
When age, presence of barriers to intervention recommendations, and number of 
physical therapy visits were entered into the logistic regression model, only barriers to 
intervention recommendations (p<0.001) and number of physical therapy visits (p=0.007) 
were influential in predicting PGI-I outcome (Table 4.6). The odds of success for women 
who did not report barriers to intervention recommendations were 12.8 times greater than 
those for women who reported barriers to intervention recommendations (OR 12.82; 95% 
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CI 4.05-40.55).  In addition, as the number of physical therapy visits increased, a woman 
was more likely to attain treatment success. Specifically, for each additional treatment 
visit received, the odds for a woman to achieve treatment success increased 1.26 times 
(OR 1.26; 95% CI 1.07-1.50).   
Table 4.6:  PGI-I success logistic regression model 
 
Predictor 
 
Regression 
Coefficient 
Standard Error p-value 
Constant               -1.105 1.362  
Age in years              - 0.028 0.019 0.151 
Presence of barriers 2.551 0.587 0.000 
Number of PT visits 0.233 0.086 0.007 
*The overall accuracy of predicting success is 80% based on this logistic regression 
model. 
 
 
4.4 Treatments Received 
 
4.4.1 Education 
94% of women in this study received some type of patient education (see Table 
4.7).  Education in body mechanics, relaxation techniques to decrease muscle tension, 
and voiding without straining were most often prescribed for women with pelvic pain. 
Education in soft tissue massage was provided most often to women who reported all 3 
types of pelvic symptoms, urinary, bowel and pelvic pain. Alternately, therapists 
provided education in bowel/bladder scheduling less often to women with concomitant 
urinary, bowel and pelvic pain symptoms.    
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Table 4.7: Education by category 
 
  Body 
mechanics 
Bladder/ 
bowel schedule 
Relaxation Soft tissue 
massage 
Void without 
strain 
Categories n n (%) n (%) n (%) n (%) n (%) 
UI only 10 2 (20) 2 (20) 1 (10) 2 (20) 2 (20) 
UI + bowel 31  2 (6.5)  10 (32.2) 3 (9.6)  2 (6.5)   6 (19.4) 
UI + pelvic pain 5 2 (40) 2 (40) 3 (60) 1 (20) 2 (40) 
UI + bowel +  
pelvic pain 
54   19 (35) 7 (13) 37 (68.5) 33 (61) 30 (55) 
 
Fifty four women had SUI symptoms, 35 had UUI symptoms, and 38 women had 
symptoms of constipation. Education in strategies to prevent UI episodes (stress strategy 
for SUI and urge suppression strategy for UUI) was provided to 51.9% and 71.4% of the 
women with SUI and UUI, respectively. For women with constipation, 71.1% were 
educated in toileting strategies to promote bowel emptying.   
 Physical therapists educated 92.6% (25/27) of the women who indicated that they 
consumed excessive caffeine to reduce caffeine intake; and 50% (8/16) of the women 
who drank at least one carbonated beverage per week to reduce carbonated beverage 
intake. Seventy-two percent of women (31/43) who consumed <3 glasses of water per 
day received education on increasing water intake; and none of the 9 women drinking >6 
glasses of water per day received education on decreasing water intake.  In addition, 
education to increase fiber intake was provided to 26/38 (68.4%) of the women with 
symptoms of constipation.  
 
4.4.2 Exercise 
PFM training was included in the physical therapy plan of care for 98% of women 
(Table 4.8). Downtraining was most often prescribed for women with pelvic pain 
symptoms. Manual facilitation of the levator ani was included in the plan of care for 61% 
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of the women.  Gravity-eliminated PFM exercise was prescribed for 52% of women. 
Finally, 75% of women performed PFM exercises in antigravity positions.  In addition to 
PFM training, ≥50% of women in each symptom category received core stabilization 
training. Interestingly, women who received core stabilization training were significantly 
more likely to obtain treatment PGI-defined success (Fisher’s exact test p-value=0.031) 
than women who did not perform core stabilization exercises (see Table 4.9).  Flexibility 
exercises of the lumbar spine and hip were incorporated into the treatment plans of 20 
women with UI + bowel + pelvic pain (37%) and 1 woman with UI only (10%). Women 
in the other categories did not perform flexibility exercises. 
Table 4.8: Exercise by category 
  PFM manual 
facilitation 
PFM gravity 
eliminated 
PFM anti-
gravity 
PFM 
downtraining 
Core 
stability 
Categories n n (%) n (%) n (%) n (%) n (%) 
UI only 10 4 (40)   3 (30)   9 (90) 1 (10) 5 (50) 
UI + bowel 31  21 (67.7) 18 (58) 28 (90)    4 (12.9)  19 (61.3) 
UI + pelvic pain   5 2 (40)   3 (60)   1 (10) 4 (80) 3 (60) 
UI + bowel +  
pelvic pain 
54     34 (63) 28 (52)   37 (68.5) 43 (79.6)  33 (61.1) 
 
Table 4.9:  Performance of Core stabilization exercise and Treatment Success on PGI-I 
 Treatment Success 
on PGI-I 
Treatment Failure 
on PGI-I 
Total 
Women who performed core 
stabilization 
45 (45%) 15 (15%) 60 (60%) 
Women who did not perform 
core stabilization 
21 (21%) 19 (19%) 40 (40%) 
Total 
 
66 (66%) 34 (34%)      100 (100%) 
*Fisher’s exact test p-value=0.031 
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4.4.3 Modalities 
 Physical therapists included modalities of hot/cold, biofeedback, and/or electrical 
stimulation in the plan of care for 42% of women (Table 4.10).  Only women with all 
three pelvic symptoms received hot/cold modalities as part of their physical therapy 
intervention.  17% of the total sample of women received biofeedback, while 22% 
received electrical stimulation. 
Table 4.10: Modalities and Manual Physical Therapy Procedures by category 
  Hot /cold Biofeedback Electrical 
Stimulation 
Joint 
mobilization 
Soft tissue 
mobilization 
Categories n n (%) n (%) n (%) n (%) n (%) 
UI only 10    0 (0) 5 (50) 2 (20)       0 (0) 2 (20) 
UI + bowel 31    0 (0)    7 (22.6)  11 (35.5)   1 (3.2)    7 (22.6) 
UI + pelvic pain   5    0 (0) 1 (20) 2 (40)       0 (0) 3 (60) 
UI + bowel +  
pelvic pain 
54  14 (25.9)  4 (7.4) 7 (13)  16 (29.6) 46 (85.1) 
 
4.4.4 Manual physical therapy procedures 
 72% of the sample received some type of manual physical therapy procedures 
(Table 4.10).  Joint mobilization was predominantly prescribed for women with all 3 
pelvic symptoms. Physical therapists performed soft tissue mobilization most often on 
women with pelvic pain.    
 
4.4.5 Barriers to intervention recommendations and changes in intervention 
Thirty one women in the study reported barriers to intervention recommendations. 
71% (22/31) of the women reported 1 barrier, 22.6% (7/31) reported 2 barriers, and 6.5% 
(2/31) reported 3 barriers.  The most common barriers noted were that the patient failed 
to attend all recommended physical therapy visits, that patient’s comorbidities 
contributed to UI or interfered with the patient’s ability to follow the plan of care, and the 
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patient did not adhere to the home exercise program (Table 4.11).  In response to these 
barriers, physical therapists altered the plan of care of 87.1% (27/31) of the women.  The 
most common change in treatment plan was a change in exercise intensity (Table 4.11).  
Functional PFM activation and introduction of core exercises to promote PFM 
recruitment were the most frequently endorsed changes in exercise recommendations. 
Table 4.11:  Barriers to Intervention Recommendations and Changes in Plan of Care 
 
Barrier to intervention recommendations (n=31) 
 
n (%) 
Patient did not attend all recommended physical therapy visits 
 
Patient was not adherent to home exercise program 
 
Patient did not adhere to recommended lifestyle modifications (fluid management, 
diet modification, urge/stress, strategy, etc) 
 
Comorbidities contributed to UI or interfered with the patient’s ability to follow 
the plan of care 
 
Medications contributed to UI, limiting outcomes 
 
Sensory loss limited patient’s ability to recognize correct muscle contraction 
 
Profound muscle weakness/muscle denervation limited potential for increased 
muscle function 
10 (32.3) 
 
  8 (25.8) 
 
  6 (19.4) 
 
 
10 (32.3) 
 
 
  2 (6.5) 
 
  1 (3.2) 
 
  5 (16.1) 
Changes in plan of care due to barriers encountered during physical therapy 
sessions 
 
 
Patient education on importance of visit attendance 
 
Change in exercise intensity (increased intensity to promote strength, decreased 
intensity due to lack of patient adherence to home exercise program) 
 
Internal PFM facilitation due to lack of ability to contract PFM 
 
Functional PFM activation (progression of PFM exercise in standing postures) 
 
Further interdisciplinary or specialist consultation 
 
Increase in core (abdominal, lumbar extensor) exercises to promote PFM 
recruitment 
 
Other  
 
10 (32.2) 
 
21 (67.7) 
 
 
  5 (16.1) 
 
13 (41.9) 
 
  1 (3.2) 
 
11 (35.5) 
 
13 (41.9) 
 
121 
 
Chapter 5 
Discussion 
5.1 Patient Characteristics 
Similar to other reports, this investigation found that women with UI seeking 
physical therapy services often complain of additional pelvic symptoms. Of the 100 
community dwelling women seeking physical therapy for UI, nearly half (48%) reported 
other co-existing pelvic symptoms as indicated by their responses to the Colorectal-Anal 
and Pelvic Organ Prolapse subscale items of the PFDI-20.  Co-existing bowel conditions 
reported by women included constipation (38%), irritable bowel syndrome (30%), and/or 
fecal incontinence (12%).  The prevalence rates of bowel conditions in women with UI in 
the present study are similar to rates previously reported.   Specifically, previous 
investigators have found the prevalence of constipation ranges from 31
34
-36%
33
; and  the 
presence of  fecal incontinence in women with UUI to be 18%  (mean age = 57).
64
 The 
prevalence of irritable bowel syndrome in women with urinary symptoms has not been 
previously reported.  The current study also found that more than half of the women 
(59%) reported PFM pain upon palpation. Questionnaires that address the whole 
spectrum of pelvic symptoms are prudent in understanding the various impairments 
women may possess when seeking physical therapy for UI.  
 
5.2 Physical therapy outcome measures 
This study found that physical therapy interventions provided within a pragmatic 
setting are effective in improving pelvic symptoms, including urinary, bowel, and 
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prolapse symptoms.  It is well established that physical therapy interventions aimed 
toward improving urinary symptoms are effective.
11, 12, 14-18, 24, 70, 76, 108, 141, 143, 144, 182, 192-195
  
However, there are too few published data to conclude whether or not these physical 
therapy interventions can effectively manage women with urinary and concurrent bowel 
and/or pelvic organ prolapse symptoms. Even data to describe the types of interventions 
used by physical therapists to manage women with a myriad of pelvic symptoms are 
scarce.  This study was unique in that it obtained data that described current physical 
therapy practice from a large group (15) of physical therapists within one outpatient 
physical therapy company (Centers for Rehab Services). It was not an aim of this study to 
discern which intervention(s) were most successful. Thus, study conclusions are limited 
toward the overall effectiveness of the physical therapy plan of care to reduce women’s 
pelvic symptoms. Within this sample of convenience, this study found evidence that 
Centers for Rehab Services physical therapists were very effective in reducing their 
client’s pelvic symptoms.  
Pre- to post intervention PFDI-20 and PFIQ-7 scores improved significantly by 
37.89 and 30.25, respectively.  Such statistical improvements exceed the minimum 
important difference for both the PFDI-20 and PFIQ-7.  Barber et al. reported minimum 
important differences of 11.1 and 16.0 points for the urinary subscales of the PFDI and 
PFIQ, respectively.
190
  Thus, women in the current study experienced a clinically 
significant improvement in their symptoms. This conclusion is further validated by the 
fact that 66% of women achieved at least or greater than a PGI-I score of 2, indicating 
that symptoms were “much better”. 
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A major limitation of the study is the small sample size.  In order to determine 
statistical difference in the baseline to post-intervention PFDI-20 and PFIQ-7 scores, the 
power analysis revealed a sample size of 138.   Although we had a large pool of medical 
records in the database (500), only 100 subjects met the inclusion criteria. Of these 100 
subjects, just over half of the patients completed both baseline and post-intervention 
PFDI-20 (54 patients) and PFIQ-7 (52 patients) questionnaires.  When smaller sample 
sizes are used, true statistical differences are less likely to be recognized.
167
 Even with 
this smaller sample size, we were able to detect a true difference between baseline and 
post-treatment PFDI-20 and PFIQ-7 scores. The differences  also exceeded the minimum 
important difference as reported by Barber.
190
  Because women who did not complete the 
questionnaires at discharge may have had poorer outcomes, intention-to-treat analyses 
including these women were performed. The results of the intention to treat analyses 
were congruent with the results of the efficacy analyses. That is both PFDI-20 and PFIQ-
7 scores significantly improved following physical therapy intervention. 
We chose a global impression of improvement as a primary outcome measure in 
order to obtain a very simple and direct appraisal of the patient perception of 
improvement.  The PGI-I is a global index used in recent research trials to assess patient 
perception of treatment intervention.
170-173
 The PGI-I  has been shown to have good 
construct validity.
77
 Sixty-six percent of the women in our study achieved treatment 
success as defined by the PGI-I.  This is a slightly higher success rate than reported by 
Richter et al. who also used the PGI-I.  Richter et al. reported a per-protocol success rate 
of 61.6% and an intention-to treat success rate of 49% for women who received physical 
therapy management for SUI.
182
   In Richter’s study, treatment consisted of interventions 
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aimed only at UI (PFM exercise and additional skills and strategies for active use of 
muscles to prevent SUI and UUI).
182
 The present study included additional interventions 
that may have contributed to the higher percentage of women attaining success. Our 66% 
success rate is similar to the 60%-85% range for reduction in incontinence episodes 
reported in other behavioral intervention trials.
11, 16, 17, 24, 70, 141, 196, 197
   
 
5.3 Factors associated with Physical Therapy Outcomes  
This study explored a number of variables that were thought to have potential for 
influencing physical therapy outcomes.  Regression analysis revealed that only two 
variables influenced treatment success as defined by the PGI-I score.  Patients without 
barriers to intervention recommendations and patients who attended more physical 
therapy visits were more likely to attain PGI-I defined success.   
 An absence of barriers to intervention recommendations was a strong predictor of 
patient defined success.  The odds of success for women who did not report barriers were 
12.8 times greater than those for women who reported barriers.  Our finding is similar to 
Grindley et al. who reported a negative correlation between the total number of barriers 
and treatment efficacy (r=-0.380) for patients of various diagnoses receiving outpatient 
physical therapy for 4-8 weeks.
198
  In addition, Borello-France et al. reported that the 
total number of barriers was significantly associated with a lower number of PFM 
exercises performed by women with predominant UUI (p<0.05).
199
  One of the most 
common barriers in the present study was non-adherence to the prescribed home exercise 
program.  Eight percent of all women in the study (8/100) reported not adhering to the 
home exercise program during the intervention period. This rate is similar to non-
125 
 
adherence rates (7%-13%)
11, 199
 to behavioral therapy previously reported.   Additionally, 
patient non-attendance was another common barrier.  It is generally believed that the 
failure of a patient to attend therapy sessions can interfere with rehabilitation process and 
potentially impact outcomes.  In our study, 10% of the women did not attend physical 
therapy regularly which may have impacted their outcomes.  Forkan et al. reported that 
barriers, and not motivators, predicted adherence to physical therapists’ recommendations 
following discharge.
200
  The evidence from this and other cited studies strongly support 
the need for physical therapists to engage their patients in order to identify and resolve 
barriers to intervention recommendations. 
The number of physical therapy visits received was associated with PGI-I defined 
treatment success.  The odds of success for a woman receiving one additional physical 
therapy visit increased 1.26 times.  This finding confirms that of Hay-Smith who reported 
treatment effect may be greater in women with SUI who receive a longer duration of 
PFM training (6 months versus 8 weeks).
17
  Yet, research investigating a relationship 
between number of physical therapy visits and treatment outcome is lacking.  Trials 
exploring predictors of physical therapy outcomes routinely have little variability in the 
number of physical therapy visits administered.
13, 201-203
 The pragmatic design of the 
present study captured a large variance of physical therapy visits (2-29 visits) and 
subsequently, statistical analysis was possible.   
Most of study variables identified as possible predictors of outcomes were not 
confirmed statistically as such. Parity which is a known risk factor for UI
48, 51-54
 was 
unrelated to physical therapy outcomes.  Our finding is similar to Theofrastous et al. who 
found no relationship between parity and reduction of incontinent episodes per week in 
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community-dwelling women (mean age 60.6±10 years) with SUI, UUI, or mixed 
incontinence following treatment that included biofeedback-assisted pelvic floor muscle 
exercise training or bladder training.
203
  Similarly, Burgio et al. reported no relationship 
between parity and reduction of incontinent episodes in ambulatory, community-dwelling 
women with UI that were managed with behavioral treatment.
13, 204
  Burgio’s conclusion 
was based on pooled data from 3 prospective randomized clinical trials  that tested 
behavioral therapy (PFM exercise, stress/urge strategies, and self-monitoring with 
bladder diaries) in women with UUI, urge-predominant mixed incontinence, or SUI.
13
   
Although comorbidities may influence the complexity of the intervention,
7
 they 
did not relate to treatment outcomes in this study.  This finding is similar to those of 
McDowell et al
205
 and Burgio et al.
13
 McDowell reported no relationship between the 
number of medical diagnoses and degree of improvement in incontinent episodes per 
week in persons with UI and multiple comorbidities (mean 6.0 problems)  receiving 
behavioral intervention (PFM exercise and stress/urge suppression strategies).
205
  
Similarly, Burgio reported that treatment outcomes did not associate with medical history 
(including arthritis, bladder infections, constipation, age at menopause, duration of 
menopause, hysterectomy, and use of alcohol).
13
  The influence of comorbidities may 
have been minimized in our study due to the selection and categorization procedure used.  
For example, the comorbidities selected for exploration in our study included only those 
identified as documented risk factors for UI (body mass index >30, lung disease, 
diabetes, bowel/constipation/irritable bowel syndrome/fecal incontinence, neurological 
diseases, pain [lumbar or pelvic pain], pelvic surgery [hysterectomy, abdominal, rectal, 
bladder, urethral dilation], and pelvic organ prolapse).  Yet, results of the present study, 
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along with results of previous investigations,
13, 205
 suggest that the complexity of a 
woman’s medical history does not relate to treatment outcomes.  Consequently, a woman 
may be able to respond favorably to physical therapy interventions despite a complex 
medical history. 
In univariate analysis, women who achieved treatment success had a lower mean 
age than those who did not perceive symptom improvement.  Previous investigations 
have found that age was not related to reduction of incontinence.
35, 38, 46-50
  However, 
unlike studies that explored age within a restricted range (minimum 40 to maximum 97 
years),
35, 38, 46-50
 the age range of women in our study was not restricted (minimum 20 to 
89 yrs) which may have contributed to our significant findings.  The only other trial with 
a similar age range (range 25 to 81 years, mean age 54 years), conducted by Smith et al, 
found a significant difference in improvement noted on bladder diaries between those 
<40 years and those >60 years of age. Younger women reported more improvement than 
older women with SUI, UUI, and mixed UI in episodes of incontinence per day following 
behavioral therapy.
51
  
Although significant in the univariate analysis, age was not a significant predictor 
of treatment success in the logistic regression model. The advantage of multivariable 
analysis is the ability to examine several variables within a single study and account for 
their potential interrelationship in the analysis of data.
24
   Using multivariable analysis, 
we found that barriers to intervention recommendations and number of physical therapy 
visits were most influential in predicting treatment success when age was held constant.  
Our result is similar to Burgio
35
 who also found no relationship between age and 
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treatment success using multivariable analysis.  Consequently, age may not be a barrier to 
a woman’s ability to respond to physical therapy. 
Consumption of carbonated beverages is a risk factor for development of OAB.  
Dallosso and colleagues found that women who consumed 2-6 carbonated beverages per 
week had nearly a 50% increased risk for onset OAB (OR 1.44; 95% CI 1.12-1.185) 
compared to those consuming <1 carbonated beverage per week.
57
 Thus, it is reasonable 
to predict that women who consume more carbonated beverages may not achieve 
favorable outcomes. The present study did not find a relationship between consumption 
of carbonated beverages and outcomes.  The manner that data were recorded may have 
biased this result.  The database was designed to require therapists to check a box for 
patients who consumed ≥ 1 carbonated beverage weekly (database value of 1).  If this 
item was not completed, the database defaulted to a value of 0, indicating consumption of 
<1 beverage weekly.  Based on database design, there was no way to delineate if the 
value was truly 0 (consumption of <1 carbonated beverage weekly) or if the value was 
missing.  In addition, the patient’s consumption of carbonated drinks was taken at 
baseline.  If the patient received education on carbonated beverage reduction, then the 
patient may have decreased consumption by the end of treatment.  Consequently, since 
the risk factor (excessive consumption of carbonated beverages) was addressed during 
treatment, it may not relate to treatment outcomes post-intervention.  In future research 
studies, it is important to consider if this item should be dropped or reprogrammed so 
data will be valid and reliable. 
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5.4 Treatments Received 
 This study is the first to describe treatment interventions for women with UI and 
concomitant bowel symptoms, prolapse symptoms, and/or pelvic pain.  Using a 
pragmatic study design, we were able to obtain treatment information from 15 physical 
therapists to capture what interventions women were receiving in true clinical situations. 
The information will be presented to Centers for Rehab physical therapists and 
administration for their interpretation and their decision on how they would use this 
information for program quality improvement.   
Nearly all (94%) of the women in this study received some type of patient 
education.  There was a trend for physical therapists to provide education on body 
mechanics and relaxation techniques to women with pelvic pain. Patients with 
lumbopelvic pain may demonstrate faulty posture and/or lifting techniques which, if not 
corrected, may cause further injury to inert structures.
210
 Lifting with a neutral spine 
posture provides greater stability of the spine and uses both the ligamentous and muscular 
system for stabilization and control.  Subsequently, education of body mechanics to 
women with pelvic pain may help reduce chronic strain on the pelvic floor muscles
186
 
which may improve pain symptoms.  In addition, women with pelvic pain may 
demonstrate pain and/or spasm of the pelvic floor muscles and relaxation training may 
increase patient awareness and tension control over these  muscles.
210
  In this study, 
nearly 90% of women with pelvic pain (53/59) demonstrated spasm and pain of the 
levator ani upon vaginal palpation.  Of the women with levator ani muscle spasm, 71.7% 
(38/53) received education in relaxation techniques.  In a systematic review, relaxation 
techniques, in combination with other interventions, were found to reduce pain for 
130 
 
patients with chronic musculoskeletal pain.
211
 In addition, several case studies reported 
decreased pain and levator ani tenderness for patients with pelvic pain receiving 
multimodal interventions of  relaxation techniques, manual physical therapy, and 
exercise.
165, 212
  Thus, it appears that education of relaxation techniques, in combination 
with other interventions, seems to be a reasonable way to address pain due to muscle 
spasm.  Centers for Rehab Services physical therapists included the education of 
relaxation techniques for the majority of women with levator ani spasm and pain.  
Physical therapists who did not incorporate education of relaxation techniques for women 
with levator ani spasm may have instead selected equally effective interventions 
including: education of soft tissue techniques, PFM downtraining, biofeedback for PFM 
relaxation, or soft tissue mobilization.     
We also examined if the distribution of selected treatment interventions was 
consistent with evidence in the literature. Physical therapists indicated that they provided 
education on the stress strategy for 51.9% of the women with SUI.  The stress strategy, as 
a single intervention, has been shown to be highly effective in reducing urine leakage in 
women with mild SUI.  Miller et al. reported a 98.2% reduction in urinary leakage for a 
medium cough, and a 73.3% reduction for a deep cough when women with mild SUI 
used the stress strategy. 
73
  Moreover, behavioral therapy including PFM exercise and the 
stress strategy has been shown to reduce episodes of incontinence and improve quality of 
life. 
12, 16, 173, 182
 Thus, it is surprising that the stress strategy was not included for a larger 
proportion of women with SUI.   However, out of the 26 women in the study that did not 
receive education on the stress strategy, 9 women had spasm of the levator ani noted on 
initial examination, and an additional 15 had symptoms of UUI.  It is possible that 
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physical therapists did not utilize the stress strategy for women with spasm of the levator 
ani because contracting an already tightened muscle quickly and forcefully may actually 
perpetuate the spasm.  Of the 15 women with mixed UI (symptoms of SUI and UUI) who 
did not receive education on stress strategy, 8 received urge suppression strategy 
education.  A common element of both urge and stress suppression techniques is 
instructing the patient to contract her pelvic floor muscles to prevent UI when the 
precipitating event occurs.  The 8 patients who received urge suppression strategy 
education may have automatically applied the PFM contraction to their stress symptoms 
and consequently did indirectly receive education in preventing SUI episodes.  However, 
17% (9/54) of women with SUI did not receive any stress strategy education.  Because 
the stress strategy has been shown to be effective by itself 
73
   or as a component of 
multimodal intervention trials,
12, 16, 173, 182
 a quality improvement initiative regarding this 
discrepancy is recommended.  
Seventy one percent of women included in this study that had UUI were taught 
urge suppression strategies. Urge suppression strategies along with PFM exercise has 
been shown to decrease UI episodes.
75, 76, 142
  Out of the 10 women with UUI that did not 
receive education on urge suppression strategies, 2 had mixed UI and received education 
on the stress strategy.  Consequently, these 2 women may have applied the stress strategy 
to automatically address their UUI symptoms and indirectly received education on urge 
suppression techniques.  Thus, 23% (8/35) of women with UUI did not receive education 
on the urge suppression strategy.  Because the urge suppression strategy has been shown 
to be effective as part of a comprehensive treatment plan, a quality improvement 
initiative regarding this discrepancy is recommended. However, it must be noted that 6 of 
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the 8 women who did not receive education on urge suppression strategies were treated 
with PFM downtraining. Physical therapists may have focused on downtraining in these 
women, rather than repeated PFM contraction as in urge suppression, to promote 
relaxation of PFM in an attempt to decrease urgency.   
Sixty-eight percent (26/38) of women with constipation were educated to increase 
fiber intake. Of the 32% (12/38) of women who did not receive this education, half 
indicated at the initial examination they already included fiber in their diet. Subsequently, 
it is possible that the physical therapist decided further fiber education was not necessary.  
Evidence for increasing fiber intake to reduce constipation in women with constipation is 
divided.  One study found favorable results with supplementing participants’ diets with 
high-fiber cereal.
160
  Alternately,  a review of four studies that examined dietary fiber 
intake by people with chronic constipation, found no differences compared to controls.
159
  
In the present study, it appears that physical therapists are educating the majority of 
women who lack appropriate fiber intake. Although evidence on increasing fiber intake 
for constipation is inconclusive, it seems reasonable to suggest that women consume 20-
25 g of fiber daily as recommended by the National Academy of Sciences Institute of 
Medicine to promote bowel health.
160
   
Most (92.6%) of the women who indicated that they consumed excessive caffeine 
were educated by physical therapists to reduce caffeine intake.  This finding was 
expected because of the common belief that caffeine worsens UI symptoms; however 
little evidence exists to support this assumption. Although the stimulatory effect of 
caffeine has been shown to directly influence the bladder by increasing bladder pressure 
during filling,
155
 altering caffeine intake does not necessarily decrease UI symptoms.
152
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For example, Dowd found no association between caffeine intake and UI episodes in 32 
women >50 years.
154
 Conversely, Ayra and colleagues reported a significant association 
between high caffeine intake (>400mg) and OAB.
56
  Despite conflicting evidence to 
support caffeine restriction, it is clinically reasonable to educate patients to decrease 
caffeine since excessive caffeine is a risk factor for OAB.  
Recommendations to increase water intake was provided to 72% (31/43) of 
women who consumed <3 glasses of water per day.  It is recommend that adults consume  
0.5 oz of water  per lb of body weight/day.
62
  Drinking less than the recommended 
amount may lead to concentrated and low-volume urine production. Subsequently, 
inadequate water intake may lead to bladder irritation, urgency and frequency, urinary 
tract infection and/or fecal impaction. Thus, it is surprising that 28% of women drinking 
<3 glasses were not educated to increase water intake. However, the manner that data 
were recorded may have biased this result.  The database was designed to require 
physical therapists to check a box for patients who consumed 3-6 or >6 glasses of water 
per day.  If this item was not completed, the database defaulted to the selection of <3 
glasses of water per day and based on database design, there was no way to delineate if 
the value was truly <3 glasses of water per day or if the value was missing.  In future 
research studies, it is important to consider reprogramming this item so data will be valid 
and reliable. 
Nearly all women in the study (98%) were prescribed PFM training.  Because 
PFM exercise has been shown to decrease UI episodes,
11, 16-18, 23, 25, 70, 142-144
 improve 
quality of life,
11, 18, 70, 144
 and increase PFM strength for women with UI;
11, 25, 70
it appears 
that Centers for Rehab Services physical therapists were consistent with the evidence in 
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prescribing PFM exercise.  There was more of a trend for physical therapists to elicit 
PFM contraction with manual facilitation for women with bowel symptoms.  Since 71% 
(27/38) of women with constipation demonstrated PFM spasm upon vaginal palpation, 
manual facilitation may have been used to confirm relaxation of the PFM after 
contraction.  In addition, it is possible that women with dual incontinence (urinary 
incontinence and fecal incontinence) demonstrated weaker pelvic floor muscles.  In the 
present study, 50% (6/12) of women with dual incontinence demonstrated PFM atrophy 
during vaginal palpation. Consequently, physical therapists may have decided that 
manual facilitation was the most appropriate intervention to promote awareness of PFM 
activity.   
Over half of all women in the study (60%) were prescribed core stabilization 
exercises.  Because the percentages of women prescribed core stabilization were similar 
across pelvic floor diagnoses, a Chi-square analysis was performed to determine if there 
were differences in PGI-I defined success between women who were and were not 
prescribed core stabilization exercises.  Interestingly, women who received core training 
were significantly more likely to obtain treatment success than woman who did not 
perform core stabilization exercises.  There is a growing body of evidence that suggests a 
relationship between the function of the pelvic floor muscles and transverse abdominus 
muscle. One study that included 6 healthy women and 1 man found that PFM EMG rose 
above the resting level when a voluntary transverse abdominus contraction was 
performed in the supine position. Interestingly, when these same subjects were asked to 
perform a strong transverse abdominus contraction, levels of synergistic PFM activity 
were similar to that observed when subjects were asked to perform a strong isolated  
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PFM contraction.
151
  Neumann and Gill
149
 and Sapsford
150
 also observed a synergistic 
activation of the levator ani when healthy women performed a transverse abdominus 
contraction in supine.  In addition, the relationship between weak abdominal muscles and 
the development of SUI has been discussed.
71
  Sapsford noted that during coughing and 
nose-blowing, the abdominal wall of women with SUI bulges forward, especially when 
they assume poor posture and fail to contract their abdominal muscles.   In comparison, 
healthy women pull their abdomen inward and contract their pelvic floor muscles during 
a cough to increase intra-abdominal pressure to maintain continence.
71, 150
  The inclusion 
of core strengthening or transverse abdominus exercises in the plan of care may have 
contributed to women achieving PGI-I defined success. However, because the 
intervention plans for women in our study were multimodal, conclusions regarding the 
effectiveness of core stabilization exercises are limited.  Women who achieved PGI-I 
success may have received a different intervention other than core stabilization or a 
combination of interventions that influenced PGI-I success.  
Biofeedback and electrical stimulation to augment PFM exercises were prescribed 
for only 13% and 12% of women, respectively. Based on the literature, PFM exercise 
with biofeedback is not more efficacious than PFM exercise alone for women with SUI
23-
25
 or UUI.
76, 144, 146
  Likewise, investigations that compared electrical stimulation to PFM 
exercise, or combined electrical stimulation and PFM exercise, have not shown superior 
results to PFM exercise used alone.
11, 16, 141
 The use of adjunctive modalities for PFM 
strengthening by physical therapists in this study was consistent with the scientific 
evidence.  Only a small percentage of women received biofeedback and electrical 
stimulation.  In some cases, the physical therapist may have only used these modalities 
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for women who demonstrated difficulty performing PFM exercise due to very extreme 
muscle weakness.  Of the 13 women who received biofeedback for PFM strengthening, 
over half (7/13) demonstrated levator ani atrophy upon physical therapy examination.  
Similarly, 83% (10/13) of women who received electrical stimulation for PFM 
strengthening demonstrated levator ani atrophy at initial examination.  
Flexibility exercises of the lumbar spine and hip, joint mobilization, and soft 
tissue mobilization were provided mostly to women with all 3 pelvic symptoms (urinary, 
bowel, and pelvic pain).  Physical therapists may have decided to utilize manual therapy 
interventions to address common impairments that woman with pelvic pain possess 
including restricted joint motion of the hip and/or pelvis;
128
 hypertonic PFM and/or 
spasm of hip, lumbar or pelvic musculature;
127, 130
 and/or shortening of hip, low back or 
pelvic muscles.
132
  In fact, 90.5% (49/54) and 31.5% (17/54) of women with all 3 pelvic 
symptoms demonstrated levator ani muscle spasm and low back pain, respectively.   
However, women with all 3 pelvic symptoms also received a significantly higher number 
of mean physical therapy visits (8.92±5.72) compared to women without all 3 pelvic 
symptoms (6.69±3.51) (p<0.020).  Thus, because women with all 3 pelvic symptoms had 
more visits, physical therapists may have had additional time/opportunity to implement 
manual physical therapy and flexibility exercise interventions.  
A major limitation of the study is that data entry may have been inconsistently 
performed across physical therapists.  In addition, it was assumed that physical therapists 
entered information accurately. However, there is a chance that they did not enter the data 
accurately.  Additionally, they may have recorded an intervention(s) in the plan of care 
but were not able to administer it because the patient did not return for follow-up visits. 
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5.5 Conclusion 
In our sample of convenience, physical therapy interventions provided within a 
pragmatic setting significantly improved the pelvic symptoms and health-related quality 
of life of women with a primary diagnosis of UI.  Women’s global impression of 
improvement was favorable, with sixty-six percent of women achieving the study criteria 
for PGI-I treatment success.  Patients without barriers to intervention recommendations 
and patients who attended more physical therapy visits were more likely to attain PGI-I 
defined success.   Commonly used interventions for women in the study included patient 
education on diet modification and relaxation techniques, PFM training, core stabilization 
exercises, and manual physical therapy procedures. 
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APPENDIX 
 
Table A1.1:  PFDI-20 and PFIQ-7 scores of study participants (Intention-to-treat 
analysis) 
 
 Baseline Post-
Intervention 
Change Score 
±SD 
95% CI t- 
statistic 
p-
value 
PFDI-20  
(n=97) 
87.95± 45.99 
 
67.77±48.15 20.18±41.12 
 
11.89-
28.46 
4.833 0.000 
PFIQ-7  
(n=97) 
56.54±59.57 40.46±53.52 16.07±40.47 
 
7.93-
24.21 
3.921 0.000 
 
 
Table A1.2 (a-c): Relationships between dichotomous independent variables and PFDI-
20 and PFIQ-7 mean change scores 
 
Table A1.2a:  Comparison of mean PFDI-20 and PFIQ-7 change scores when subjects are  
divided based on parity  
 Parity=No 
deliveries 
Parity=1 or 
more 
deliveries 
Mean 
difference 
±SD 
95% CI t- 
statistic 
p-
value 
PFDI-20 
change 
score 
(n=53) 
-18.43±19.38 
(n=7) 
-41.30±51.90 
(n=46) 
-22.88±19.96 
 
-17.20-
62.95 
1.146 0.257 
PFIQ-7 
change 
score 
(n=51) 
-39.14±28.41 
(n=7) 
-29.73±54.30 
(n=44) 
-9.42±21.09 
 
-51.80-
32.97 
-0.466 0.657 
 
 
Table A1.2b:  Comparison of mean PFDI-20 and PFIQ-7 change scores when subjects 
are divided based on presence of barriers 
 No barriers 1 or more 
barriers 
Mean 
difference 
±SD 
95% CI t- 
statistic 
p-
value 
PFDI-20 
change 
score 
(n=54) 
-41.00±44.08 
(n=44) 
-24.20±67.69 
(n=10) 
-16.80±17.16 
 
-51.24-
17.64 
- 0.979 0.332 
PFIQ-7 
change 
score 
(n=52) 
-29.14±48.46 
(n=42) 
-34.90±64.65 
(n=10) 
5.76±18.18 
 
-30.76-
42.27 
0.317 0.753 
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Table A1.2c:  Comparison of mean PFDI-20 and PFIQ-7 change scores when subjects are  
divided based on parity consumption of carbonated beverages 
 
 <1  
carbonated 
beverage / 
week 
 
≥ 1 
carbonated 
beverage / 
week 
Mean 
difference 
±SD 
95% CI t- 
statistic 
p-
value 
PFDI-20 
change 
score 
(n=54)  
-39.80± 51.37 
(n=46) 
-26.88±32.09 
(n=8) 
-12.93±18.85 
 
-50.76-
24.90 
- 0.686 0.316 
PFIQ-7 
change 
score 
(n=52) 
-30.93±54.28 
(n=81) 
-25.86±25.73 
(n=16) 
-5.08±21.00 
 
-47.26-
37.11 
- 0.242 0.810 
 
 
Table A1.3:  Correlations between independent variables of age, number of physical 
therapy visits and number of comorbidities and PFDI-20/PFIQ-7 change 
scores 
 Age  Number of physical 
therapy visits  
Number of 
comorbidities 
 r p-value r p-value r p-value 
PFDI-20 
change score 
(n=54) 
   0.167  0.227  - 0.153 0.273 -0.105 0.448 
PFIQ-7 
change score 
(n=52) 
- 0.005  0.975  - 0.178 0.211 -0.009 0.950 
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Table A1.4:  Comparison of mean age, number of physical therapy visits and number of 
comorbidities when subjects are divided based on PGI-I success/failure 
 
 PGI-I 
Success 
(n=66) 
PGI-I 
Failure  
(n=34) 
Mean 
difference 
±SD 
95% CI t-
statistic 
p-
value 
Age  51.86±15.59 59.29±13.15 7.43±3.127 
 
  1.22-
13.64 
  2.376 0.019* 
Number of 
physical 
therapy 
visits 
9.05±5.51 5.74±2.55 - 3.31±0.82 
 
- 4.93-    
 -1.69 
- 4.06 0.000* 
Number of 
co-
morbidities  
2.25±1.23 
 
2.18±1.11 - 
0.066±.251 
 
-0.565-   
 0.433 
- 0.262  0.794 
*p<0.10 
 
 
Table A1.5 (a-b):  Relationships between dichotomous variables and PGI-I 
success/failure 
 
Table A1.5a:  Parity 
 PGI-I Success PGI Failure Total 
Nulliparous 10 (10.2%) 6 (6.1%) 16 (16.3%) 
Parous 54 (55.1%) 28 (28.6%) 82 (83.7%) 
Total 64 (65.3%) 34 (34.7%)       100 (100%) 
Fisher’s Exact Test p-value=0.782 
 
 
Table A1.5b:  Carbonated Beverage 
 PGI-I Success 
 
PGI-I Failure Total 
<1 carbonated beverage / week 56 (56%) 28 (28%) 84 (84%) 
≥1 carbonated beverage / week 10 (10%) 6 (6%) 16 (16%) 
Total 66 (66%) 34 (34%) 100 (100%) 
Fisher’s Exact Test p-value=0.778 
 
 
